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1Abstract.
The overall aim of this thesis is to understand better the control of triglyceride 
metabolism in both human and rat models.
Triglyceride metabolism is governed to a large part by the action of two 
enzymes, lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL), whose activities 
are co-ordinately regulated by insulin. This thesis has two inter-related aims: firstly to 
investigate the effect of postprandial chylomicronaemia on the metabolism of VLDL 
subfractions in both normal and diabetic subjects and secondly to investigate the 
antilipolytic mechanism of action of several agents on HSL activity and adipocyte 
lipolysis in isolated primary rat adipocytes. Nicotinic acid was administered to Alderley 
Park (Wistar-derived) and Zucker rats to study its effects on plasma free fatty acid 
(FFA) levels in vivo with a view to using it as a model compound to influence the 
postprandial chylomicron-VLDL interaction in man.
Postprandial lipoprotein metabolism has been extensively studied in normals, 
hypertriglyceridaemics and diabetics using oral fat loads and measuring plasma 
triglyceride levels. It is only in recent years that immunoaffinity chromatography 
techniques have been developed and implemented by a few groups, with studies 
concentrating on normal and hypertriglyceridaemic subjects. Before the present human 
studies could begin an immunoaffinity chromatographic method using a monoclonal 
(LDL A4) antibody for the separation of triglyceride-rich lipoproteins (TRL) 
(chylomicrons and VLDL) had to be developed and tested to ensure it was operating 
under optimal conditions.
In normal subjects, mean plasma, apoB48, apoBlOO and VLDLj triglyceride 
concentrations were significantly elevated (p<0.05) above the fasting concentration 1 to 
8, 1 to 8, 2 to 5 and 2 to 4 hours respectively, postprandially. ApoBlOO and VLDLj 
triglyceride concentrations decreased rapidly after 8 hours. VLDL2 triglyceride 
concentrations did not change significantly during the course of the experiment. The 
increase in apoB48 TRL triglyceride was 5 times greater than the increase in apoBlOO 
TRL triglyceride. Seventy nine percent of the postprandial increase in TRL 
(d<  1.006g/ml) triglyceride was due to apoB48 TRL, with apoBlOO TRL accounting for 
15%. The increase in VLDLj triglyceride was 11 times greater than the increase in 
VLDL2 triglyceride. Seventy five percent of the postprandial increase in total apoBlOO 
triglyceride was due to VLDLj, with 10% accounted for by VLDL2. Plasma FFA 
concentrations were significantly increased (p<0.05) above fasting levels 3 - 1 1  hours
2postprandially with a consistent initial decrease in plasma FFA concentrations 1 - 2  
hours after ingestion of the fat meal in virtually all subjects followed by the subsequent 
rise and a fall back towards baseline concentrations. Plasma insulin concentrations were 
significantly elevated above fasting levels 2 hours postprandially. This increase was 
significantly correlated with apoBlOO and VLDI4  areas under the curve and also with 
the changes in apoBlOO and VLDI4  triglyceride concentrations.
Twenty five diabetic subjects were screened and from those, 5 diabetic subjects 
agreed to take part in the fat feeding study. From the initial fasting blood sample 
obtained from the normal and diabetic patients during the screening procedure, plasma 
triglyceride, cholesterol and apoB concentrations were found to be significantly elevated 
(p<0.005) in the diabetic patient population.
In diabetic subjects, triglyceride response curves showed similar behaviour to 
those observed in normal subjects with the mean plasma, apoB48, apoBlOO, and 
VLDI4  triglyceride concentrations significantly elevated (p<0.05) above fasting 
concentrations from 2 to 5 hours postprandially. VLDL2 triglyceride concentrations 
remained unchanged and relatively constant. In the latter hours of lipaemia, differences 
were observed between diabetic and normal subjects, diabetic triglyceride response 
curves were elevated and prolonged. Diabetic mean apoBlOO and VLDLj triglyceride 
response curves were significantly elevated above that of the normal subject group 
throughout the course of the experiment ( 0 - 1 1  hours postprandially). The increase in 
apoB48 TRL triglyceride was again almost 5 times greater than the increase in apoBlOO 
TRL triglyceride. Eighty three percent of the postprandial increase in TRL (d<  1.006 
g/ml) triglyceride was due to apoB48 TRL, apoBlOO TRL accounted for 16%. The 
increase in VLDLj triglyceride was 12 times greater than the increase in VLDL2 
triglyceride. Seventy three percent of the postprandial increase in total apoBlOO 
triglyceride was due to VLDLj, with 13% accounted for by VLDL2. Plasma insulin 
concentrations were significantly elevated above fasting concentrations 2 hours 
postprandially. Mean FFA concentrations were not increased significantly but there was 
a significant correlation between FFA area under the curve and apoB48 area under the 
curve; a relationship which failed to reach significance in the normal subjects.
In vitro rat adipocyte studies to elucidate the antilipolytic mechanism of action of 
a series of compounds on HSL showed insulin to be the most potent antilipolytic agent, 
nicotinic acid (and analogues) were found to be Gj receptor agonists (depending on 
adenosine removal to exert their antilipolytic effect), and compound 304205 was 
observed to be a direct inhibitor of HSL. Thiazolidinediones (TZD), fibrates and a 83
3agonist had no inhibitory effects on HSL activity in the isolated rat adipocyte. Studies 
administering nicotinic acid to Zucker rats were conducted and allowed the in vivo 
antilipolytic effects of nicotinic acid, primarily on plasma FFA concentrations, to be 
observed.
This thesis extends the current knowledge of the regulation of triglyceride 
metabolism, namely the effects of postprandial chylomicronaemia on VLDL subfraction 
metabolism in normal and diabetic subjects, and on the antilipolytic mechanism of action 
of a series of compounds on adipocyte lipolysis. It demonstrates that the lipid and 
lipoprotein responses to a fat meal in normal and NIDDM subjects depends on the 
fasting triglyceride concentration and not necessarily the underlying diabetic state. In 
vitro adipocyte work targeting HSL showed that not even the best antilipolytic agent was 
as potent as insulin.
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Chapter I Introduction.
1 The regulation of triglyceride metabolism.
1.1 An overview.
The regulation of triglyceride metabolism is complex. Transport of this lipid 
through the circulation involves the plasma lipoprotein system, while the adipose tissue, 
liver and muscle are the most important tissue sites of triglyceride storage and utilisation 
(Coppack, Jensen and Miles 1994). The plasma lipoprotein system comprises 5 major 
groups: chylomicrons, VLDL, IDL, LDL, and HDL, which can be differentiated by 
size, density, and composition (Alaupovic 1971). Two enzymes have a particular 
involvement in lipolysis, lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL).
Lipolysis refers to processes in which triglyceride is hydrolysed, via di- and 
monoglyceride intermediates, to fatty acids and glycerol. Fatty acids (derived from the 
action of two different lipases; LPL and HSL) circulate in plasma bound to albumin 
(Fredrickson, Levy and Lees 1967, Spector 1975 and Coppack et al 1994). Lipolysis 
occurs both intra- and extracellularly, and is an essential component of both lipid storage 
and mobilisation.
LPL (Goldberg 1996) is an extracellular enzyme associated with the luminal side 
of capillaries and arteries where it hydrolyses triglyceride in triglyceride-rich 
lipoproteins (TRL) to produce glycerol and free fatty acids (FFA). Fatty acids, from 
either dietary or endogenous lipoproteins (chylomicrons and VLDL respectively), can be 
released and delivered to the adipose tissue for storage or taken up by the muscle or 
liver for their metabolic requirements. LPL (Eckel 1989) is therefore of prime 
importance for the regulation of fat deposition in adipose tissue.
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HSL is responsible for the mobilisation of fatty acids in adipose tissue which are 
then transported to the liver. It (Yeaman 1990, Frayn et al 1993) is an intracellular 
enzyme, which hydrolyses the adipose tissue stores of triglyceride and is the major 
source of FFAs used for fuel in the fasting state. The fatty acids liberated by lipolysis 
may also be re-esterified into newly synthesised triacylglycerol (Amer 1990, Edens, 
Liebel and Hirsch 1990). Adipose tissue lipolysis is the major regulator of the body's 
supply of lipid energy because it controls the release of FFA into the plasma, (the rate 
limiting step of adipose tissue triglyceride lipolysis being HSL), which are transported 
back to the liver bound to albumin (Spector 1975). Both LPL and HSL are under 
hormonal control, and are co-ordinately regulated by insulin. The hormone activates 
LPL activity and inhibits HSL activity (Eckel 1989).
Triglyceride-rich lipoproteins (TRL) are a heterogeneous population of 
lipoprotein particles comprising chylomicrons and VLDL, which compete for a common 
lipolytic pathway (Brunzell et al 1973), involving LPL. Chylomicrons are formed in the 
intestinal cells (Green and Glickman 1981) during fat absorption, and are released into 
the intestinal lymphatic system entering the bloodstream via the thoracic duct. They 
appear as a wave of particles following a fatty meal and are cleared rapidly from the 
bloodstream. Triglyceride-rich VLDL are secreted by the liver to provide tissues with a 
source of lipoprotein triglyceride in the absence of chylomicrons i.e. in fasting 
conditions. The regulation of hepatic VLDL production is primarily substrate driven, 
the most important regulatory substrate being fatty acids (Lewis 1997). Hepatic fatty 
acids are derived from 4 sources (figure 1.1):
de novo lipogenesis, 
cytoplasmic triglyceride stores,
fatty acids derived from lipoproteins taken up directly by the liver or 
plasma free fatty acids.
In the postprandial state the plasma is flooded with chylomicrons. They are 
delipidated by the action of LPL (mediated by apolipoprotein CII as cofactor) and the 
remnants produced are cleared rapidly by the liver. Chylomicrons and VLDL compete 
for a common lipolytic pathway. Chylomicrons are the preferred substrate for LPL, 
therefore postprandially VLDL, mainly large VLDLj, accumulates in the plasma as a 
result of increased synthesis and/ or decreased catabolism (Karpe et al 1993), but the 
majority of the triglyceride increase is due to the presence of chylomicrons in the 
plasma. HDL exchanges neutral lipid with chylomicrons by the action of CETP. The 
longer chylomicrons reside in the plasma the more cholesterol enriched they become.
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These cholesterol rich chylomicrons are believed to be highly atherogenic (Packard and 
Shepherd 1990). Conversely, HDL becomes triglyceride rich. VLDL are secreted into 
the plasma by the liver in response to hormonal control of hepatic triglyceride synthesis, 
entering at the top of the delipidation cascade. They are sequentially delipidated first to 
IDL by LPL and then to LDL by hepatic lipase (HL). LDL are then cleared from the 
plasma by the LDL receptor, with binding mediated by apolipoprotein (apo) B on the 
particles surface.
The homoeostasis of triglyceride metabolism and the metabolism of lipoproteins 
between fasted and fed states is largely controlled by local factors such as lipid 
concentration, but also responds to more distant hormonal influences such as sex 
steroids and more importantly insulin.
Insulin is the major antilipolytic hormone (Coppack et al 1994) functioning, 
primarily in the postprandial state, to produce the following (Frayn 1993):
inhibition of HSL, thereby suppressing fatty acid release from adipocytes, 
decreasing hepatic VLDL production and
increasing LPL activity in adipose tissue, so clearing triglyceride from the 
circulation.
Primary hyperlipidaemias are genetically determined while secondary 
hyperlipidaemias such as those seen in diabetes and obesity, account for approximately 
40% of all hyperlipidaemias, with the lipid abnormalities being reversible on correction 
of the underlying condition. In insulin resistant states where the antilipolytic action of 
insulin is lost (Reaven 1988, Garg 1996, and Lewis and Steiner 1996) e.g. diabetes, 
obesity and coronary heart disease (CHD), increased hepatic triglyceride production and 
secretion of VLDL is observed, as a result of increased lipolysis in adipose tissue, and 
increased delivery of FFAs to the liver. Decreased clearance of TRL and low HDL 
levels result also from reduced LPL activity in these insulin resistant states (Howard 
1987, Bianchi and Erkelens 1994, Boden 1996). Thus the development of antilipolytic 
drugs, directed at selective inhibition of HSL and hereby improving insulin resistance 
and lowering fasting plasma triglyceride levels, are attractive targets.
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1.2 Epidemiology of triglyceride and CHD.
Large intra-individual variation in triglyceride, relatively imprecise 
measurements, individual genetic susceptibility and the inverse correlation with HDL- 
cholesterol all play a role in masking the relationship between plasma triglyceride levels 
and CHD (Lippel et al 1981, Austin 1991). In univariate analysis, fasting plasma 
triglyceride levels are associated significantly with the risk of coronary artery disease 
(CAD). However in multivariate analyses including other lipid parameters, this 
association is often not maintained, primarily because HDL cholesterol, by virtue of its 
strong inverse association with triglycerides eliminates triglyceride as a risk factor for 
CAD (Hulley et al 1980, Austin 1991). The large variability of triglyceride 
measurements and the correlation of triglyceride values with other lipid measurements 
appears to result in the underestimation of the association between triglyceride and 
disease in multivariate analyses.
A relationship between postprandial lipaemia and coronary heart disease (CHD) 
was originally suggested in the 1950's. A recent study (Patsch et al 1992) reaffirmed 
this idea. It provided evidence that the postprandial triglyceride concentration is an 
independent predictor of CAD, finding that postprandial but not fasting triglyceride 
levels exhibited an association with CAD that was statistically independent and stronger 
than that of HDL cholesterol.
As humans spend most of their lives in a postprandial state, in order to to look at 
the effects of postprandial lipaemia on the progression of CAD, research should include 
postprandial studies of TRL metabolism in addition to the study of traditional fasting 
state levels of plasma risk factors (Patsch et al 1992).
2 Lipids, lipoproteins and their metabolism.
2.1 Lipids (Feher and Richmond 1991).
Three unique lipid families are found in the human body: cholesterol and its 
esters, triglycerides and phospholipids (Fredrickson et al 1967). As a group they are 
water insoluble organic molecules characterised by the hydrocarbon nature of a major 
portion of their structure. Fatty acids (FA) are simple lipids classified into three groups 
according to the presence of double bonds in their hydrocarbon chain: saturated (no 
double bonds), monounsaturated (1 double bond) and polyunsaturated (2 or more double 
bonds). Fatty acids are an important energy source and an integral component of
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complex lipids. FFA are the form in which fatty acids are transported from their 
storage site in adipose tissue to their sites of utilisation in the liver and muscle. Fatty 
acids are stored in the adipose tissue as triglyceride. The rate limiting step in the 
mobilisation of this triglyceride is HSL. Lipolysis (via the action of HSL) releases FFA 
and glycerol into the plasma, where the FFA circulate bound to albumin (Spector 1975). 
Once in the plasma the FFA are taken up by liver and muscle and oxidised or re- 
esterified to triglyceride (figure 1.2).
Complex lipids are produced when fatty acids combine with molecules 
containing alcohol (-OH) groups to form esters. The major complex lipids in the plasma 
are cholesteryl esters and glyceryl esters (triglycerides and phospholipids).
2.1.1 Cholesteryl esters.
Cholesterol with its free alcohol group is relatively polar but becomes non-polar 
when esterified with fatty acids. The majority of plasma cholesterol (75%) is esterified 
with cholesteryl linoleate (43%) and cholesteryl oleate (24%) being the most abundant 
forms.
2.1.2 Glvcervl esters.
Triglycerides.
When all 3 hydroxyl groups of glycerol are esterified with fatty acids the 
molecule becomes non-polar and is called triacylglycerol (or triglyceride). Triglycerides 
(TG) are stored in adipose tissue and represent an energy source from which fatty acids 
can be released during periods of starvation.
Dietary triglycerides (exogenous) are lipolysed, absorped, and packaged into 
chylomicrons which transverse the intestinal lymphatics and enter the systemic 
circulation via the thoracic duct. Triglycerides derived from endogenous fatty acids also 
originate in the small intestine but their chief source is the liver where they are secreted 
in the form of VLDL.
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Phospholipids.
They differ from triglycerides in that the terminal hydroxyl group of glycerol is 
esterified to phosphate containing molecules rather than fatty acids. Possession of a 
polar phosphate ester head group together with a non-polar hydrocarbon tail, enables 
phospholipids to play an important structural role in cell membranes and lipoprotein 
complexes.
2.1.3 Cholesterol. (Grundy 1991)
Cholesterol is an insoluble lipid containing a steroid ring nucleus. Cholesterol is 
structurally different from the other major lipids of the body, triglycerides and 
phospholipids, both of which have fatty acids as their major constituent. Cholesterol 
has several vital functions in the body: it is an essential component of cell membranes, 
important for stability and transmembrane transport functions. It also plays an 
important role in the transport of triglyceride in the plasma by being an essential 
component of plasma lipoproteins. It is the precursor of bile acids (required for fat 
absorption), adrenal steroids and sex hormones (oestrogens and androgens). Cholesterol 
entering the intestine originates from either bile or the diet, with about 50% being 
reabsorbed and returning to the liver while the remainder is excreted in stool.
Lipids (triglyceride, cholesterol, cholesterol ester and phospholipids) being 
insoluble in aqueous solution are transported in plasma in association with specialised 
proteins, apolipoproteins, in spherical lipoprotein complexes.
2.2 Lipoproteins; structure and function.
The basic structure of lipoproteins consists of a core of neutral lipids, consisting 
of cholesterol ester and triglycerides and a surface coat of more polar lipids (unesterified 
cholesterol and phospholipids) and apolipoproteins (Grundy 1991) (figure 1.3).
Plasma lipoproteins are routinely fractionated by ultracentrifugation into 5 major 
groups: chylomicrons, VLDL, IDL, LDL and HDL (Alaupovic 1971) which can be 
differentiated according to size, density (table 1.1) and composition (table 1.2). The 
main cholesterol carrying lipoproteins are LDL and HDL. In a normal individual LDL 
and HDL contain approximately 70% and 20% respectively, (Thompson 1989) of the 
total plasma cholesterol. The main triglyceride carrying lipoproteins are chylomicrons
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and VLDL. Chylomicrons are not normally present in the blood after a 12 hour fast; in 
the fasting state VLDL accounts for 60% of the total plasma triglyceride.
Table 1.1: The density classes o f plasma lipoproteins (Thompson 1989).
Lipoprotein
class
S f  values 
or
F values*
Density
(g/ml)
Sources Mean
diameter
(nm)
Chylomicron >400 <0.95 Intestine 500
VLDL 2 0 -4 0 0 <1.006 Liver 43
IDL 1 2 -2 0 1.006- 1.019 VLDL delipidation 27
LDL 0 - 12 1.019- 1.063 VLDL delipidation 22
HDL 0 -9 * 1.063 - 1.21 Chylomicron and VLDL 
catabolism; intestine and 
liver
8
*Sf values are measured at a background solute density o f 1.063g/ml: F values at a 
density o f 1.21g/ml.
Table 1.2: Composition o f human plasma lipoproteins by weight (% o f total).
Constituent Chylomicron VLDL IDL LDL HDL
Protein 2 10 18 25 55
Triglyceride 85 50 26 10 4
Cholesterol 1 7 12 8 2
Cholesterol
ester
3 13 22 37 15
Phospholipid 9 20 22 20 24
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Table 1.3: Apoprotein distribution in human lipoprotein classes.
Chylomicrons VLDL IDL LDL HDL
B48 B100 B100 B100 AI
Cl cm B48* All
CII E E D
cm Cl Cl
E CII CII
AI AI E
All All
*Chylomicron remnants only.
2.2.1 Chylomicrons.
Chylomicrons (S f > 400) are triglyceride-rich lipoprotein (TRL) particles formed 
in the intestine during lipid absorption (Fredrickson et al 1967, Green & Glickman 
1981). They are heterogeneous with a size range from 100 - 1000 nm (Fraser 1970). 
Size is largely determined by the flux of triglyceride through the intestinal cell. 
Chylomicrons are small at the beginning and larger during the peak of lipid absorption. 
The major lipid is triglyceride, reflecting the role of chylomicrons in lipid absorption 
r (Zilversmit 1965, Fredrickson et al 1967) (table 1.2). Several apolipoproteins are found
in the surface coat (figure 1.4, table 1.3). The major structural apolipoprotein of 
chylomicrons is apoB48 (chylomicrons are referred to as apoB48 containing particles). 
Apolipoproteins of the A series (Al, All, AIV) are also secreted on chylomicrons. As 
chylomicrons leave the thoracic duct and enter into the plasma they undergo rapid 
structural changes essential for subsequent metabolism, acquiring apoC and E primarily 
by transfer from HDL (Patsch et al 1987). Chylomicrons are the form in which most of 
the dietary triglyceride is transported from its intestinal site of absorption into the 
systemic circulation. Peak chylomicronaemia normally occurs between 3 - 6  hours after 
ingestion of a fat rich meal and then generally declines with a return to near fasting 
levels at 8 hours post ingestion.
ApoCII, as a cofactor, (Eckel 1989, Goldberg et al 1990) activates LPL. The 
major sites of LPL activity in human subjects are adipose tissue and skeletal muscle, 
which are also the most important determinants for the removal rate of triglyceride-rich 
particles. LPL does not circulate freely in plasma but is attached to the surface of cells
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where its action occurs (Taskinen and Kuusi 1987). LPL hydrolyses the triglyceride 
core of the chylomicron and liberates FFA and glycerol for utilisation by these tissues. 
As chylomicron delipidation proceeds much of the surface coat becomes redundant, 
with loss of part of the surface coat to HDL. The particle shrinks to a so-called 
'remnant' while selectively retaining all of its apoB and the majority of the apoE. The 
LDL receptor binding site is absent from apoB48 but apoE is able to recognise and bind 
specific receptors on hepatocyte membranes, triggering remnant uptake and delivery of 
dietary cholesterol to the liver (Mahley et al 1981, Sherrill 1980) (figure 1.5).
2.2.2 Very low density lipoprotein (VLDL).
In the fasting state, VLDL is the main carrier of triglyceride (Sata, Havel and 
Jones 1972). In contrast to the pattern of intermittent chylomicron production by the 
intestine, VLDL secretion by the liver is continuous. Both particle types share many 
metabolic characteristics. VLDL (Sf 60 - 400) has a size range from 25 - 100 nm 
(Thompson 1989). The major structural apolipoprotein is apoBlOO (hence they are 
referred to as apoBlOO containing lipoproteins) (figure 1.6, table 1.3), but apoC & E 
are also present, acquired as for chylomicrons, primarily by transfer from HDL. VLDL 
are similar to chylomicrons, in that they are TRL but they have two important 
differences. Firstly, the triglyceride transported by VLDL is of endogenous origin 
(Havel 1961), and secondly, the major apolipoprotein is apoBlOO rather than apoB48. 
The major lipid component of the non-polar core of VLDL is triglyceride but cholesterol 
ester is also present (Sata et al 1972). The surface coat contains unesterified cholesterol 
and phospholipids. Hepatic VLDL production is primarily substrate driven, the most 
important regulatory substrate being fatty acids (Lewis 1997). Fatty acids can be 
derived from either de novo synthesis in the liver, cytoplasmic triglyceride stores, fatty 
acids derived from lipoproteins taken up directly by the liver, or from exogenous fatty 
acids (plasma free fatty acids) (figure 1. 1).
VLDL is composed of a heterogeneous population of particles (Streja, Kallai and 
Steiner 1977) which can be usefully divided into 2 major subfractions with distinct 
metabolic properties i.e. larger, triglyceride-rich VLDLj (Sf 60 - 400) and a smaller 
relatively cholesterol-enriched VLDL2 (Sf 20 - 60) (Shepherd & Packard 1987). Both 
VLDLj and VLDL2 can be synthesised directly by the liver and, in addition, VLDL2 
are formed by the delipidation of VLDL^. It appears that smaller VLDL2 particles 
continue through the lipolytic cascade to IDL, while large VLDLj remnants are more 
likely to be cleared directly from the circulation (Packard et al 1984). Following 
hepatic synthesis the VLDL are released into the systemic circulation where they acquire
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apoC and E before undergoing a stepwise delipidation by LPL (in a similar manner to 
chylomicrons). As the triglyceride core is hydrolysed, the particle becomes smaller 
forming a remnant particle or IDL. This is then delipidated further to LDL by hepatic 
lipase or cleared by the LDL receptor (figure 1.7).
2.2.3 Intermediate density lipoprotein (IDL).
Intermediate density lipoproteins (IDL) are formed in an intermediate step in the 
conversion of VLDL to LDL. The plasma concentration of IDL is usually low (one 
tenth that of LDL) due to the rapid turnover rate of these particles. IDL are smaller, 
denser (1.006 - 1.019g/ml) and more cholesteryl ester enriched than VLDL with the 
main protein component being apoBlOO (table 1.3). As with VLDL, IDL can be further 
divided into several subfractions (Musliner, Giotas and Krauss 1986).
2.2.4 Low density lipoprotein (LDL).
Low density lipoprotein (LDL) is the major cholesterol carrying lipoprotein of 
normal plasma. LDL consists of a lipid core composed almost entirely of cholesteryl 
esters, and is formed by the delipidation of IDL. The only protein is apoBlOO (table 
1.3). LDL is cleared from the plasma by receptor uptake and by non-receptor 
pathways. LDL can be fractionated into several subfractions varying in size, density 
and composition (Shen et al 1981, Krauss & Burke 1982) with small, dense LDL being 
particularly atherogenic.
2.2.5 High density lipoprotein (HDL) (Thompson 1989).
High density lipoproteins (HDL) are the most abundant lipoproteins in particle 
number, in the plasma, isolated at a density of 1.063 - 1.21g/ml. HDL is subdivided 
into HDL2 (1.063 - 1.125g/ml) and HDL3 (1.125 - 1.21g/ml). They are synthesised in 
both the liver and small intestine. Over 90% of the protein on HDL is apoAI, and 
apoAII (table 1.3). The surface coat of HDL also contains apoC's and E which can be 
readily transferred to TRLs (chylomicrons and VLDL). HDL acts as a reservoir for apo 
C derived from chylomicrons and VLDL during lipolysis (Patsch et al 1987), the apoC 
being picked up by chylomicrons entering the blood via the thoracic duct during 
alimentary lipaemia.
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2.2.6 Lipoprotein (a).
Lipoprotein (a), (Lp(a)), is a relatively recently discovered lipoprotein whose 
physiological function is unclear. It is linked not only to coronary artery disease but 
also to stenosis of the carotid and cerebral arteries. Lp(a) has both atherogenic and 
thrombogenic potential (interference in several reactions involving plasminogen due to 
its lysine binding capability). Lp(a) is structurally related to LDL; both have 1 molecule 
of apoBlOO per particle and similar lipid compositions. The distinctive feature of Lp(a) 
is that it contains a second polypeptide chain, disulphide linked to apoBlOO and referred 
to as apolipoprotein (a). Lp(a) particles are spherical in shape, with an average diameter 
of 21 nm and a density pattern consistent with a low density core surrounded by a high 
density shell. Apo(a) is synthesised by the liver and has a high degree of sequence 
homology with plasminogen. It is a highly glycosylated, hydrophilic protein, composed 
of a kringle-containing domain and a serine protease domain, that has very little affinity 
for lipids. Lp(a) is recognised by the LDL receptor, although its affinity is considerably 
lower than that of LDL (Marcovina & Morrisett 1995). As a consequence, little, if any, 
is metabolised by the LDL receptor in vivo.
2.3 Apolipoproteins.
Alaupovic (1971) was responsible for the classification and introduction of the 
alphabetical nomenclature that is now widely used for apolipoproteins. Lipoproteins 
cannot be synthesised and secreted from the liver or intestine without the corresponding 
structural apolipoprotein. In addition to their structural role in lipoprotein metabolism, 
apolipoproteins play a dynamic role as enzyme activators and receptor ligands. The 
apolipoproteins serve several important functions (Thompson 1989, Grundy 1991, 
Mahley et al 1984). They are required for secretion of lipoproteins, stabilisation of the 
surface coat and hence maintain the structure of the whole lipoprotein transport system 
(table 1.4). They also serve as cofactors for activation of enzymes that modify 
lipoproteins (table 1.5) and finally they interact with specific cell-surface receptors that 
remove lipoproteins from the circulation thus determining the sites of uptake and rates 
of degradation (apoBlOO and E mediate interactions of lipoproteins with receptors). 
There are 4 major classes of apolipoproteins A, B, C and E (table 1.6).
Table 1.4: The structural apolipoproteins (Grundy 1991).
Apolipoprotein Lipoprotein Source
AI HDL Liver, Intestine
B100 VLDL, IDL, LDL Liver
B48 Chylomicrons Intestine
Table 1.5: Apolipoproteins involved in enzyme activation.
Apolipoprotein Lipoprotein Enzyme
AI HDL3, nascent HDL Lecithin cholesterol 
acyl-transferase (LCAT)
cn Chylomicrons, VLDL Lipoprotein lipase
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Table 1.6: Human apolipoprotein classification.
Apolipoprotein Molecular
weight
(kDa)
Lipoprotein
association
Source Plasma
concentration
(mg/dl)
B48 264 Chylomicrons Intestine -
B100 550 VLDL, IDL, 
LDL
Liver 80 - 100
AI 28 HDL,
Chylomicrons
Intestine,
Liver
100 - 150
AH 17 HDL,
Chylomicrons
Intestine,
Liver
3 0 -4 0
AIV 46 HDL,
Chylomicrons
Intestine 15
Cl 5.8 Chylomicrons, 
VLDL, IDL, 
HDL
Liver 6
c n 9.1 Chylomicrons, 
VLDL, IDL, 
HDL
Liver 4
c m 8.7 Chylomicrons, 
VLDL, IDL, 
HDL
Liver 12
E's 35 Chylomicrons, 
VLDL, IDL, 
HDL
Liver,
Peripheral
tissues
3 - 7
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2.3.1 Apolipoprotein A.
The A apolipoproteins consist of 3 main proteins; apoAI, All and AIV (table 
1.6). ApoAI circulates in the plasma primarily as a component of HDL but it is also 
present on chylomicrons (being rapidly transferred to HDL during lipase-mediated 
hydrolysis of chylomicrons). The protein has two major sites of synthesis; the intestine 
and the liver. Since apoAI binds lipid and is the major protein constituent of HDL it is 
clear that it must be an important structural component of lipoproteins. Its other major 
function is to serve as a cofactor for lecithin cholesterol acyl-transferase (LCAT). 
ApoAII occurs primarily as the second most abundant protein component of HDL. It is 
a dimer with its major site of synthesis being the liver. It activates LCAT and appears 
to enhance the lipid binding properties of apoAI. ApoAIV is present on newly secreted 
chylomicrons, although the majority of apoAIV is found free in the plasma.
2.3.2 Apolipoprotein B.
Apolipoprotein B is the primary apolipoprotein of chylomicrons, VLDL, IDL, 
and LDL. It is heterogeneous and exists in 2 forms; apoB48 and apoBlOO (table 1.6). 
ApoBlOO is synthesised by the liver and is found on VLDL, IDL and LDL. ApoBlOO 
is the protein determinant on LDL that recognises the LDL (apoB/ E) receptor. ApoB48 
is synthesised by the intestine and secreted on chylomicrons. It is identical to the amino 
terminal 48% of apoBlOO (hence the nomenclature), being formed by post-translational 
modification of apoBlOO mRNA (Scott 1990). The metabolism of apoB48 and apoBlOO 
is different. In man apoBlOO is produced by the liver (Edge et al 1985), secreted on a 
nascent particle of VLDL and transferred with the particle to IDL and finally LDL. 
ApoB48 is produced by the intestine and secreted on a chylomicron particle. The 
triglyceride in chylomicrons is partially hydrolysed and the resulting remnants are taken 
up by the liver. In the rat, apoB48 and apoBlOO are both synthesised in the liver with 
apoB48 found on both chylomicrons and VLDL.
2.3.3 Apolipoprotein C.
The C apolipoproteins are 3 low molecular weight apolipoproteins; Cl, CII and 
CIII (table 1.6) that are surface components of chylomicrons, VLDL and HDL. The C 
apolipoproteins appear to be diverse in their metabolic functions but they share a 
common property of redistributing among lipoprotein classes (like apoE and apoAI, II 
and IV). The liver appears to be the major site of apoC protein synthesis. In the fasting 
state C apolipoproteins are mainly associated with HDL. During absorption of dietary
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fat by the intestine and chylomicron production or during active VLDL synthesis by the 
liver, the C apolipoproteins redistribute to the surface of the triglyceride-rich 
chylomicrons and VLDL. In reverse, as the triglyceride core of chylomicrons and 
VLDL is hydrolysed and depleted by the action of LPL, C apolipoproteins are 
transferred back to HDL (Patsch et al 1987). ApoCI is the smallest of the three and 
acts as an activator of LCAT. ApoCII is a cofactor of LPL (Goldberg et al 1990, Eckel 
1989), while apoCIII has an inhibitory effect on the hydrolysis and clearance of 
chylomicrons and VLDL (Thompson 1989). CIII exists in 3 forms CIIIq, CIIIi and 
CIII2 depending on the number of sialic acid residues that are present.
2.3.4 Apolipoprotein E.
Apolipoprotein E is a constituent of chylomicrons, chylomicron remnants, 
VLDL and HDL (table 1.6). Its major site of synthesis is the liver. ApoE functions as 
a ligand for the hepatic uptake of chylomicron remnants and VLDL. Isoelectric 
focussing reveals three common apoE isoforms; E2, E3, and E4 (Davignon, Gregg and 
Sing 1988). The 3 isoforms differ by an amino acid residue at one or both sites 
(residues 112 and 158) on the 299 amino acid chain of the mature apoE molecule.
The six common phenotypes revealed by isoelectric focussing, are homozygotes 
for E4/4, E3/3 and E2/2, the most common phenotype in the human population being 
E3/3 (present in approximately 60% of the population) and heterozygotes for E4/3, 
E4/2, E3/2. The different isoforms have varying effects on plasma lipoprotein 
metabolism, in particular on the metabolism of LDL precursors.
2.4 Enzymes involved in lipoprotein metabolism.
Lipoprotein metabolism is regulated by various enzymes.
2.4.1 Lipoprotein lipase.
Lipoprotein lipase (LPL), an extracellular lipase (Olivecrona et al 1993), 
functions to hydrolyse triglycerides in TRLs (both chylomicrons and VLDL) (Eckel 
1989, Goldberg 1996) circulating in the blood and requires apoCII as a cofactor 
(Goldberg et al 1990). Fatty acids can thus be released from either dietary or 
endogenous lipoproteins and delivered to adipose tissue for storage or to skeletal muscle 
and the liver for their metabolic requirements (figure 1.2). The dominant tissues in LPL 
production are the muscle and adipose tissues, where it is attached by heparan sulphate
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proteoglycans to the endothelial lining of the capillaries perfusing these tissues. LPL 
(Nilsson-Ehle, Tornquist & Belfrage 1972) is of prime importance for the regulation of 
fat deposition in adipose tissue. Its activity (Braun & Severson 1992) can be altered in a 
tissue specific manner, which is important because it directs fatty acid utilisation 
according to the metabolic demand of the individual tissues i.e. the degradation of TRL 
can be targeted to specific sites. Multiple factors seem to be involved in the regulation 
of LPL activity. LPL is bound to the endothelial surface where it acts, and its binding 
appears to be weakened by the fatty acids released by the enzymatic hydrolysis of 
triglyceride (Saxena, Witte and Goldberg 1989, Olivecrona et al 1993, Coniglio 1994), 
thus feedback control of LPL by released fatty acids may be one factor involved in LPL 
regulation.
On fasting and feeding (Doolittle et al 1990), LPL activity alters in adipose 
tissue compared to muscle and heart tissue. In the latter state, LPL activity increases in 
adipose tissue compared to heart and muscle, resulting in a channelling of circulating 
triglyceride-fatty acids into lipid depots. However during fasting the inverse is true. 
Thus the co-ordinated regulation (Sugden, Holness and Howard 1993) of LPL in 
adipose tissue and muscle during fasting and feeding is critical for maintaining 
triglyceride levels. LPL is bound to the vascular endothelial cell surface via attachment 
to heparan sulphate proteoglycans (Goldberg et al 1990) which provide high affinity 
binding sites on the endothelium for LPL (Cisar et al 1989). LPL is thought to mediate 
binding of lipoproteins (Eisenberg et al 1992) to the heparan sulphate proteoglycans on 
the cell surface. This interaction brings the lipoproteins into close proximity with the 
cell surfaces and may promote metabolic events that occur at the cell surface. LPL can 
be released from the endothelial cell surface and removed from the circulation (Saxena 
et al 1989) as part of an LPL remnant particle complex (Vilella et al 1993). Active LPL 
is a non-covalent homodimer (Vilella et al 1993) which, when converted to the 
monomeric form, loses its catalytic activity. Once bound to the endothelial cells, LPL 
activity must be modulated by cellular uptake or release of LPL protein from the cell 
surface into the circulation (Cisar et al 1989).
Studies (Olivecrona et al 1993) suggested that adipocytes contain inactive forms 
of LPL which can be recruited and released into the medium as active LPL by 
incubating cells with appropriate signals e.g. insulin, under conditions such that 
synthesis of the new enzyme molecules was blocked, concluding that insulin increases 
LPL active secretion. It appears that newly synthesised LPL is either released rapidly or 
degraded within the cells. The release of LPL from the cell surface of the adipocytes 
(Cisar et al 1989) prevents its degradation. Binding of LPL to the cell surface can be
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eliminated by two treatments either addition of heparin or removal of heparan-sulphate 
with endoglycosidases, both treatments preventing LPL degradation. Cells appear to 
produce LPL in excess so that the tissue is able to respond quickly to meals and during 
food deprivation most of the newly synthesised LPL is degraded. LPL activity may also 
be regulated post-translationally (Ashby et al 1978) and these mechanisms appear to be 
involved in the acute changes of LPL activity in adipose tissue. Activation of LPL is 
an intracellular event. It seems enzyme activity can be either protein synthesis 
dependent (synthesis of LPL, control at a pre-translational mRNA level) or protein 
synthesis independent (post-translational).
2.4.2 Hormone-sensitive lipase.
Hormone-sensitive lipase (HSL) catalyses the mobilisation of fatty acids from 
adipose tissue (Fredrickson et al 1981, Yeaman 1990, Frayn et al 1993 and Yeaman et 
al 1994), thereby generating substrate for hepatic VLDL-triacylglycerol synthesis (Lewis 
1997). HSL catalyses the rate limiting step in the breakdown of triglyceride and its 
activity is regulated in the short term via reversible phosphorylation, involving a signal 
transduction pathway. HSL is phosphorylated and activated in response to a variety of 
lipolytic hormones (Yeaman 1990) with insulin (Egan et al 1990) exerting a major 
antilipolytic action. HSL activity is under both neural and hormonal control and 
stimulatory or inhibitory agents exert their effects via the adenylate cyclase-A-kinase 
signal transduction pathway (figure 1.8). After fasting (prolonged) HSL activity in 
adipose tissue increases (Sztalryd and Kraemer 1994 a).
The stimulatory/ inhibitory compounds bind to receptors on the adipocyte cell 
membrane. These receptors are coupled to either stimulatory (Gs) or inhibitory (Gj) G 
proteins which in turn activate/ inhibit adenylate cyclase. Adenylate cyclase activation 
is reflected in intracellular levels of cyclic adenosine monophosphate (cAMP), the 
second messenger which activates cAMP protein dependant kinase A (Stralfors and 
Belfrage 1983) which in turn catalyses the phosphorylation and resulting activation of 
HSL at the regulatory site (serine 563). HSL phosphorylation is paralleled by an 
enhanced triglyceride lipase activity (Fredrickson et al 1981), while the antilipolytic 
effect of insulin (Yeaman 1990) involves the dephosphorylation of HSL. Two serine 
residues are phosphorylated on HSL, cAMP-dependent protein kinase acts at the 
regulatory site (serine 563) of HSL. The basal site (serine 565) has no apparent direct 
effect on the enzyme activity but inhibits subsequent phosphorylation of the 'regulatory 
site'. The basal site is phosphorylated by adenosine monophosphate (5'AMP) activated 
protein kinase (Garton and Yeaman 1990, Hardie 1992) under basal conditions of
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lipolysis (Okuda, Morimoto and Tsujita 1994). These two phosphorylations on the 
regulatory (serine 563) and basal (serine 565) sites are mutually exclusive (Garton et al 
1989) meaning that phosphorylation by AMP kinase on the basal site would prevent 
further phosphorylation on the regulatory site and HSL activation.
The dephosphorylation and inactivation of HSL in adipocytes in response to 
insulin has been proposed to involve the action of protein phosphatases (Wood et al 
1993) upon HSL. Protein phosphatases (PP2A and 2C) were the only protein 
phosphatases to display activity towards HSL phosphorylated at the regulatory site. 
PP1, PP2A and PP2C were detected within rat adipocytes at significant levels.
Rat HSL preferentially releases polyunsaturated FA from triglyceride (Gavino 
and Gavino 1992). Rat HSL structure (Fredrickson et al 1981, Smith et al 1993) has 
been elucidated (Gabriele et al 1993). It is an 84 kDa polypeptide of 768 amino acids, 
with an active site at serine 423.
2.4.3 Hepatic lipase.
Hepatic lipase (HL) is involved in the catabolism of chylomicron and VLDL 
remnants (IDL). Hepatic lipase hydrolyses triglyceride and phospholipids in HDL2 and 
in doing so mediates the conversion of HDL2 to HDL3. Additionally, hepatic lipase 
delipidates IDL to form LDL and is thought to be involved in the interconversion of 
LDL subclasses. Hepatic lipase mRNA is detected in the liver only. Unlike LPL, this 
enzyme does not require a cofactor.
2.4.4 3-hvdroxv-3-methvl glutarvl coenzvme A reductase (HMG Co A-
reductase) (Feher and Richmond 1991).
Most of the cholesterol present in tissues is either absorbed from the diet or 
generated by de novo synthesis which occurs in many tissues. Cholesterol is derived 
from acetate, with the rate limiting step in the sequence catalysed by HMG CoA- 
reductase; this enzyme is suppressed by cholesterol, the end product, via feedback 
inhibition.
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2.4.5 Lecithin cholesterol acvl-transferase (LCAT). (Glomset & Verdery 1977)
LCAT is synthesised in the liver and circulates in plasma. The enzyme requires 
apoAI as cofactor, and esterifies free cholesterol acquired by HDL2 and HDL3 particles 
by transfer of a fatty acid from lecithin. The esterified cholesterol is transferred to the 
core of the particle, forming mature, cholesteryl ester rich HDL2.
2.4.6 Cholesterol ester transfer protein (CETP).
CETP transfers a proportion of cholesteryl esters from mature HDL2 to TRL 
particles. Triglyceride is transferred by the same protein simultaneously in the reverse 
direction to modify HDL2. Both CETP and LCAT are involved in reverse cholesterol 
transport.
2.5 Receptors (Feher and Richmond 1991).
2.5.1 The LDL (apoB/ E) receptor.
The LDL receptor recognises as ligands both apoBlOO and apoE, and will thus 
bind LDL and VLDL remnants (IDL). The role of the LDL receptor is to provide 
cholesterol to cells throughout the body and to deliver excess cholesterol to the liver for 
recycling or excretion as bile acids. Receptors are synthesised in response to a fall in 
cellular free cholesterol concentration.
2.5.2 The LDL receptor-related protein (LRP).
LRP in its function as a lipoprotein receptor, appears to bind mainly chylomicron 
remnants and 15-VLDL, through apoE and lipases; LPL and HL, which mediate binding 
of chylomicrons to LRP. The liver expresses high levels of LRP; appropriate for the 
main site of chylomicron remnant catabolism (Beisiegel 1995). Expression of LRP in 
other tissues might indicate an additional non-hepatic removal of TRLs. LRP in 
macrophages and smooth muscle cells might be important in the clearance of 
lipoproteins in the arterial wall, thus contributing to the development of atherosclerotic 
plaques (Lupu et al 1994).
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2.5.3 The VLDL receptor (Beisie2el 1995).
The VLDL receptor is most abundant in muscle and adipose tissue, suggesting 
that it may be involved in delivering endogenous triglycerides carried in VLDL or IDL 
from the liver to sites of fatty acid metabolism. As a result the VLDL receptor might 
play a major role in VLDL catabolism.
3 Postprandial lipoprotein metabolism in normal subjects.
Plasma triglyceride is gaining increased recognition as a risk factor for CHD, 
although the mechanisms underlying this association have not been settled (Austin 1991). 
Lipid and lipoprotein studies have traditionally been confined to the post-absorptive 
(overnight fasting) state, but interest in analysing lipoproteins in the postprandial state 
has increased since it has been demonstrated that triglycerides in the postprandial state 
can serve as an independent predictor/ risk factor for CHD (Patsch et al 1983, Patsch et 
al 1992). It was Zilversmit (1979) who first hypothesised that postprandial lipoproteins 
(chylomicrons and their remnants) (Zilversmit 1995) were important in atherogenesis in 
humans. Both chylomicron and VLDL levels have been shown to increase after a fat 
intake (Cohn et al 1988 b, Karpe et al 1993 and Schneeman et al 1993). The increment 
in TRL particle number is mainly accounted for by VLDL (Schneeman et al 1993), 
whereas 80% of postprandial triglyceride is carried by lipoprotein particles containing 
apoB48 (chylomicrons).
Karpe and Hultin (1995) reaffirmed in rats that accumulation of endogenous 
VLDL in the plasma was due to competition (for a common lipolytic pathway) between 
chylomicrons and VLDL (Brunzell et al 1973), and not due to increased synthesis of 
VLDL. As a result of delayed clearance of VLDL, the presence of chylomicrons and 
their remnants may lead to increased risk of atherogenesis. When considering the direct 
atherogenic potential of TRLs the question as to whether they can enter the artery wall is 
of importance, with lipoprotein size an important determinant of arterial wall flux. Rapp 
et al (1994) showed that VLDL and remnants can indeed cross the endothelial wall, but 
these apoB containing lipoproteins differed in size from plasma lipoproteins. Thus the 
postprandial state has been postulated to be atherogenic on the basis that intestinal 
chylomicrons and their remnants have the potential to cause lipid deposition in the cells 
of the artery wall (Zilversmit 1979). There is evidence that apoE is involved in the 
metabolism of TRLs. It is a key protein in the modulation of the metabolism of the 
highly atherogenic apoB containing lipoproteins. The findings of Brown and Roberts 
(1991) suggested that controlling for apoE phenotype may help to decrease inter­
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individual variation in the postprandial response to a fat meal. Possible genetic variation 
in apoE could be a major component in the accumulation of chylomicron and VLDL 
remnants related to triglyceride metabolism and is associated with increased risk of 
atherosclerosis (Davignon et al 1988).
4 Diabetes mellitus and triglyceride metabolism.
The current classification and diagnosis of diabetes was developed by the 
National Diabetes Data Group (NDDG) and published in 1979, which recognised 2 
major forms of diabetes, termed insulin-dependent (IDDM) and non-insulin-dependent 
diabetes mellitus (NIDDM), now termed type 1 and type 2 diabetes respectively. It is 
considered to be important to move away from a system that appears to base its 
classification of the disease, in large part, on the type of pharmacological treatment used 
in its management toward a system based on the disease etiology where possible. The 
vast majority of cases of diabetes fall into 2 broad categories. In one category (type 1 
diabetes), the cause is an absolute deficiency of insulin secretion resulting from a 
cellular-mediated autoimmune destruction of the 15-cells of the pancreas. In the other, 
(type 2 diabetes), the cause is a combination of resistance to insulin action and an 
inadequate compensatory insulin secretory response (relative insulin deficiency). The 
current expert committee (1997) have now proposed changes and modifications to the 
NDDG diagnosis and classification scheme (Report Committee 1997). The revised 
criteria for the diagnosis of diabetes mellitus are a casual plasma glucose (PG) (casual is 
defined as any time of the day without regard to time from last meal) concentration > 
200 mg/dl (11.1 mmol/L, or a fasting (fasting defined as no calorie intake for 8 hours) 
PG _> 126 mg/dl (7.0 mmol/L) or a 2 hour PG _>_200mg/dl during an OGTT (oral 
glucose tolerance test). This new criteria would not alter the status of the diabetic 
patients recruited here (appendix 35).
4.1 Insulin resistance.
Insulin is the major antilipolytic hormone (Coppack et al 1994) functioning 
primarily in the postprandial state. The normal effects of insulin on lipid metabolism 
are (Frayn 1993): inactivation of HSL resulting in suppression of NEFA release from 
adipose tissue, suppression of hepatic VLDL triglyceride secretion and activation of 
LPL in adipose tissue to clear triglyceride from the circulation.
In states of insulin resistance (NIDDM, obesity), described by Reaven (1988) 
subjects have impaired glucose tolerance and the antilipolytic effects of insulin are
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diminished, with excess circulating fatty acids released from adipose tissue resulting in 
increased hepatic triglyceride-rich VLDL synthesis and with reduced LPL activity 
impeding the removal of triglyceride from the circulation. Insulin is overproduced by 
the pancreas to try to compensate for the insulin resistance.
4.2 Non insulin dependent diabetes mellitus (NIDDM) (Type 2 diabetes).
Individuals with NIDDM are insulin resistant and often have high concentrations 
of insulin, both fasting and postprandially. FFA are also elevated in these individuals, 
although it is not certain if this is as a result of their insulin resistance or a cause of it 
(Boden 1996). Individuals with NIDDM are not dependent on insulin therapy, allowing 
it to be possible to study lipoprotein metabolism in NIDDM in the absence of hormone 
therapy.
4.3 Lipid and lipoprotein abnormalities in Type 2 diabetes (NIDDM).
The basic dyslipidaemia that accompanies diabetes was described several years 
ago (Howard 1987). Recent work has focussed on abnormalities in lipoprotein 
alterations, composition and apolipoprotein content and the metabolic mechanisms that 
govern these changes. In states of insulin resistance (NIDDM); first described by 
Reaven (1988) the antilipolytic effects of insulin are diminished (Frayn 1993). Indeed 
the most common abnormality of lipid metabolism in patients with diabetes is 
hypertriglyceridaemia with an elevation in VLDL (Laws 1996), accompanied by a 
decrease in HDL cholesterol concentrations. Abnormalities in both production and 
clearance of VLDL triglyceride have been reported in NIDDM. Several studies 
(Abrams, Ginsberg and Grundy 1982, Kissebah et al 1982, Reaven 1987) have reported 
an over-production of VLDL triglyceride. Defective clearance of VLDL triglyceride, 
with decreased fractional catabolic rates for triglyceride is seen in more severe 
hypertriglyceridaemia (Abrams et al 1982, Kissebah et al 1982, Howard et al 1983, 
Taskinen et al 1986). Kissebah (1982) also found that the hypertriglyceridaemic 
diabetics had elevated rates of VLDL apoB production but there also appeared to be 
changes in the composition of VLDL (Schonfeld et al 1974 a, Taskinen et al 1986), 
suggesting that diabetics had larger, triglyceride-rich VLDL, as indicated by a higher 
triglyceride: apoB ratio which reverts to normal on sulphonylurea therapy. The driving 
force for the increased synthesis of VLDL particles seems to be an increased substrate 
flux of FFA (Bjomtop 1994).
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The magnitude of postprandial lipaemia is known to be highly dependent on the 
fasting plasma triglyceride concentration (Patsch 1987); since NIDDM patients 
generally have a higher fasting plasma triglyceride, a disturbed postprandial triglyceride 
metabolism would be expected.
5 The Zucker (fa/fa) rat.
Humans and rats share similar triglyceride metabolism pathways. Both produce 
apoB48 containing chylomicrons from the intestine and liver synthesised VLDL. 
Human livers only make apoBlOO containing VLDL particles. However, the rat liver, 
unlike the human liver, secretes apoB48 VLDL containing particles. Rats also have 
decreased levels of CETP, resulting in increased HDL levels. These differences limit 
the amount of extrapolation that is possible between rat experimental work and humans. 
However, as yet there appear to be no substantive differences in FFA metabolism 
between humans and rats that would invalidate the use of the rat model for the studies 
described here.
The two strains of rat used in the current work were the Alderley Park and 
Zucker rat. The Alderley Park rat is Wistar-derived and is considered to have a normal 
genetic make up. Some studies have shown the genetically obese Zucker (fa/fa) rat to 
have increased levels of leptin due to a defect in the leptin receptor (Zimanyi IA, Fathi 
Z, Parker E 1997).
The Zucker rat inherits obesity as an autosomal Mendelian recessive trait (Bray 
1977). This characteristic autosomal recessive obesity is linked to an allele termed fa  
which has been mapped to chromosome 5. The Zucker rat is homozygous for this trait, 
and cannot be distinguished from normal animals until the 3rd or 4th week of life. By 5 
weeks of age, there are visible differences in body fat content and shape (Zucker 1965). 
The genetically obese Zucker rats (fa/fa) were first described by Zucker and Zucker in 
1961 and are frequently used as models of early onset human obesity and NIDDM. An 
increase in plasma triglyceride and lipoproteins is one of the earliest abnormalities 
described in the Zucker rat (Barry and Bray 1969). The model displays
hyperinsulinaemia and hyperlipidaemia; in contrast blood glucose levels are normal. 
Livers from these mutants are characterised by an increased glycolytic flux, abnormally 
high fatty acid synthesis and esterification, triglyceride accumulation and an excessive 
output of VLDL. It has been suggested that the hypertriglyceridaemia which 
characterises these animals is due to hypersecretion of hepatic VLDL (Schonfeld, Felski 
and Howald 1974b, Wang, Fukuda and Oruko 1984) without any defect in clearance
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(Bray 1977)] plasma levels of all lipids were elevated including LDL, HDL and FFA. 
Attempts to alter plasma lipids in Zucker rats have produced variable results, as 
summarised by Cleary et al (1987) and Fukuda, Azain and Ontto (1982) who have 
suggested that the altered hepatic metabolism of FFA in this strain of rat was an 
underlying factor in the hypersecretion of VLDL. Adipocytes appear to be increased in 
size (Johnson et al 1971) and number, with the subcutaneous fat depot showing the 
largest increase in the number of fat cells. Both in vitro and in vivo studies are 
consistent with the conclusion that Zucker rats mobilise fat at an above normal rate with 
a greater output of FA from the adipose tissue and in terms of cellularity of the tissue 
there is also increased fat mobilisation per cell (Zucker 1972). The increased flux in 
FFA may come from the adipose tissue since these rats are hyperinsulinaemic; i.e. HSL 
activity in the adipose tissue may be elevated. Bray, Mothon and Cohen (1970) showed 
that mobilisation of FFA from adipose tissue was normal or increased both in vivo and 
in vitro in Zucker rats. In a recent study (Kasim et al 1992) it was shown that in the 
Zucker rat model, HMG CoA-reductase inhibitors can reduce the rate of secretion of 
VLDL. The disturbed metabolism displayed by the Zucker rat may provide useful 
information on the mechanism of action of hypolipidaemic drugs, in particular on FFA 
metabolism.
6 Aims and objectives.
The aim of this thesis was to better understand the role of the regulation of 
triglyceride metabolism in both man and rat models. Triglyceride metabolism is 
controlled by two enzymes, LPL and HSL whose activity is regulated by insulin. Most 
of the research concentrated on two questions; the first to study the effect of 
postprandial chylomicronaemia on the metabolism of VLDL subfractions in both normal 
and diabetic patient groups, the second to investigate the antilipolytic mechanisms of 
action of selected agents on HSL.
(1) In human subjects, the study of triglyceride metabolism focussed upon 
postprandial metabolism, more specifically the effect of postprandial chylomicronaemia 
upon the metabolism of VLDL subfractions (large VLDL, (VLDLj) and small VLDL, 
(VLDL2)). This was to be investigated in both normal and diabetic (NIDDM) subjects. 
NIDDMs are insulin resistant, and as such have elevated triglyceride levels due to 
increased VLDL levels, so it would be of interest to observe the reaction of this system 
when it was challenged with chylomicrons (a naturally occurring postprandial 
phenomenon). In order to do this, a method to separate chylomicrons and VLDL had to 
be developed. Chylomicrons and VLDL share many structural similarities, size and
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density, making their separation by sequential ultracentrifugation, particularly in the 
postprandial state, difficult. Thus an immunoaffinity chromatography method for the 
separation of chylomicrons and VLDL on the basis of their differing apoB proteins had 
to be developed (see chapter III).
(2) HSL is the rate limiting enzyme in adipocyte lipolysis. In normal individuals 
insulin exerts an antilipolytic effect on HSL, which is lost in insulin resistant disease 
states. As a result, subjects have increased triglyceride levels due to increased VLDL 
synthesis and secretion which is driven by increased levels of FFA the product of HSL 
lipolysis. This makes HSL an attractive target for drugs to help treat this and other 
conditions characterised by insulin resistance. Abnormally high rates of adipocyte 
lipolysis are thought not only to result in elevated plasma lipid levels linked to an 
increased risk of atherosclerosis and the development of CHD, but are closely linked to 
the metabolic disturbances characterised by insulin resistance. Thus the selective 
inhibition of HSL which catalyses the rate limiting step of triglyceride hydrolysis may 
contribute towards the therapeutic control of excessive adipose tissue lipolysis in various 
disease states. The antilipolytic mechanism of action of a series of compounds was 
investigated in isolated rat adipocytes in vitro, with in vivo dose response experiments 
using nicotinic acid carried out in Zucker rats after initial experiments in Alderley Park 
rats.
The objectives of the research were therefore
• To develop a method for the separation of chylomicrons and VLDL.
• To use this method to investigate VLDL subfraction metabolism in the postprandial 
state in both normal and diabetic subjects.
• To investigate the antilipolytic mechanism of action of selected compounds on HSL.
• To investigate and construct dose response curves for nicotinic acid in both Alderley 
Park and Zucker rats (NIDDM model).
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Figure 1.1: The fo u r major sources o f  free fatty acids fo r
VLDL synthesis. The circled numbers correspond to the 
four major sources o f free fa tty  acids fo r  VLDL synthesis, (I) 
hepatic de novo lipogenesis (DNL), (2) cytoplasmic triglyceride 
stores, (3) fatty acids derived from  lipoproteins taken up directly 
by the liver and (4) exogenous (plasma) fa tty acids.
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Figure 1.3:
Figure 1.4:
General lipoprotein structure.
Structure o f  chylomicrons.
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Figure 1.5: Basic steps in the catabolism o f  chylomicrons -
exogenous transport system .
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Figure Structure o f  VLDL.
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Figure 1.7: Basic steps in VLDL catabolism - endogenous
transport system .
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Figure 1.8: The adipocyte signal transduction pathway.
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Chapter II General methods.
1 Materials.
Names and addresses of manufacturers and suppliers of reagents, hardware and 
software used for this thesis are given in appendix 1.
2 Laboratory methods.
2,1 fi-Ouantification of lipids and lipoproteins.
Blood was collected into Na2EDTA tubes (final concentration 1 mg/ml), plasma 
was separated by centrifugation (3000 rpm (1300 g), 4°C, 15 minutes), and kept at 4°C 
until analysis. Plasma cholesterol and triglyceride concentrations were measured using 
reagent kits (704121 and 704113 Boehringer Mannheim GmbH) on an automated 
discrete analyser (BM/Hitachi 717). Quality control was monitored using Seronorm 
lipid (Nycomed Pharma AS) and Precipath U (Boehringer Mannheim GmbH). Plasma 
cholesterol, VLDL, LDL and HDL cholesterol concentrations were analysed according 
to the Lipid Research Clinics Program Manual of Laboratory Operation (1975), by a 
combined ultracentrifugation/ precipitation technique. Five ml of plasma was placed in 
a 6.5 ml thermoplastic ultracentrifugation tube (Ultraclear Beckman Instruments, Inc) 
and overlayered with normal saline until a meniscus appeared at the top. The tubes 
were sealed, placed in a 50.4 rotor (Beckman Instruments, Inc) and centrifuged (35000
rpm (130000 g), 4°C, 18 hours). The supernatant was then removed by tube slicing
and transferred to a 3 ml volumetric flask, the cutter was washed with normal saline and 
the washings used to make up 3 ml. The infranatant was transferred to a 5 ml 
volumetric flask and made up to volume with normal saline. One ml of the infranatant 
was then transferred to a second ultracentrifuge tube and the apoB containing 
lipoproteins were precipitated by adding 50 /zl of sodium heparin (5x10^ units)- 
manganese chloride reagent (92 mM). This was made up by mixing 9.56 grams 
MnCl2-4H20 in 6 ml dH2 0  with 1.05 grams heparin (5x10^ units; Sigma H - 3125) 
dissolved in 12.5 ml normal saline, made up to 25 ml with dH2 0  and stored at 4°C.
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The tubes were mixed, vortexed and incubated (4°C, 15 minutes), then spun (10000 
rpm (11000 g), 30 minutes) in the Ti 50.4 rotor with the vacuum off to pellet the 
precipitate. Aliquots of the VLDL fraction, the original infranatant (LDL and HDL) 
and the second supernatant (HDL) were transferred to autoanalyser cups and their 
cholesterol concentrations determined as above and in section 2.2.1. The LDL 
cholesterol concentration was calculated as the difference between that in the infranatant 
and the second supernatant.
This routine analysis is a globally accepted standard method used to produce 
patient lipid profiles. It was kindly performed by staff of the Routine Lipid Section of 
the Biochemistry Department of the G.R.I.
2.2 Compositional analysis.
2.2.1 Cholesterol.
Cholesterol was determined using a Boehringer kit (kit number 704121) in which 
cholesteryl esters in the sample were converted to cholesterol by an esterase. The 
enzyme cholesterol oxidase then oxidised all the cholesterol to form 4-cholesterenone 
and hydrogen peroxide, which is then converted in the presence of the enzyme 
peroxidase, phenol and 4-aminophenazone to produce 4-(p-benzoquinone-mono-imino)- 
phenazone. Absorbance of this product was measured at 505 nm on a Hitachi 704 or 
717 autoanalyser. Coefficient of variation was 1.6%.
2.2.2 Triglyceride.
Triglyceride was determined using a Boehringer kit (kit number 704113). The 
assay was performed on the Hitachi 717. Triglyceride is converted to glycerol by lipase 
enzyme. In the presence of ATP, glycerol kinase further converts glycerol to glycerol-
3-phosphate which is oxidised by a third enzyme, glycerol phosphate oxidase to form 
dihydroxyacetone phosphate and hydrogen peroxide which is converted in the presence 
of the enzyme peroxidase, phenol and 4-aminophenazone to produce 4-(p-benzoquinone- 
mono-imino)-phenazone. Absorbance of this product was measured at 505 nm on a 
Hitachi 704 or 717 autoanalyser. Coefficient of variation was 2.1%.
Both triglyceride and cholesterol assays were performed by the staff of the 
Routine Lipid Section of the Biochemistry Department of the G.R.I.
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2.3 Protein (modified Lowrv) assay.
The measurement of protein was performed on lipoprotein fractions using a 
modification of the method of Lowry et al (1951), involving measurement of proteins 
with the Folin phenol reagent (BDH 19058B 3Q) after alkaline copper treatment. Biuret 
reagent was made freshly from stock solutions; 100 ml 2% Na2CC>3 (BDH 10240) in 
0.1 M NaOH (BDH 10252), 1 ml 2% NaK tartrate in deionised water and 1 ml 1% 
CUSO4 (BDH 10091), with 1 ml SDS (Bio-Rad 161-0416) (added if sample to be 
assayed was turbid). Stock Folin Ciocalteu was diluted 1:1 with deionised water. A 
stock solution of human albumin (Fraction V, Sigma) 1 mg/ml, stored at -70°C, was 
used to prepare a working standard curve in the range of 0 - 50 fig protein, by taking 
volumes of stock standard (0 - 50 p\) then adjusted to a final volume of 400 fi\. 
Volumes of two stock (quality control) solutions, (15 and 30 fig/ 100 fi\) of bovine 
serum albumin (BSA) (Fraction V, Sigma) stored at -70°C, were adjusted to a volume 
of 400 fi\. Samples requiring dilution should be adjusted to a final volume of 400 fi\ 
with deionised H2O. Two ml Biuret reagent was added to 400 fi\ standard, quality 
control and sample, tubes were vortexed and left to stand for 10 minutes. Tubes were 
mixed immediately after addition of 200 fi\ Folin Ciocalteu reagent, and left to stand for 
30 minutes. The optical density at 750 nm was read within two hours. The within 
batch coefficient of variation was 1.9% and between batches was 2.4%.
2.4 Measurement of apolipoprotein B and AI.
Apolipoprotein B and AI in plasma and the TRL (d<  1.006g/ml) fraction was 
quantified by immunonephelometry using kits from Orion Diagnostica (catalogue 
numbers 67249 for apolipoprotein B and 67265 for apolipoprotein AI). The method is 
based on the measurement of immunoprecipitation in the liquid phase at 292 nm on the 
Encore clinical chemistry centrifugal analyser (Baker instruments). In conditions of 
antibody excess, the amount of precipitate is proportional to the apolipoprotein 
concentration (Riepponen, Mamiemi, Rautaoja 1987). The sensitivity of the assay was 
0.3 g/L with a coefficient of variation of 5%. Quality control was monitored using 
lyophilised materials from Immuno (code nos 4977006) and Behring (catalogue number 
OUPG).
This assay was performed on a semi-routine basis by Mr Michael McConnell of 
the Lipid Research Group.
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2.5 Apolipoprotein E phenotvping.
Three isoforms of apoE (E2, E3 and E4) can be separated by isoelectric 
focussing gel electrophoresis. These are then transferred to nitrocellulose by Western 
blotting. The apoE bands are visualised using a monoclonal antibody to apoE followed 
by an anti-IgG antibody linked to horse-radish peroxidase (HRP) and completed by the 
addition of 4-chloronaphthol which produces an insoluble dark blue stain.
ApoE phenotypes were determined by isoelectric focussing followed by Western 
blotting using an adaptation of the method of Havekes et al (1987). Ten /d of plasma 
was incubated with 28.5 mU neuraminidase (Sigma N-3001) in 20 mmol/L sodium 
acetate buffer, pH 5.1 (BDH 10235), then delipidated overnight with pre-cooled 
ethanol: ether (3:1, v/v) at -20°C. The mixture was precipitated (3000 rpm, 30 minutes) 
and further washed with ether and incubated for a minimum of one hour at -20°C. 
Again the mixture was precipitated as before. The precipitate was next dissolved in 
solubilising buffer (0.1 M Tris base (Sigma T-1503), 1% SDS, 8 M Urea, pH 10.0 
(Pierce Chem Company 29700)) to which 10 pci 15-mercaptoethanol (Sigma M 7154) was 
added and incubated at 4°C for 30 minutes. Thirty /cl of sample was applied to a 
vertical slab gel of 5% polyacrylamide in 8 M urea containing 1% (v/v) ampholines pH
4 - 6  (Serva). Electrophoresis was carried out in a Hoefer SE 600 tank (Pharmacia) at 
250 V, 12 mA per gel overnight at room temperature, with water cooling and then at 
500 V for 60 minutes. The upper buffer was 0.08% NaOH (w/v), pH 10.1 and lower 
buffer 0.1 M sodium phosphate, pH 2.3 (BDH 10248). Transfer from acrylamide gel to 
nitrocellulose was carried out at room temperature with water cooling at 100 V for 3 
hours in 0.2 M glycine (BDH 101196X), 0.02 M Tris base, 20% (v/v) methanol, pH 
9.0 in a Biorad transblot cell (figure 2.1). The nitrocellulose strips were first soaked in 
blocking buffer (0.01 M Tris HC1, 0.05% (v/v) Tween 20 (Sigma P1379), 0.15 M 
NaCl (BDH 10241), pH 7.4) containing 5% (w/v) milk powder (Marvel) as a blocking 
agent. The nitrocellulose was washed for 20 minutes with 3 changes of buffer. 
Incubation with the first antibody (mouse monoclonal anti-apoE) was overnight at room 
temperature with slow shaking. The nitrocellulose was washed for 20 minutes with 
buffer and incubated with the second antibody (goat anti-mouse horseradish peroxidase 
conjugate) for 2 hours at room temperature with gentle shaking. After a final 20 minute 
wash with buffer, the nitrocellulose was developed by incubation in the dark, at room 
temperature, with 4-chloro-naphthol and hydrogen peroxide (BDH 101284N) in 0.9% 
saline with buffer. ApoE isoforms were identified by reading against a known apo E2/ 
E2 phenotype.
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ApoE phenotyping was carried out on a semi-routine basis by Mrs Dorothy 
Bedford or Mrs Liz Murray.
2.6 Free fattv acid (FFA) assay .
FFAs were quantitatively determined using a Wako NEFA C (enzymatic 
colorimetric) kit (code no. 994-75409 E). The principle of the assay is described below. 
When FFA in plasma are treated with acyl-Co A synthetase (ACS) in the presence of 
ATP, magnesium cations and Co A, thiol esters of CoA known as acyl CoA are formed. 
The by-products AMP and pyrophosphate (PPi) are also formed. In the second part of 
the procedure, the acyl Co A is oxidised by added acyl CoA oxidase to produce 
hydrogen peroxide which in the presence of added peroxidase allows the oxidative 
condensation of 3-methyl-N-ethyl-N-(fl-hydroxy-ethyl)-aniline with 4-aminoantipyrine to 
form a purple coloured adduct with an absorption at 550 nm. The amount of FFA in the 
sample can be determined from the optical density measured at 550 nm. A standard 
curve from 0 - 1  mmol/L was prepared. Coefficient of variation was <5% .
2.7 Sequential flotation ultracentrifugation for isolation of chylomicrons.
VLDL. IDL and LDL.
Since plasma lipoproteins have lower hydrated densities than that of other plasma 
proteins and since the densities of each class are discrete from one another, 
progressively raising the solvent density of plasma between ultracentrifugation steps 
allows the isolation of defined lipoprotein classes. This provides the simplest method of 
simultaneously isolating lipoproteins from a number of samples in a form that does not 
require further concentration.
Chylomicrons and VLDL, IDL, and LDL were isolated at the density limits of
1.006, 1.019 and 1.063g/ml as originally described by Havel, Eder and Bragdon 
(1955). The density solutions were prepared from stock solutions at d =  1.006g/ml 
(0.195 M NaCl (BDH 10241), 0.001% Na2EDTA (BDH 10093)) and d =  1.182g/ml 
(0.195 M NaCl, 2.44 M NaBr (BDH 3011645), 0.001% Na2EDTA). Densities were 
measured to 3 decimal places on a Paar scientific (DMA 35) density meter.
For fed samples, 4 ml of plasma was placed in a 6.5 ml thermoplastic 
ultracentrifuge tube (Ultraclear; Beckman Instruments, Inc) overlayered with 2 ml 
normal saline and centrifuged in a Beckman Ti 50.3 rotor (10000 rpm, (7100 g) 4°C, 
30 minutes). The top 2 ml containing chylomicrons was aspirated using a finely drawn
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glass Pasteur pipette. The remaining 4 ml was overlayered with 2 ml d=1.006g/ml 
solution and centrifuged overnight in a Beckman Ti 50.3 rotor (39,000 rpm (108000 g), 
16 hours, 15°C). The top 2 ml containing VLDL was aspirated as previously. The 
remaining 4 ml was adjusted to d =  1.019g/ml by the addition of 0.32 ml d = 1.182g/ml 
solution and overlayered with 1.68 ml d =  1.019g/ml. After an overnight centrifugation 
(39000 rpm (108000 g), 16 hours, 15°C), IDL was removed in the top 2 ml. The 
infranatant (4 ml) was adjusted to d = 1.063g/ml by the addition of 1.47 ml 
d=1.182g/ml and overlayered with 0.5ml d=1.063g/ml. After an overnight 
centrifugation (39000 rpm (108000 g), 16 hours, 15°C), LDL was harvested in the top 
1 - 2 ml. Note in fasting samples the chylomicron ultracentrifugation step is not 
necessary. Alternatively after feeding, chylomicrons and VLDL can be isolated in the 
same fraction by overlayering 4 ml plasma with 2 ml d = 1.006g/ml solution, and after 
overnight centrifugation (39000 rpm (108000 g), 16 hours, 15°C) removing the top 2 
ml.
2.8 Cumulative flotation for isolation of VLDL\ (Sf  60 - 400) and \L D L q (S f 20 -
60).
This method allows the fractionation of VLDLj, VLDL2, IDL and LDL from 
plasma by a modification of the cumulative ultracentrifugation density gradient 
technique described by Lindgren and Jensen (1972), using a Beckman SW40 rotor and 
tubes pre-coated with polyvinyl alcohol. This method was used to separate VLDL^ and 
VLDL2 from a total VLDL sample previously isolated by immunoaffinity 
chromatography (chapter III). Density solutions were prepared from stock solutions at 
d=1.006g/ml (0.195 M NaCl, 0.001% Na2EDTA) and d =  1.182g/ml (2.44 M NaBr, 
0.195 M NaCl, 0.001% Na2EDTA). The densities were measured to 3 decimal places 
on a Paar scientific (DMA 35) density meter.
The density of 2 ml of 1 M NaSCN (Sigma S 7757) eluted VLDL, obtained by 
immunoaffinity chromatography, was adjusted to d=1.118g/ml by the addition of 0.224 
grams NaCl, calculated from the equation below;
NaCl (g) = 2(1.118 - x)/ (1 - 0.34) at 20°C, where x = density of NaSCN (0.4)
and this was carefully layered over 0.5 ml d = 1.182g/ml NaBr solution in an ultraclear 
Beckman SW40 ultracentrifuge tube which had been coated with polyvinyl alcohol 
(Holmquist 1982). A discontinuous salt gradient from 1.0988 - 1.0588g/ml
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(d =  1.0988g/ml (1 ml), d = 1.0860g/ml (1 ml), d =  1.0790g/ml (2ml), d =  1.0722g/ml (2 
ml), d = 1.0641g/ml (2 ml), d = 1.0588g/ml (2 ml)) was carefully constructed above it 
(figure 2.2). Tubes were centrifuged in a Beckman SW40 rotor in a Beckman L8 
centrifuge, (39,000 rpm, 23°C, 1 hour 38 minutes). One ml containing large VLDI4  
(Sf 60 - 400) was aspirated using a finely drawn glass Pasteur pipette and replaced with 
1 ml d = 1.0588g/ml solution. VLDL2 (Sf 20 - 60) was removed in the top 0.5 ml 
following a second centrifugation (18,500 rpm, 15 hours 41 minutes, 23°C). Rotors 
were decelerated without the brake.
2.8.1 Surface modification of Beckman ultraclear centrifuge tubes.
The procedure for coating the interior of Beckman ultraclear centrifuge tubes 
with polyvinyl alcohol to allow salt solutions to gravity feed smoothly down the sides of 
the tubes was described by Holmquist (1982). It involves coating Beckman ultraclear 
tubes with a polyvinyl alcohol solution containing propan-2-ol for 15 minutes, the 
solution is removed and tubes left to dry overnight. The tubes were washed overnight 
with distilled H2O, then flushed once with H2O and left to dry.
2.9 Apolipoprotein identification.
The apolipoprotein content of the isolated lipoproteins was resolved by sodium 
dodecyl sulphate glycerol polyacrylamide slab gel electrophoresis (SDS PAGE) 
(Maguire, Lee and Connelly 1989). Electrophoresis was performed using vertical slab 
gel apparatus (SE 600; Hoefer Scientific Instruments), 1.5 mm thick gels and a 15 tooth 
well former. The gel consisted of 3.6% acrylamide, with an acrylamide (BDH 44353 
5P)-bisacrylamide (BDH 44355 5R) ratio of 20:1, 19% glycerol (v/v) (BDH 101186M),
1.2 % SDS, 0.08% TEMED (Electran (BDH) 44308), 0.019% ammonium persulphate 
(BDH 44307) in 0.8 M Tris/phosphate pH 6.8 and was made up according to the 
author's protocol.
Samples were prepared according to the method of Mindham and Mayes, 1992. 
One ml of lipoprotein fraction, obtained by sequential flotation ultracentrifugation 
(section 2.7) and containing up to 1 mg protein was shaken with 10 ml diethyl ether 
(BDH 10094) for 2 minutes, after which 3.6 mM sodium deoxycholate (0.2 ml) (Sigma 
D6750) and 4.9 M trichloroacetic acid (0.2 ml) (BDH 10286) were added, samples were 
vortexed briefly and the top layer of diethyl ether was removed by aspiration and a 
stream of nitrogen. The bottom layer was centrifuged at 6500 rpm, 10 minutes, 4°C, to 
pellet the precipitated apolipoproteins. The supernatant was aspirated with a fine tipped
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Pasteur pipette (Alpha Laboratories Ltd LW 4233). The pelleted apolipoproteins were 
dissolved in sample buffer (containing 0.174 M Tris base pH 6.8 (25 ml) (Sigma 
T1503), 20% SDS solution (10 ml) (Biorad 161-0418), 10% bromophenol blue (10 fx 1) 
(BDH 44305), glycerol (10 ml) (BDH 10118), 2-mercaptoethanol (5 ml) (Sigma M 
7154)), and heated (80°C, 5 minutes) in a Techne heating block. Where necessary 5 M 
NaOH (BDH 10252) was added to neutralise samples. The samples were applied to 
gels. The lower buffer chamber was filled with 4 litres of 0.1 M sodium dihydrogen 
phosphate buffer (BDH 307165 U) pH 7, and the upper chamber with the same buffer 
containing 0.1% SDS. Electrophoresis was carried out at a constant current of 20 mA 
for 30 minutes and then at 60 mA for 4.5 hours at room temperature, water cooled. 
Gels were fixed in 4% formaldehyde (BDH 10113) for 30 minutes, stained overnight in 
0.023% Coomassie Brilliant Blue G-250 (Bio-Rad 161-0406) in 45.4% methanol 
(Hayman Limited SIN 1230), 9.2% acetic acid (BDH 45001), and then destained with 
7.5% acetic acid, 5% methanol and stored in 5% acetic acid.
High and low molecular weight markers (LMW and HMW-SDS Pharmacia AB 
(Lot nos. 6080446011. 6010445011, 6080615011) were included in each run. Apo 
B100 and apoB48 peptides were identified using molecular weight markers and LDL as 
an apoBlOO marker (prepared as samples) and also by Western blot analysis. The 
method was used to identify the presence of apoB48 and apoBlOO in lipoprotein 
fractions isolated by immunoaffinity chromatography and in Western blotting of apoB 
for screening antibodies to generate the immunoaffinity chromatographic column.
2.10 Staining methods.
2.10.1 Coomassie Brilliant Blue stain.
Coomassie Brilliant Blue staining is based on non-specific binding of Coomassie 
Blue dye to proteins. Separated proteins are simultaneously fixed and stained in the gel, 
and then destained to remove the background prior to storage and photocopying. The 
proteins are detected as blue bands on a clear background (Wilson 1983). For 
Coomassie Blue staining the gels were fixed in 4% formaldehyde for 30 minutes, 
stained overnight in 0.023% Coomassie Brilliant Blue G-250 in 45.4% methanol, 9.2% 
acetic acid, and then destained with 7.5% acetic acid, 5% methanol and stored in 5% 
acetic acid. The detection limit of Coomassie Blue was approximately 0.3 - 1.0 /xg 
protein. Coomassie Blue staining is semi-quantitative, with different proteins having 
different dye binding characteristics.
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2.10.2 Ponceau S stain.
This was a rapid reversible staining method, which was used to verify transfer 
efficiency after Western blotting before proceeding with immunodetection (Salinovich 
and Montelano 1986). The protein bands appeared after the membrane was stained with 
Ponceau S with a detection limit of 1 - 2 ^g. Protein on nitrocellulose (after Western 
blotting) was stained with Ponceau Red S (Sebia) (0.1% w/v Ponceau S, 5% acetic acid) 
for 5 - 30 minutes. The nitrocellulose was washed in distilled H2O to remove 
background staining, colour photocopied and was then completely destained with 
distilled H2O allowing immunodetection to proceed.
2.11 Preparation of lipoprotein deficient plasma (LPDP).
Blood was collected into Na2EDTA tubes, and placed on ice. Plasma was 
separated from red cells after centrifugation (3000 rpm, 15 minutes, 4°C). The plasma 
density was raised to 1.225g/ml by adding 0.35 grams KBr (BDH 10195)/ ml of 
plasma, and the density checked using a Paar DMA 35 densitometer (Stanton Redcroft), 
placed in 26 ml polycarbonate ultracentrifuge tubes (Beckman instruments Inc.) and 
overlayered with 2 ml of KBr solution d=1.225g/ml (approximately 3.49 grams KBr in 
dH2 0 ). The tubes were centrifuged (48 hours, 50000 rpm, 4°C) in a Ti 60 rotor on a 
L5 ultracentrifuge (Beckman instruments). The lipoproteins were removed in the top 2 
ml and the remaining infranatant, the LPDP, dialysed overnight against 0.15 M NaCl, 
10 mM Tris base, 1 mM EDTA, 0.05% NaN3 pH 7.4 at 4°C. A sample of dialysed 
LPDP was prepared and run on SDS-PAGE (section 2.9) to check it was free of 
lipoproteins.
3 Statistical analysis.
3.1 Human studies.
Mean and standard deviation of means for plasma parameters (lipid, 
apolipoproteins and insulin) were reported. Paired t-tests were used to determine the 
statistical significance for the plasma parameters between measurements obtained from 
fasting (0 hour) and postprandial samples. Unpaired t-tests were used to determine 
statistical significance between triglyceride response curves and for area under the 
curves obtained from normal and diabetic subjects, where the baseline was the fasting 0 
hour concentration. Area measurements were expressed as mmol.hour. The Minitab 10
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statistical package was used to calculate regression and p  values for correlations. The 
Microsoft Excel package was also used for statistical analysis.
3.2 Animal studies.
For the Zucker rats, the mean and standard deviation of means (before log 
transformation) for each plasma parameter were reported. An Anderson-Darling test for 
normal distribution was carried out on the data. Where data was not found to be 
normally distributed, it was log transformed. An analysis of variance (ANOVA) was 
performed on the log transformed data. The significance level was set at p <  0.05. 
When overall significant differences were observed a Fisher’s pairwise comparison was 
carried out to identify the groups that contributed to the significant difference. Minitab 
10 and Microsoft Excel packages were used for statistical analysis.
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Figure 2.1: Diagram o f the assembly o f  an immunoblot
sandwich fo r  Western blot transfer.
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Chapter III Development of an immunoaffinity 
chromatography method to separate 
triglyceride-rich lipoproteins (TRL) 
into apoB48 (chylomicrons) and apo 
B100 (VLDL) TRL species.
1 Introduction.
The postprandial state has been postulated to be potentially atherogenic on the 
basis that intestinal chylomicrons and their remnants have the potential to cause lipid 
deposition in the cells of the artery wall (Zilversmit 1979). The long term effects of 
repeated and prolonged alimentary lipaemia may also be derangements in the 
metabolism of endogenous lipoproteins that are atherogenic. When considering a direct 
atherogenic potential for TRL the question as to whether they can directly enter the 
artery wall due to lipoprotein size is of importance. A recent study used pauciclonal 
sheep anti-human apoBlOO antibodies to isolate and characterise apoB containing 
lipoproteins from human atherosclerotic plaques and plasma (Rapp et al 1994). Their 
results support the view that VLDL and VLDL remnants are potentially atherogenic and 
can indeed cross the endothelium and enter both human atherosclerotic plaques and the 
arterial wall, but these apoB containing lipoproteins differ in size from their plasma 
counterparts. With chylomicrons and VLDL (and their remnants) being potentially 
atherogenic, it is of importance to study both chylomicron and VLDL subfraction 
metabolism during alimentary lipaemia, since we spend most of our time in the 
postprandial state. A recent study by Bjorkegren et al (1996) concluded that 
chylomicrons (and their remnants) impede the normal lipolytic degradation of VLDL 
and could be indirectly implicated in the generation of atherogenic remnant lipoproteins 
after a 60 minute intravenous triglyceride infusion.
Postprandial lipoprotein metabolism has traditionally been evaluated by 
measuring triglyceride concentrations in whole plasma and in lipoprotein fractions after 
an oral fat load (Foger and Patsch 1993). A few studies have investigated the changes 
in concentration of apoB48 and apoBlOO, the main structural components of TRL of
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both intestinal and hepatic origin respectively (Scott 1990). These are quantified after 
ultracentrifugation and separation of TRL, by sodium dodecylsulphate polyacrylamide 
gel electrophoresis (SDS PAGE) and subsequent densitometric scanning of the protein 
bands (Poapst, Uffelman and Steiner 1987, Zilversmit and Shea 1989, Karpe and 
Hamsten 1994, Kotite, Bergeron and Havel 1995). Quantification of apoB48 by 
immunological methods has proved to be very difficult because apoB48 is a fragment of 
apoBlOO (Scott 1990) and only reaches postprandial peak concentrations in plasma of 
approximately 2% of those of apoBlOO. Also the expression of apoB epitopes may vary 
depending on the lipid content of the particle, thus restricting the use of 
immunochemical techniques to quantify the two apoB species.
Postprandial triglyceridaemia may represent the presence in the plasma of large 
apoB48 TRLs (chylomicrons) from the intestine, but also reflects the plasma 
accumulation of apoBlOO TRLs of hepatic origin (VLDL). In order to investigate this 
behaviour, more detailed analysis using immunoaffinity chromatographic techniques was 
required. Several groups have already devised methods using monoclonal antibodies to 
separate TRL into apoB48 and apoBlOO TRL species. Peel et al (1992, 1993) reported 
using an antibody specific for apoB48 to develop an immunologically-based assay for 
the routine detection of lipoproteins of dietary origin. Schneeman et al (1993) used an 
antibody which specifically bound to apoBlOO but not to apoB48 or apoBlOO VLDL 
rich in apoE. The monoclonal antibody Jl-H , has been used by this group to study 
postprandial levels of apoBlOO and apoB48 fractions (Campos et al 1992). The 
antibody binds to VLDL, IDL and LDL but fails to recognise a minor fraction of VLDL 
that is apoE rich and it also fails to bind apoB48 particles. Milne et al (1984) developed 
a series of monoclonal antibodies raised to apoBlOO which were used to separate apoB48 
and apoBlOO TRL fractions in subjects with Type III hyperlipoproteinaemia.
Cohn et al (1988 a and b) initially studied TRLs collectively and then moved on 
to study apoB48 and apoBlOO associated triglyceride separately. Separation of TRL 
fractions by immunoaffinity chromatographic techniques allowed the quantification and 
contribution of both apoB48 and apoBlOO fractions during postprandial lipaemia to be 
determined. More recently, Bjorkegren et al (1997) used two monoclonal antibodies 
that recognised apoBlOO and not apoB48 epitopes to separate VLDL from chylomicrons 
(and their remnants) after an oral fat load, to allow the study of VLDL composition, to 
see if its composition influenced its metabolic behaviour.
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2 Principle.
The aim was to establish a method to separate the heterogeneous population of 
TRL particles (freshly isolated by sequential flotation ultracentrifugation at a density of 
d<1.006g/m l, chapter II, section 2.7), into apoB48 and apoBlOO TRL fractions 
(chylomicrons and VLDL respectively) using immunoaffinity chromatography. The 
approach was to develop an immunoaffinity chromatographic technique that would allow 
their separation, by passage through an immunoaffinity column which retains VLDL but 
not chylomicrons. The former are dissociated from the column in a second step. This 
would allow further isolation of large VLDLj and small VLDL2 by cumulative flotation 
from the apoBlOO TRL species eluted from the immunoaffinity column.
3 Method development.
A collection of rabbit and sheep polyclonal LDL antisera and mouse monoclonal 
antibodies raised to human LDL were available. These had been prepared previously in 
the laboratory.
3.1 Preparation of sheep and rabbit polyclonal LDL antisera.
Production of both rabbit and sheep polyclonal LDL antisera was carried out by 
Dr. Muriel Caslake and Prof. James Shepherd. LDL was purified from normal 
volunteers by rate zonal ultracentrifugation, as described by Putsch et al 1974. Purified 
LDL was used to raise antisera in New Zealand White rabbits and sheep. One mg of 
apo LDL was emulsified with complete Freunds adjuvant using ultrasonification, prior 
to subcutaneous injection in multiple sites. Injections were repeated at monthly intervals 
using incomplete Freunds adjuvant until an adequate titre was obtained (usually 3 to 4 
injections). The antisera obtained gave a single immunoprecipitin arc with plasma and 
LDL, but did not react with albumin, HDL or purified apoAI and AIL Antisera were 
stored in 1 ml aliquots at -70°C.
3.2 Preparation of mouse monoclonal antibodies to human LDL.
Production of mouse monoclonal antibodies was carried out by Mrs. Isobel
Cameron. LDL was prepared according to the method described in chapter II, section
2.7. Five mice were injected intraperitoneally with 10 human LDL emulsified with 
complete Freund's adjuvant. Booster injections were applied every 4 weeks using 
dosage and route of injection identical to the first injection, until an adequate titre was
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obtained (usually two to three injections). Two weeks later the animals were 
anaesthetised with ether and 1 - 2  blood spots from the tail vein were collected on filter 
paper for antibody binding tests.
A 6 mm disc was punched from the filter paper dried bloodspot and incubated 
overnight in 300 /xl saline. Plasma was eluted with 0.9% saline at an estimated dilution 
of 1:500. A further dilution of 1:1000 was prepared using the same buffer. Aliquots 
(100 /xl) were taken in duplicate for each dilution and 200 /xl PBS containing l d l  
(about 10000 cpm) added. Samples were mixed thoroughly and incubated at room 
temperature overnight. Then 200 /xl solid phase sheep anti-mouse immunoglobulin 
(prepared using carbonyldiimidazole activated Sepharose-CL 4B) was added and 
incubated on an orbital shaker for another 1 hour. After 3 washes with saline plus 0.2% 
Tween 20, radioactivity in the Sepharose pellet was determined and expressed as 
percentage of initial radioactivity. Non-specific binding of 125j LDL was determined in 
controls containing saline instead of plasma.
Murine immortalised myeloma cells (ICN) and spleen lymphocytes obtained after 
LDL immunisation were fused to form hybridoma cells. Metabolic selection of such 
hybrids then followed favouring their growth at the expense of unfused cells. 
Hybridoma cell lines were screened for secretion of LDL-specific antibodies by a 
qualitative enzyme-linked immunosorbent assay (ELISA) using human LDL-coated cell 
culture plates.
Two ml LDL was dissolved in 0.3 ml of 0.05 M sodium carbonate buffer, pH
9.6 and protein concentration was measured by the Lowry method (Lowry et al 1951) 
(chapter II, section 2.3). Protein concentration was adjusted to 2 /xg/ml and aliquots of 
150 /xl per well were dispensed on 96 well culture plates. Plates were incubated for 4 
hours at room temperature, emptied and filled with 3% BSA, in 0.05 M sodium 
carbonate buffer, pH 9.6. After another 3 hour incubation, plates were again emptied 
and covered with transparent foil and stored at -20°C until required. Screening for anti- 
LDL antibodies involved the displacement of 5 /xg/ml cold LDL (see previously).
Cloning anti-LDL producing hybridoma cell lines.
Cell lines secreting anti-LDL antibodies had to be cloned to ensure that the 
antibody originated from a single hybridoma cell. Cell lines which were found to 
secrete anti-LDL antibodies (200 /xl from a 96 well plate) together with 2 ml RPMI- 
1640, containing peritoneal macrophages (acting as feeders) were placed into 2 ml wells
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(24 well plate) and grown to 50% confluence. One hundred /xl of this cell suspension 
was transferred into each well of the eight wells of the far left row of a 96 well plate 
which had previously been primed with 100 /xl RPMI-1640 per well. A serial dilution 
of cells ranging from 1:2 to 1:2 ^  Was carried out by subsequent transfer of 100 /xl 
aliquots per well from one vertical row to the next, working left to right. After addition 
of another 100 /xl of RPMI-1640 containing peritoneal macrophages, the plate was 
sealed and incubated for 7 - 14 days at 37°C. Then 6 vertical rows with the lowest cell 
concentrations were screened for anti-LDL antibodies. Cells in the highest dilution still 
positive for anti-LDL antibodies were assumed to be monoclonal.
3.2.1 Production of murine ascites containing monoclonal anti-LDL
antibodies.
A hybridoma clone producing an anti-LDL antibody was transferred from a 
cloning plate into a 25 cm^ flask and grown up in 5 ml RPMI-1640 in the presence of 
peritoneal macrophages. After 7 - 1 4  days, cells were centrifuged (800 rpm, 10 
minutes) and resuspended in six 0.5 ml aliquots RPMI-1640. Five female mice ( 8 - 1 0  
weeks old) who had been primed by an intraperitoneal injection of 0.5 ml pristane 
(Sigma) 1 - 3  weeks earlier were injected with 0.5 ml of the above cell suspension 
(5x10^ to 8x10^ hybridoma cells) into the peritoneal cavity. Thereafter their weight 
was checked every second day. When weight increased by 5 - 10 grams, ascites fluid 
was collected via a peritoneal cannula. This procedure was repeated a maximum of two 
times. The ascitic fluid was centrifuged (3000 rpm, 10 minutes), aliquoted and stored at 
-20°C. Hybridoma cell lines not used for intraperitoneal re-injection directly after 
cloning were resuspended in FCS, 10% DMSO at a concentration of 10^ cells per 0.5 
ml and stored in liquid nitrogen.
3.3 Immunodetection of apoB. bv Western blotting.
To assess the binding specificity of the rabbit/ sheep polyclonal and mouse 
monoclonal antibodies prepared previously, to apoB48 or apoBlOO, epitopes the 
antibodies were screened by Western blotting. TRL particles, (chylomicrons and 
VLDL) were isolated separately from plasma samples by sequential flotation 
ultracentrifugation (chapter II, section 2.7). Chylomicrons were isolated from 
postprandial plasma samples and VLDL from fasted plasma samples. The 
apolipoproteins of freshly isolated chylomicron and VLDL samples were prepared for 
SDS gel electrophoresis according to the method of Mindham and Mayes (1992) 
(chapter II, section 2.9). Apolipoproteins present were resolved by SDS PAGE
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(Macguire, Lee and Connelly 1989). Electrophoresis was performed using vertical slab 
gel apparatus (SE 600; Hoefer Scientific Instruments), 1.5 mm thick gels and a 15 tooth 
well former. The gel consisted of 3.6% acrylamide, with an acrylamide (BDH 44353 
5P) - bisacrylamide (BDH 44355 5R) ratio of 20:1, 19% glycerol (v/v) (BDH 
101186M), 1.2% SDS, 0.08% TEMED (Electran (BDH) 44308), 0.019% ammonium 
persulphate (BDH 44307) in 0.8 M Tris/phosphate pH 6.8 and was made up according 
to the author's protocol. The samples were applied to gels (up to 1500 /xg of 
chylomicron protein and approximately 500 /xg VLDL protein). The lower buffer 
chamber was filled with 4 litres of 0.1 M sodium dihydrogen phosphate buffer (BDH 
307165 U) pH 7, and the upper chamber with the same buffer containing 0.1% SDS. 
Electrophoresis was carried out at a constant current of 20 mA for 30 minutes and then 
at 60 mA for 4.5 hours at room temperature, water cooled. ApoBlOO and apoB48 
peptides were identified using molecular weight markers and LDL as a apoBlOO marker 
(prepared as samples in chapter II, section 2.9) and also by Western blot analysis.
The method was used to identify the presence of apoB48 and apoBlOO in 
lipoprotein fractions isolated by immunoaffinity chromatography and for Western 
blotting of apoB for screening antibodies to generate the immunoaffinity 
chromatographic column.
3.3.1 Western blotting.
Samples and gels were prepared and gel electrophoresis carried out as above. 
Antibodies raised to apoB to be used for screening were prepared as in sections 3.1 and 
3.2. The efficiency of transfer was assessed by staining blots with Ponceau S (chapter II 
section 2 . 10.2), a total protein stain that does not interfere with subsequent 
immunodetection.
For blotting SDS PAGE gels, nitrocellulose membranes, blotting paper 
(Whatman 3MM) and Scotch-brite pads were soaked in transfer buffer (192 mM 
glycine, 25 mM Tris base, 20%(v/v) methanol, pH 7.9) for 30 minutes, assembled 
(chapter II, figure 2.1) and blotted overnight (4°C, at 10 - 14 V) using the Transphor 
transfer cell (Hoefer Scientific Instruments). The blots were stained with Ponceau S 
(0.1% (w/v), 5% acetic acid) for 5 - 3 0  minutes to visualise the transferred peptides, 
and destained with distilled H2O until the background was white, (the gel was also 
stained with Coomassie Brilliant Blue, see chapter II, section 2.10.1 to verify that 
transfer had occurred). The blot was colour photocopied and then completely destained 
with distilled H2O. The blot was then incubated with blocking buffer (0.01 M Tris
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HC1, 0.055% (v/v) Tween 20, 0.15 M NaCl, pH 7.4 containing 5% (w/v) milk powder 
(Marvel)) (as in apoE phenotyping chapter II, section 2.5) for 60 minutes, on an orbital 
mixer (Denley-Tech Ltd) and washed in two changes of buffer A (10 mM Tris HC1,
0.055% (v/v) Tween 20, 0.15 M NaCl pH 7.4). The blot was incubated with the 
primary antibody (either the polyclonal sheep or rabbit anti-apoB antibody or the 
monoclonal murine anti-LDL antibody (LDL A4) diluted in buffer A (20 /xl serum/ 
ascites in 20 ml buffer A) overnight at room temperature and washed as before. It was 
then incubated with the secondary antibody (either anti-sheep IgG HRP, anti-rabbit IgG 
HRP or goat-anti-mouse IgG HRP, depending on the chosen primary antibody) for 2 
hours. The blot was washed as before then developed for 45 minutes in a substrate 
solution containing 60 mg 4-chloronaphthol (Sigma 8890) in 10 ml methanol, gently 
mixed with 60 ml saline and 30 /xl hydrogen peroxide (30%) in the dark, washed with 
distilled water, dried at room temperature, photocopied and stored in the dark.
3.3.2 Results.
Lanes 1 - 11 of figure 3.1, contain the apolipoprotein content resolved from 
freshly isolated TRL (d<  1.006g/ml) fractions. Several repetitions of the Western 
blotting procedure were carried out using these antibodies to ensure that the results 
obtained were reproducible. The immunoblots showed that the sheep and rabbit 
polyclonal antibodies bound to both apoBlOO or apoB48 isolated from TRL (d<  1.006 
g/ml) samples. Figure 3.1 shows examples of rabbit (lanes 6 - 9)1 sheep (lanes 1 - 5 )  
polyclonal antibodies and a mouse monoclonal LDL A4 antibody (lanes 10, 11) binding 
to apoB, with the polyclonal antibodies binding to all apoB fragments on the Western 
blot, and the mouse monoclonal antibody seeming to be more specific in its binding. As 
a result the sheep and rabbit polyclonal antibodies were discounted as potential tools for 
separation, although their lack of specificity made them useful for showing the presence 
of both apoB48 and apoBlOO protein bands previously isolated from chylomicron and 
VLDL fractions respectively, thus allowing the specificity of other antibodies for either 
apoB48 or apoBlOO to be clearly determined.
Figure 3.2 shows Ponceau S staining of proteins after transfer to a nitrocellulose 
membrane before antibody incubations. High and low molecular weight markers are 
present at either side of the nitrocellulose membrane. Lanes 1, 2, 3, 9, 10, and 11 
contain chylomicron apolipoproteins (apoB48) and lanes 4 - 8  contain VLDL 
apolipoproteins (apoBlOO). The presence of apoBlOO protein bands can be clearly seen 
in lanes 4 - 8 ,  with faint apoBlOO protein bands also present in the lanes containing 
chylomicron samples. ApoB48 protein bands can be clearly seen in lanes 1, 2, 3, 9, 10
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and 11. After complete destaining, the blot was cut in half with lanes 1 - 5 in one half 
and incubated with the primary mouse monoclonal (LDL A4) antibody followed by a 
secondary antibody goat-anti-mouse IgG HRP. The other half containing lanes 6 - 1 1  
was incubated with the primary polyclonal rabbit antibody, followed by the secondary 
antibody anti-rabbit IgG HRP.
Figure 3.3 shows immunoblot results after above incubation with both primary 
and secondary antibodies. In lanes 1 - 5  there is an apoBlOO protein band (faint in lanes 
1 - 3 )  with no detectable apoB48 protein band present in any the lanes which from 
figure 3.2 we know should be present in at least lanes 1 - 3  (apoB48 containing 
fractions). This indicates that the monoclonal antibody (LDL A4) is specific for 
apoBlOO with no reaction to apoB48. In lanes 6 - 1 1 ,  incubated with the non-specific 
polyclonal rabbit antibody, there were clearly detectable levels of both apoBlOO (in 
VLDL and chylomicron samples) and apoB48 (strong protein bands in chylomicron 
samples and faint apoB48 protein bands in VLDL samples) present.
It was concluded from Western blotting results that the mouse monoclonal 
antibody LDL A4, binds selectively to apoBlOO (present on VLDL) and not to apoB48 
(present on chylomicrons). On the basis of these results it was decided to set up a 
monoclonal antibody column, using LDL A4 to attempt to physically separate TRL 
particles into apoB48 and apoBlOO TRL species (chylomicrons and VLDL) by 
immunoaffinity chromatography.
3.4 Preparation of an immunoaffinity chromatography column.
The total protein concentration of the ligand (LDL A4) to be coupled to the 
CNBr A Sepharose gel was measured and calculated by Lowry assay (chapter II, section
2.3) and was found to be 25 mg/ml.
Lipoprotein fractions were prepared for immunoaffinity chromatography by 
sequential flotation ultracentrifugation according to the method described in chapter II, 
section 2.7. The required amount of freeze dried CNBr A Sepharose (1 gram = 3.5 ml 
final volume of swollen gel, a final volume of 10 ml of gel =  2.86 grams) (Pharmacia 
Biotech code no. 17-0430-01) was weighed out and suspended in 1 mM HC1 (Sigma H 
7020). The gel swells immediately and was washed for 15 minutes with 1 mM HC1 on 
a sintered glass filter (approximately 200 ml 1 mM HC1/ gram freeze dried powder).
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3.4.1 Coupling the ligand.
The ligand (LDL A4 antibody - 2 ml as determined by Lowry assay, chapter II, 
section 2.3) was dissolved in coupling buffer, (0.1 M sodium hydrogen carbonate 
(NaHCC>3) pH 8.3 containing 0.5 M NaCl, 5 ml coupling buffer/ gram freeze dried 
powder). About 5 - 10 mg protein per ml gel was used. The swollen gel and coupling 
buffer containing the ligand were placed in a stoppered vessel and the mixture rotated 
overnight at 4°C on a spiramixer (Denley). Excess ligand was removed by washing on 
a sintered filter with 5 gel volumes of coupling buffer (70 ml). Protein levels in the 
washings were determined by Lowry assay, (chapter II, section 2.3) to allow 
determination of % ligand bound to the gel, using the equation below;
% Ligand bound = (total ligand (protein before coupling) - total unbound
ligand (protein in washings x volume of washings)/ total 
ligand protein) xlOO.
The column was prepared and Lowry assays performed to determine the total 
protein concentration of the ligand and the washings after coupling of ligand to resin, in 
order to estimate the amount of unbound ligand. This value was used to calculate % of 
ligand bound to resin. The calculation used is below.
Total ligand protein concentration =  25098 /xg/ml x 2 ml (volume of ligand
coupled)
50196 /xg 
= 50.2 mg
(10 ml column, 5.2 mg/ml ligand)
Total unbound ligand protein concentration = 43.7 /xg/ml x 75 ml (total volume of
washings)
3277 /xg 
= 3.28 mg.
Ligand bound to resin = 50.2 - 3.28
= 46.92 mg
% ligand bound to resin = (46.92/ 50.2) x 100
93.5%
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i.e. 93.5 % of ligand (LDL A4) was coupled to the gel.
The coupled gel was suspended in 0.1 M Tris HC1 (Sigma T-3253) buffer pH 8 
for 2 hours to block any remaining active groups and washed on a sintered filter with 3 
cycles of alternating pH. Each cycle consisted of a wash with 0.1 M acetate buffer 
(BDH 10235) pH 4.0 containing 0.5 M NaCl followed by 0.1 M Tris HC1 buffer pH 
8.0 containing 0.5 M NaCl.
The gel slurry was packed in a column and equilibrated with 10 column volumes 
of phosphate buffer (0.0675 M sodium dihydrogen orthophosphate (NaH2P0 4 ), 0.01% 
Na2EDTA, pH 7.3). A 10% LPDP solution (prepared according to the method in 
chapter II, section 2.11) was passed down the column to block any remaining non­
specific binding sites followed by a further 10 column volumes of phosphate buffer. 
Two ml fractions were collected and the absorbance at 280 nm measured. The 
absorbance increased and then decreased to starting levels as the unbound LPDP was 
washed from the column. The column was stored at 4°C until required for use.
3.5 Testing of the LDL A4 monoclonal antibody immunoaffinity
chromatography column.
Once the LDL A4 monoclonal antibody immunoaffinity column was equilibrated 
with phosphate buffer, samples of both human VLDL (as a check of Western blotting 
results) and LDL (to which to antibody was originally raised) were applied to the resin 
on separate occasions. Once the sample was bound to the resin, an agent for elution had 
to be decided upon.
Initially the flow rate was set at 1 ml/ minute. One ml of VLDL isolated from a 
fasted plasma sample (according to the method in chapter II, section 2.7) was applied to 
the top of the column using a plastic pipette. The sample was allowed to run into the 
resin and the resin overlayered (in the same manner as the sample application) with 
phosphate buffer and left to stand (1 hour) to allow binding to occur. Five column 
volumes (50 ml) of phosphate buffer were passed through the column, with 2 ml eluant 
fractions collected. The absorbance of these fractions was read at 280 nm to monitor 
protein (sample) elution (figure 3.4).
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The absorbance at 280 nm did not alter, suggesting that the VLDL remained 
bound to the column. Several agents for elution of VLDL from the immunoaffinity 
column were tested. The possibilities included and tried were solutions with 
' high pH,
high salt concentrations and 
chaotropic agents.
The immunoaffinity column was equilibrated with phosphate buffer, 2 ml 
fractions were collected and the absorbance read at 280 nm. Next, 5 column volumes 
(50 ml) of phosphate buffer (containing 0.5 M NaCl), followed by 5 column volumes 
(50 ml) of phosphate buffer (this time containing 1 M NaCl) were passed through the 
column. As previously, 2 ml fractions were collected and their absorbance read at 280 
nm. There was no change in the absorbance at 280 nm in the fractions eluted using 
either phosphate buffer, phosphate buffer containing 0.5 M or 1 M NaCl (figure 3.4) 
detected. That is high salt concentrations did not dissociate VLDL from the affinity 
column.
The immunoaffinity column was pre-washed with phosphate buffer as before, 
glycine buffer pH 10.3 (15 ml) was passed through the column. Again, 2 ml fractions 
were collected and their absorbance read at 280 nm. Phosphate buffer was washed 
through the immunoaffinity column until washings returned to pH 7, as determined with 
pH paper. There was no alteration in the absorbance at 280 nm (figure 3.4) suggesting 
that the VLDL remained bound to the column, thus high pH conditions did not release 
VLDL from the immunoaffinity column.
The column was pre-washed with phosphate buffer. It was decided to use 1 M 
sodium thiocyanate (NaSCN) to try and dissociate VLDL from the column. Two and a 
half column volumes (25 ml) of 1 M NaSCN buffer were passed through the column. 
One ml fractions were collected and the absorbance at 280 nm measured. The 
absorbance at 280 nm increased, peaked between fractions numbers 4 - 15, then 
decreased (figure 3.4). This indicated that VLDL was being eluted from the column. 
The eluted fractions (4 - 15) with the highest absorbances at 280 nm, were pooled and 
concentrated using the Amicon concentration system in a Ti 60 rotor by centrifugation 
(5000 rpm, 20 minutes then 2000 rpm, 2 minutes). The resulting concentrated fraction 
was then prepared for gel electrophoresis to determine if there was any apoBlOO present 
in the fraction to indicate the presence of VLDL. A pooled, concentrated sample of the 
phosphate buffer eluted fractions was also prepared for gel electrophoresis.
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An faint apoBlOO protein band was detectable in the NaSCN eluted fraction. No 
apoBlOO protein band was detectable in the phosphate buffer eluted fraction. This 
suggested that VLDL had been bound to the monoclonal LDL A4 antibody and could be 
dissociated from the column using 1 M NaSCN. For future reference, fractions eluted 
using phosphate buffer were designated the apoB48 (unbound) fraction while fractions 
eluted with 1 M NaSCN were designated the apoBlOO (bound) fraction.
3.5.1 Testing of LDL A4 monoclonal antibody immunoaffinity column using
VLDL and LDL isolated from a fasted plasma sample.
VLDL and LDL fractions were prepared from fasted plasma samples by 
sequential flotation ultracentrifugation (chapter II, section 2.7). Both VLDL (1 ml) and 
LDL (1 ml) were applied to the immunoaffinity column on separate occasions. On each 
occasion, the column was washed with phosphate buffer (2 column volumes) (20 ml) 
followed by 2 column volumes (20 ml) of 1 M NaSCN. Eluted fractions (0.5 ml) were 
collected and their absorbances read at 280 nm.
In both VLDL and LDL elution profiles, measurement of the absorbance at 280 
nm (figure 3.5) detected the presence of 2 elution peaks. The first elution peak was 
detected in the apoB48 (unbound) fraction in fraction numbers 10 - 20. The second 
elution peak, as expected was detected in the apoBlOO (bound) fraction over fraction 
numbers 40 - 80.
The absorbance of all eluted fractions was also measured at 500 nm (figure 3.6). 
Absorbance at 500 nm is a measure of sample turbidity; lipoproteins scatter light at this 
wavelength but free proteins do not, they only absorb at 280 nm. As a result the elution 
peak present in the apoB48 (unbound) fraction all but disappeared, while the apoBlOO 
(bound) fraction elution peaks were still detectable. These results indicate that free 
proteins, maybe plasma proteins, but not lipoproteins, were responsible for the elution 
peak detected in the apoB48 (unbound) fraction. The lipoproteins, VLDL and LDL 
were responsible for the elution peak present in the apoBlOO (bound) fraction only.
The eluted fractions with the highest absorbances at 280 nm, fraction numbers 10 
- 20 (apoB48 (unbound) fraction) and fraction numbers 40 - 80 (apoBlOO (bound) 
fraction) were pooled, concentrated and any apolipoproteins present resolved by gel 
electrophoresis. SDS glycerol gel electrophoresis results confirmed previous results 
(figures 3.7, 3.8). ApoBlOO protein bands were detectable in the apoBlOO (bound)
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fractions from both VLDL (figure 3.7) and LDL (figure 3.8) eluted fractions, with no 
apoBlOO protein bands detectable in either of the apoB48 (unbound) fractions.
In conclusion, both VLDL and LDL bind to the monoclonal antibody, LDL A4, 
which is coupled to activated CNBr Sepharose resin. Elution from the column is 
accomplished with the use of 1 M NaSCN. Measurement of absorbance at 500 nm is 
now no longer required since the presence of the peak in the apoB48 (unbound) fraction 
was determined and found to be of no importance in that it was not produced by the 
lipoproteins and did not contain detectable levels of triglyceride.
Once the basic immunoaffinity chromatographic methodology was set up, the 
next step was to use the immunoaffinity column, now known to bind VLDL, to test 
whether physical separation of TRL fractions into apoB48 and apoBlOO TRL containing 
fractions is possible from a postprandial plasma sample.
3.5.2 Method for elution of lipoprotein samples from the monoclonal antibody 
immunoaffinity column.
One ml of lipoprotein sample was applied to the column and overlayered with 
phosphate buffer and left to stand for 1 hour. The apoB48 (unbound) fraction was 
washed from the column in a first step with 2 column volumes of phosphate buffer. The 
apoBlOO (bound) fractions were dissociated using 2 column volumes 1 M NaSCN, 
0.0675 M NaH2P0 4 , 0.01% Na2EDTA buffer, pH 7.3 and eluted fractions collected. 
The column was finally washed with phosphate buffer and stored at 4°C. Triglyceride 
and cholesterol levels were measured in eluted fractions by the methods described in 
chapter II, sections 2.2.1 and 2.2.2.
3.5.3 Testing of the monoclonal antibody immunoaffinity column using 
postprandial plasma samples.
A subject was given a fat rich meal. Blood (40 ml) was collected into 
Na2EDTA tubes 3 - 4  hours after ingestion of the meal. Plasma was harvested by 
centrifugation (3000 rpm, 15 minutes, 4°C). The TRLs (chylomicrons and VLDL) 
were isolated together from plasma by a single sequential flotation centrifugation step 
(39000 rpm (108000 g), 16 hours, 4°C) at a density of d <  1.006g/ml and removed in 
the top 2 ml.
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After washing the immunoaffinity column with 2 column volumes (20 ml) of 
phosphate buffer, 1 ml of the freshly prepared TRLs was applied to the column and left 
to stand for 1 hour. Phosphate buffer was passed through the column (2 column 
volumes - 20 ml) followed by 1 M NaSCN (2 column volumes - 20 ml) followed by 
further washing with phosphate buffer (10 column volumes - 100 ml). The flow rate 
was as previously. One ml fractions were collected with the absorbance measured at 
280 nm (figure 3.9). Fractions with the highest absorbances were pooled and (for both 
unbound and bound fractions) concentrated using the Amicon Centrificon method as 
previously. Triglyceride and cholesterol concentrations were measured in pooled 
fractions (according to the method in chapter II, section 2.2)
Results.
Absorbance at 280 nm (figure 3.9) showed the presence of 2 peaks. The first 
large peak appears during washing with phosphate buffer (fraction numbers 1 - 8) in the 
apoB48 (unbound) fraction, suggesting the elution of light scattering chylomicrons from 
the immunoaffinity column. The second smaller peak (fraction numbers 24 - 37) 
appears during column washing with 1 M NaSCN, in the apoBlOO (bound) fraction, 
suggesting dissociation of VLDL from the column. The absorbance peak for 
chylomicrons is large since these particles scatter more light than VLDL because of their 
size. The fractions contributing to both peaks (fraction numbers 1 - 8  and 24 - 37 for 
the apoB48 (unbound) and apoBlOO (bound) fractions, respectively) were pooled and 
concentrated using the Amicon Centrificon system. SDS gel electrophoresis detected 
the presence of an apoBlOO protein band in the apoBlOO (bound) fraction. There was 
no apoB48 protein band visible in the apoB48 (unbound) fraction. Triglyceride and 
cholesterol levels were measured in the pooled samples and adjusted to plasma levels to 
account for any dilutions (chapter II, section 2.2) (table 3.1).
Table 3.1: Triglyceride and cholesterol levels in pooled samples isolated from
postprandial samples by immunoaffinity (LDL A4 monoclonal antibody) 
chromatography.
Sample Triglyceride
(mmol/L)
Cholesterol
(mmol/L)
apoB48 (unbound) fraction 8.27* 0.09
apoBlOO (bound) fraction > 11* 0.32
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*an early problem that was encountered was the very high triglyceride levels, found to 
be due to the presence o f glycerol, which is measured by the triglyceride assay, in the 
Amicon Centrificon concentration filters. This difficulty was overcome by thorough 
pre-rinsing o f filters with distilled water.
Although triglyceride levels were high and not representative of triglyceride 
present in the eluted fractions, the cholesterol levels were of use. The cholesterol 
concentrations appear consistent with concentrations found in chylomicron and VLDL 
fractions. On the basis of these results it seems possible that TRLs could be physically 
separated into apoB48 and apoBlOO TRL species (chylomicrons and VLDL respectively) 
by immunoaffinity chromatography with further testing required.
3.5.4 Further Testing.
Chylomicron, VLDL and chylomicron and VLDL mixed (TRL d<1.006g/ml) 
fractions were prepared by sequential flotation ultracentrifugation (chapter II, section 
2.7) from postprandial plasma. Chylomicron and VLDL samples were isolated 
separately and also together at d<1.006g/ml. Each sample (1 ml) underwent 
immunoaffinity chromatography. Absorbances of eluted 0.5 ml fractions were 
measured at 280 nm. Those fractions with increased absorbance at 280 nm were pooled 
and triglyceride and cholesterol levels measured and adjusted back to plasma levels (to 
correct for dilution factors)(chapter II, section 2.2).
Results.
The chylomicron sample produced a single elution peak in the apoB48 (unbound) 
fraction (figure 3.10) (fraction numbers 4 - 22) while the VLDL sample produced 2 
elution peaks (figure 3.11). The first was in the apoB48 (unbound) (fraction numbers 4 
- 20) and the second was in the apoBlOO (bound) (fraction numbers 45 - 80) fractions. 
The TRL (d<  1.006g/ml) fraction also produced 2 peaks (figure 3.12), the first in the 
apoB48 (unbound) fraction (over fraction numbers 3 - 20) and the second after elution 
with 1 M NaSCN in the apoBlOO (bound) fraction (over fraction numbers 45 - 70).
The peak detected in the apoBlOO (bound) fraction (in fraction numbers 45 - 70/ 
80) from both the VLDL and the TRL (d<  1.006g/ml), that were originally applied to 
the immunoaffinity column, is due to the dissociation of VLDL from the affinity column 
by 1 M NaSCN, a phenomenon that has been previously noted and confirmed by gel 
electrophoresis results. The elution peak present in the apoB48 (unbound) fraction of
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chylomicron, TRL (d<  1.006 g/ml) and VLDL samples, eluted over fraction numbers 4 
- 20 in each case, was suggested to be a result of washing of chylomicrons from the 
immunoaffinity column, with phosphate buffer. The presence of such a peak in the 
original VLDL sample initially applied to the immunoaffinity column could be due to 
contamination of the VLDL fraction with chylomicrons during the isolation by 
ultracentrifugation, or to the presence of small chylomicron remnants in plasma. This 
peak contained low levels of triglyceride. It is very difficult to separate chylomicrons 
and VLDL from a postprandial plasma sample by ultracentrifugation alone, which is the 
reason for establishing the immunoaffinity column. During centrifugation, large VLDL 
may spin up into the density fraction containing chylomicrons, with some of the small 
chylomicron remnants spinning down into the VLDL density fraction.
SDS gel electrophoresis (figure 3.13, lanes 1 and 2) showed detectable apoBlOO 
protein bands in the apoBlOO (bound) fractions, but no apoB48 protein bands were 
detectable in the apoBlOO (bound) fractions. Faint apoB48 protein bands were detected 
in the apoB48 (unbound) fractions. The immunoaffinity column provides very adequate 
separation of chylomicrons and VLDL. The triglyceride and cholesterol concentrations 
(table 3.2) reaffirm the results from the elution profiles and SDS gels. However 
recovery of initial sample added to the immunoaffinity column was 33 - 47% as 
estimated by measuring the recovered triglyceride in the bound and unbound fractions, 
adjusted back to plasma levels (to correct for dilution factors). This value was low and 
needed to be improved.
Conclusions.
From the triglyceride and cholesterol results, elution profiles and SDS gel 
electrophoresis results, the immunoaffinity column appears to be giving adequate 
separation of apoB48 and apoBlOO TRL species (chylomicrons and VLDL). The 
chylomicrons are eluted in a first step using phosphate buffer with VLDL dissociated 
from the column in a second step with 1 M NaSCN. However the % recovery of initial 
TRL added to the column is low, ranging from 33 - 47%. It is clear that the 
methodology is working but modifications are required to improve the recovery in order 
to use the method for quantification of postprandial responses.
From the elution profiles, chylomicrons are eluted in approximately the first 11 
ml phosphate buffer and VLDL dissociated in approximately the first 15 ml NaSCN (or 
in 20 - 35 ml of total volume), therefore instead of collecting all fractions and 
measuring absorbances and pooling the relevant fractions, which is very time
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consuming, the stated volumes of buffers representative of the apoB48 (unbound) and 
apoBlOO (bound) fractions were collected and then concentrated.
Table 3.2: Triglyceride (TG) and cholesterol (Choi) levels in samples separated by
immunoaffinity (LDL A4 monoclonal antibody) chromatography.
Samples 
applied 
to column 
and eluted 
fractions
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted
to
plasma
levels
(mmol/L)
Choi 
adjusted 
to plasma 
levels 
(mmol/L)
Lowry
(/tg/ml)
adjusted
to
plasma
levels
% TG 
recovery
Chylomicrons 1.04 0.13 0.52 0.065 523 -
apoB48
(unbound)*
0.3 0.03 0.24 0.024 102.5 46
apoBlOO
(bound)*
0 0 0 0 136.7 -
VLDL 2.09 0.7 1.045 0.35 347.5 -
apoB48
(unbound)*
0.25 0.04 0.125 0.02 119.7 33
apoBlOO
(bound)*
0.3 0.07 0.225 0.0525 276.71 -
TRL
d <  1.006fi/ml
1.75 0.45 0.875 0.225 660.5 -
apoB48
(unbound)*
0.29 0.04 0.33 0.046 362.5 47
apoBlOO
(bound)*
0.11 0.14 0.0825 0.105 167.6 -
* Samples o f chylomicrons, VLDL and TRL (d<1.006g/m l) were initially applied to 
the resin and separated into apoB48 (unbound) and apoBlOO (bound) fractions by 
immunoaffinity chromatography with the LDL A4 monoclonal antibody.
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3.5.5 Separation of chylomicrons and VLDL bv immunoaffinity chromatography 
from postprandial samples (Pilot Study) as a check of method 
reproducibility.
TRL (d<  1.006g/ml) fractions (chylomicron and VLDL mix) were prepared 
from 16 postprandial plasma samples by sequential flotation ultracentrifugation (chapter 
II, section 2.7). The freshly isolated TRL fractions were subjected to immunoaffinity 
chromatography (section 3.5.2). Triglyceride and cholesterol concentrations were 
measured in the TRL (d<  1.006g/ml), the apoB48 (unbound) and apoBlOO (bound) 
fractions (chapter II, section 2.2) then concentrations were adjusted back to plasma 
levels (to correct for dilution factors). SDS gel electrophoresis was performed to check 
for adequate separation.
Results.
SDS gels show the presence of apoBlOO protein bands in the apoBlOO (bound) 
fractions with no detectable apoBlOO and faint apoB48 protein bands in the apoB48 
(unbound) fractions. There were no detectable apoB48 bands in the apoBlOO (bound) 
fractions.
The recovery of initial TRL added to the immunoaffinity column was variable 
(table 3.3), ranging from 33 - 88%, with a mean of 58 ±  17% (mean ±  SD). Further 
individual recoveries of TRL added to the immunoaffinity column were not very 
consistent. A more reproducible method was required to maintain individual sample 
consistency of recovery of initial TRL added to the immunoaffinity column.
The major causes of failure to recover triglyceride from the immunoaffinity 
column is likely to be the multiple manipulations and concentration step in which some 
VLDL and chylomicrons may stick to the filter.
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Table 3.3: Recoveries o f initial TRL (d < 1.006g/ml) added to the LDL A4
monoclonal antibody immunoaffinity column, as estimated by 
measuring recovered triglyceride (TG) concentration (mmol/L) in the 
TRL (d<1.006g/ml) apoB48 (unbound) and the apoBlOO (bound) 
fractions.
Sample
Number
Fasting 
Plasma TG 
(mmol/L)
TRL
d<1.006g/ml 
TG (mmol/L)
ApoB48 
(unbound) 
fraction TG 
(mmol/L)
ApoBlOO 
(bound) 
fraction TG 
(mmol/L)
TG
recovered
(%)
1 1.94 1.34 0.12 0.33 33
2 2.02 1.265 0.31 0.12 34
3 2.43 1.34 0.37 0.13 37
4 2.28 1.29 0.43 0.16 46
5 1.7 1.04 0.18 0.36 52
6 1.63 1.05 0.34 0.27 58
7 1.83 1.03 0.48 0.22 68
8 2.43 1.35 0.57 0.19 56
9 1.68 0.77 0.31 0.23 70
10 1.22 0.57 0.18 0.21 68
11 1.07 0.45 0.17 0.23 88
12 0.99 0.48 0.11 0.17 58
13 1.08 0.58 0.13 0.17 51
14 1.74 0.93 0.47 0.21 73
15 1.37 0.8 0.47 0.22 86
16 1.18 0.69 0.26 0.19 65
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3.6 Immunoaffinity chromatography, modified method (Cohn et al 1993).
In the modified approach, separation of apoB48 TRL and apoBlOO TRL fractions 
was carried out in 1.5 ml Eppendorf tubes. Antibody containing sepharose gel (section
3.4) in phosphate buffer pH 7.3 (approximately 1.4 ml) was aliquoted into the 
eppendorf tubes and centrifuged (5 minutes, 1000 rpm). The supemate was aspirated 
and TRL (d<  1.006g/ml) (0.5 ml) added to the remaining 0.6 ml of packed sepharose 
gel. Tubes were mixed for 60 minutes at room temperature on a roller mixer, 
centrifuged and the supemate was collected (approximately 0.5 ml was retrieved). The 
gel was washed with 1 ml phosphate buffer, rocked for 20 minutes, and after 
centrifugation, the supemate was aspirated and added to the first supemate. The 
washing procedure was repeated with a second volume of phosphate buffer. This 
sample, termed the apoB48 (unbound) fraction contained the apoB48 TRL fraction 
(chylomicrons) (final volume = 2.5 ml). Lipoproteins bound to the gel were 
dissociated by the addition of 1 M NaSCN buffer (1.0 ml). Samples were rocked for an 
hour at room temperature, centrifuged, and the supemate was collected. The gel was 
washed with 2 further 1.0 ml aliquots of 1 M NaSCN, and these supemates were added 
to the first NaSCN supemate. This sample the apoBlOO (bound) fraction (final volume 
=  3.0 ml) contained the apoBlOO (VLDL) TRL fraction. Recovery of initial TRL 
fractions added to the immunoaffinity gel (using Eppendorfs) was estimated by 
measuring the recovered triglyceride in the bound and unbound fractions. The identity 
of the apoB protein bands was confirmed by either SDS gel electrophoresis or by 
Western blotting analysis using a polyclonal antibody, previously shown to react with 
both apoB48 and apoBlOO. Triglyceride and cholesterol concentrations in the TRL 
(d<  1.006g/ml), apoB48 (unbound) and apoBlOO (bound) fractions were measured 
(chapter II, section 2.2), and adjusted to plasma levels to allow calculation of the 
recovery of initial TRL added to the immunoaffinity gel.
Results and discussion.
Specific monoclonal antibodies for apoBlOO have been used previously (Milne et 
al 1984, Terce et al 1985) to isolate and characterise the very low density lipoprotein 
(VLDL) fraction of dyslipidaemic subjects in the fasted state. Cohn et al (1993) used 
the same antibodies to isolate the apoB48 and apoBlOO containing TRL from plasma 
obtained from subjects in a fed state. In order to obtain reliable quantitative data, Cohn 
separated single sample aliquots in individual Eppendorf tubes, containing the antibodies 
bound to sepharose, rather than eluting fractions from immunoaffinity chromatography 
columns (Milne et al 1984). With certain modifications Cohn et al (1993) achieved an
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acceptable recovery (85 - 95%) of TRL and allowed for the plasma concentration of 
different fractions to be estimated. Some contamination of the apoB48 (unbound) 
fraction with apoBlOO was noted. The adequacy of separation of chylomicrons and 
VLDL was monitored by SDS polyacrylamide gel electrophoresis.
In the present work, the method of Cohn et al (1993), which used separate single 
sample aliquots in individual Eppendorf tubes containing LDL A4 antibody bound to 
sepharose, rather than eluting fractions from the immunoaffinity chromatography 
columns (as previously described chapter III, section 3.5.2), was followed. However, 
instead of using 3 M NaSCN, 1 M NaSCN was used to dissociate the apoBlOO 
containing TRL (VLDL) fraction from the immunoaffinity gels.
This method was thoroughly and repeatedly tested to ensure reproducibility of 
results and of TRL recoveries. Several VLDL (isolated from fasted plasma samples), 
chylomicron and TRL (d<  1.006g/ml) (isolated from postprandial plasma) samples were 
prepared by sequential flotation ultracentrifugation (chapter II, section 2.7) and were 
subjected to immunoaffinity chromatography in Eppendorf tubes to separate the TRL 
into apoB48 and apoBlOO TRL fractions.
There was an apoBlOO protein band present in the apoBlOO (bound) fraction. A 
faint apoB48 protein band was detected in the apoB48 (unbound) fraction (figure 3.13, 
lanes 3 and 4), with no apoB48 protein detectable in the apoBlOO (bound) fraction, 
however there was some contamination of the apoB48 (unbound) fraction with apoBlOO 
noted, but this would only lead to an underestimation of apoBlOO TRL lipid 
concentrations. This problem was also noted by Cohn et al (1993). Additional 
chromatography was not carried out to remove contaminating apoBlOO material, as this 
would adversely effect recovery.
Triglyceride and cholesterol concentrations in each of the fractions were 
measured and results were as expected. In the VLDL samples, the majority of 
triglyceride was in the apoBlOO (bound) TRL fraction (table 3.4). In the chylomicron 
samples (table 3.5), the majority of triglyceride was detected in the apoB48 (unbound) 
TRL fraction; and finally in the postprandial TRL (d< 1.006g/ml) samples the 
triglyceride concentrations were split between the apoB48 (unbound) and apoBlOO 
(bound) containing TRL fractions, with levels varying between samples (table 3.6).
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Table 3.4: Triglyceride and cholesterol concentrations (mmol/L) (adjusted to
plasma levels) and triglyceride recoveries in the apoB48 (unbound) and 
apoBlOO (bound) fractions separated from VLDL samples were 
mixed with Sepharose bound LDL A4 monoclonal antibody in 
Eppendorf tubes, based on the method o f Cohn et al (1993).
Sample
applied
Eluted
fractions
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted 
to plasma 
levels 
(mmol/L)
Original TRL 
(d< 1.006 
g/ml) TG 
(mmol/L) 
adjusted to 
plasma levels
% TG 
recovery
VLDL apoB48
(unbound)*
0.06 0 0.15 0.75 68
apoBlOO
(bound)*
0.12 0.05 0.36
VLDL apoB48
(unbound)*
0.08 0.03 0.20 0.62 85.5
apoBlOO
(bound)*
0.11 0.06 0.33
*Samples o f VLDL were initially mixed with Sepharose bound LDL A4 monoclonal 
antibody in Eppendorf tubes and separated into apoB48 (unbound) and apoBlOO 
(bound) fractions.
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Table 3.5: Triglyceride and cholesterol concentrations (mmol/L) (adjusted to
plasma levels) and triglyceride recoveries in the apoB48 (unbound) and 
apoBlOO (bound) fractions separated from chylomicron samples 
were mixed with Sepharose bound LDL A4 monoclonal antibody in 
Eppendorf tubes, based on the method o f Cohn et al (1993),
Sample
applied
Eluted
fractions
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted
to
plasma
levels
(mmol/L)
Original 
(d< 1.006 
g/ml) TG 
(mmol/L) 
adjusted 
to plasma 
levels
% TG 
recovery
Chylomicron
1
apoB48
(unbound)*
0.28 0.06 0.7 0.76 100
apoBlOO
(bound)*
0.03 0.04 0.09
2 apoB48
(unbound)*
0.28 0.03 0.7 0.75 97
apoBlOO
(bound)*
0.01 0 0.03
3 apoB48
(unbound)*
0.27 0.02 0.675 0.75 97
apoBlOO
(bound)*
0.02 0 0.05
4 apoB48
(unbound)*
0.26 0 0.60 0.76 83
apoBlOO
(bound)*
0.01 0 0.03
*Samples o f chylomicrons were initially mixed with Sepharose bound LDL A4 
monoclonal antibody in Eppendorf tubes and separated into apoB48 (unbound) and 
apoBlOO (bound) fractions.
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Table 3.6: Triglyceride and cholesterol concentrations (mmol/L) (adjusted to
plasma levels) and triglyceride recoveries in the apoB48 (unbound) and 
apoBlOO (bound) fractions separated from postprandial TRL 
(d<1.006g/ml) samples were mixed with Sepharose bound LDL 
A4 monoclonal antibody in Eppendorf tubes, based on the method of  
Cohn et al (1993) .
Sample
applied
Eluted
fractions
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted 
to plasma 
levels 
(mmol/L)
Original
TRL
(d< 1.006 
g/ml) TG 
adjusted 
to plasma 
levels
% TG 
recovery
TRL
(d< 1.006 
g/ml)
1
apoB48
(unbound)*
0.29 0.04 0.725 1.435 90.2
apoBlOO
(bound)*
0.19 0.05 0.57
2 apoB48* 0.66 0.17 1.65 2.8 94
apoBlOO* 0.33 0.12 0.99
3 apoB48* 0.15 0.04 0.375 0.88 90
apoBlOO* 0.14 0.10 0.42
4 apoB48* 0.11 0.03 0.275 0.73 91
apoBlOO* 0.13 0.06 0.39
5 apoB48* 0.07 0 0.175 0.475 93.7
apoBlOO* 0.09 0 0.27
6 apoB48* 0.06 0 0.15 0.48 87.5
apoBlOO* 0.09 0 0.27
7 apoB48* 0.05 0.01 0.125 0.475 89
apoBlOO* 0.10 0.03 0.30
8 apoB48* 0.05 0 0.125 0.48 88.5
apoBlOO* 0.10 0.02 0.30
9 apoB48* 0.44 0.08 1.1 2.075 86
apoBlOO* 0.23 0.09 0.69
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*Samples o f TRL (d<1.006gml) were initially mixed with Sepharose bound LDL A4 
monoclonal antibody in Eppendorf tubes and separated into apoB48 (unbound) and 
apoBlOO (bound) fractions.
The individual % recoveries of initial TRL samples added to the immunoaffinity 
gel show little variation indicating the method was reproducible. The mean recovery of 
the initial TRL added to the immunoaffinity gel was calculated to be 89 ±  7 % (mean ±  
SD) based on triglyceride concentration. This value was similar to that obtained by 
Cohn et al (1993) of 92 ±  4% (based on protein concentration). The individual 
recoveries showed the method to be very reproducible, however some minor 
contamination of the apoB48 fraction was noted, which prompted a further modification. 
Additional chromatography was not carried out to remove contaminating apoBlOO 
material, as this was found to adversely affect recovery. Immunoaffinity 
chromatography( using a Sepharose bound LDL A4 monoclonal antibody in Eppendorf 
tubes) was repeated on several occasions using the same sample to check for 
reproducibility. Chylomicron samples 3 and 4 were repetitions of chylomicrons samples
1 and 2, while postprandial samples 7 and 8 were repetitions of postprandial samples 5 
and 6. From the % recoveries of initial triglyceride added to the immunoaffinity gel; 
97%, 83%, 100%, 97%, 89%, 88.5%, 93.7% and 87.5% respectively (tables 3.5 and 
3.6), it can be concluded that, using this modified method, recoveries are very 
consistent and reproducible between samples.
The modified immunoaffinity chromatography method using single sample 
aliquots in individual Eppendorf tubes increased the recovery of initial TRLs added to 
the immunoaffinity gel to 89 + 7%, while the previous method in which fractions were 
eluted from an immunoaffinity column had a recovery of 58 ±  17%. Analysis using a
2 sample t-test showed that on using individual sample recoveries for both methods that 
recovery of initial TRL added to the immunoaffinity gel was highly significantly 
(p <0.0001) improved using the new modified method. The modified method has 
severed benefits; increased recovery levels, yet using a smaller volume of sample with 
none of the sample being lost by concentration steps which were both time consuming 
and necessary when fractions were eluted from the immunoaffinity column. This new 
method is better for analysis and provides the increased recovery that was necessary to 
make using the method feasible. This methodology was used to analyse samples from 
oral fat load experiments in normal and diabetic (NIDDM) subjects.
3.7 Validation of modified Sepharose bound LDL A4 monoclonal antibody
immunoaffinity chromatography method (in Eppendorf tubes).
Due to the noted contamination of the apoB48 (unbound) fraction, a time course 
experiment using TRL fractions isolated from plasma from both postprandial (5 hours 
postprandially) and fasted (12 hour overnight fast) samples (by sequential flotation 
ultracentrifugation (chapter II, section 2.7)) were used to assess the optimum initial 
incubation time for samples without affecting recoveries of the initial TRL added to the 
immunoaffinity gel.
The time points for initial incubation were 30, 60, 90, 120 and 180 minutes with 
no other changes to the methodology. TRL fractions were freshly prepared by 
sequential flotation ultracentrifugation (chapter II, section 2.7) and then subjected to 
immunoaffinity chromatography, the only change to the methodology being the different 
initial incubation times. Triglyceride and cholesterol concentrations in the TRL 
(d<  1.006g/ml), apoB48 (unbound) and apoBlOO (bound) fractions were measured 
(chapter II, section 2.2), and adjusted back to plasma levels (to correct for dilution 
factors), to allow calculation of the recovery of initial TRL added to the immunoaffinity 
gel.
Results.
In the TRL fractions isolated from both the postprandial (table 3.7, figure 3.14) 
and fasted (table 3.8, figure 3.15) plasma samples, maximal binding of apoBlOO 
containing lipoprotein fractions to the Sepharose bound LDL A4 monoclonal antibody in 
Eppendorf tubes without affecting recovery levels was achieved with an initial 
incubation period of 90 minutes, after which time binding of the apoBlOO containing 
lipoprotein fractions to the immunoaffinity gel seems to decrease with recovery rates 
also falling slightly. The binding period was previously 60 minutes.
SDS gel electrophoresis results detected an apoBlOO protein band present in the 
apoB48 (unbound) fraction even after an initial incubation step of 90 minutes, but this 
was reduced to minor levels.
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Table 3.7: Triglyceride concentrations (mmol/L) and recoveries in apoB48
(unbound) and apoBlOO (bound) fractions. TRL fractions isolated 
from postprandial plasma samples, with varied initial incubation times, 
were mixed with Sepharose bound LDL A4 monoclonal antibody in 
Eppendorf tubes .
Sample and
eluate
fractions
Time
of
initial
incubation
(minutes)
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted 
to plasma 
levels 
(mmol/L)
% TG 
recovery
Plasma 1.62 4.52
TRL (d<  1.006g/ml) 
originally applied
2.06 0.41 1.03
apoB48 (unbound)* 30 0.28 0.03 0.70 91
apoBlOO (bound)* 0.08 0.03 0.24
apoB48 (unbound)* 60 0.27 0.00 0.67 88
apoBlOO (bound)* 0.08 0.02 0.24
apoB48 (unbound)* 90 0.26 0.01 0.65 92
apoBlOO (bound)* 0.10 0.03 0.30
apoB48 (unbound)* 120 0.25 0.01 0.62 86
apoBlOO (bound)* 0.09 0.01 0.27
apoB48 (unbound)* 180 0.27 0.01 0.67 94
apoBlOO (bound)* 0.10 0.03 0.30
*TRL fractions, isolated from postprandial plasma samples, were initially 
mixed with Sepharose bound LDL A4 monoclonal antibody in Eppendorf tubes and 
separated into apoB48 (unbound) and apoBlOO (bound) fractions.
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Table 3.8: Triglyceride concentrations (mmol/L) and recoveries in apoB48
(unbound) and apoBlOO (bound) fractions. TRL fractions isolated 
from fasted plasma samples, with varied initial incubation times, were 
mixed with Sepharose bound LDL A4 monoclonal antibody in 
Eppendorf tubes.
Samples and
eluate
fractions
Time 
of initial 
incubation 
(minutes)
TG
(mmol/L)
Choi
(mmol/L)
TG
adjusted 
to plasma 
levels 
(mmol/L)
% TG 
recovery
Plasma 0.74 4.46
TRL (d<  1.006g/ml) 
originally applied
0.95 0.46 0.475
apoB48 (unbound)* 30 0.09 0.01 0.225 100
apoBlOO (bound)* 0.10 0.04 0.30
apoB48 (unbound)* 60 0.07 0.02 0.175 100
apoBlOO (bound)* 0.10 0.03 0.30
apoB48 (unbound)* 90 0.07 0.00 0.175 100
apoBlOO (bound)* 0.10 0.04 0.30
apoB48 (unbound)* 120 0.06 0.01 0.15 88.4
apoBlOO (bound)* 0.09 0.03 0.27
apoB48 (unbound)* 180 0.06 0.00 0.15 88.4
apoBlOO (bound)* 0.09 0.04 0.27
*TRL fractions, isolated from fasted plasma samples were mixed with Sepharose 
bound LDL A4 monoclonal antibody in Eppendorf tubes and separated into apoB48 
(unbound) and apoBlOO (bound) fractions.
The binding capacity of the gel was also determined experimentally to make sure 
that the Eppendorfs were not being overloaded as this could be a reason for the presence 
of a faint apoBlOO protein band in the apoB48 (unbound) fraction. A saturation curve 
was prepared using fasting plasma samples from which VLDL was isolated by 
sequential flotation ultracentrifugation (chapter II, section 2.7), the new initial 
incubation time was used to ensure maximal binding conditions. Once isolated, the 
concentrated VLDL samples were diluted using phosphate buffer to give samples with 
triglyceride concentrations (adjusted to plasma levels) of 2.43, 1.23, 0.6, 0.3, 0.125 and
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0.08 mmol/L. Triglyceride and cholesterol concentrations were measured and adjusted 
back to plasma levels (to correct for dilution factors), in both the apoB48 and apoBlOO 
containing fractions separated by immunoaffinity chromatography, for each triglyceride 
dilution (table 3.9). A saturation curve was plotted for fasted VLDL triglyceride 
dilutions (mmol/L) vs actual triglyceride concentrations in the apoB48 and apoBlOO 
TRL fractions (mmol/L) (figure 3.16) (table 3.9).
At the triglyceride dilution concentration of 2.48 mmol/L the triglyceride 
concentration in the apoBlOO containing fraction is the highest, indicating binding of 
VLDL to the immunoaffinity gel is saturated (0.57 mmol/L). The binding levels may 
be maximal but the immunoaffinity resin is clearly overloaded with the presence of 
triglyceride in the apoB48 (unbound) fraction (2.05 mmol/L). To achieve a triglyceride 
concentration for maximal binding, a triglyceride concentration that will give as near 
maximal VLDL binding in the apoBlOO (bound) fraction with minimal triglyceride 
levels present in the apoB48 (unbound) fraction was required.
It is evident from figure 3.16 that as triglyceride concentrations in the apoB48 
containing fraction decrease (present as a result of overloading), they were also 
decreased in the apoBlOO containing fraction, a minor amount of triglyceride being 
detectable in the apoB48 fraction even although the immunoaffinity gel was not always 
at maximal binding of VLDL. The binding capacity of the gel was determined by 
extrapolation to be 0.5 - 0.7 mmol/L VLDL associated triglyceride/ 0.6 ml of gel. This 
is the point where near-maximal levels of VLDL appear to have bound to the 
immunoaffinity gel, with the least amount present in the apoB48 (unbound) fraction, 
without affecting triglyceride recovery levels. There was still minor contamination of 
the apoB48 (unbound) fraction.
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Table 3.9: Triglyceride concentrations (mmol/L) in apoB48 (unbound) and
apoBlOO (bound) fractions. VLDL fractions isolated from fasted 
plasma samples, with various concentrations o f apoBlOO VLDL TRL 
triglyceride, were mixed with Sepharose bound LDL A4 monoclonal 
antibody in Eppendorf tubes.
Eluate
Fraction
VLDL
triglyceride
dilution
applied to
column
(mmol/L)
Triglyceride
(mmol/L)
Cholesterol
(mmol/L)
Triglyceride 
adjusted to 
plasma 
levels 
(mmol/L)
% recovery 
of
triglyceride
apoB48
(unbound)*
2.48 0.82 1.31 2.05 100
apoBlOO
(bound)*
0.19 0.3 0.57
apoB48
(unbound)*
1.235 0.36 0.5 0.90 100
apoBlOO
(bound)*
0.16 0.23 0.48
apoB48
(unbound)*
0.6 0.14 0.04 0.35 100
apoBlOO
(bound)*
0.14 0.06 0.42
apoB48
(unbound)*
0.3 0.07 0.01 0.175 100
apoBlOO
(bound)*
0.10 0.03 0.30
apoB48
(unbound)*
0.125 0.04 0.01 0.10 100
apoBlOO
(bound)*
0.06 0.02 0.18
apoB48
(unbound)*
0.08 0.05 0.01 0.125 100
apoBlOO
(bound)*
0.06 0.02 0.18
93
*Samples o f VLDL were mixed with Sepharose bound LDL A4 monoclonal antibody 
in Eppendorf tubes.
4 Overall conclusions and future prospects.
The monoclonal antibody LDL A4 showed binding specificity for apoBlOO but 
not apoB48. TRL (d<  1.006g/ml) fractions isolated by sequential flotation 
ultracentrifugation can be separated into apoB48 and apoBlOO TRL species by 
immunoaffinity chromatography, using the monoclonal antibody LDL A4. Good 
separations were achieved. ApoB48 protein was not detectable in the apoBlOO (bound) 
fraction, with apoB48 protein sometimes difficult to visualise in the apoB48 (unbound) 
fraction (only accounting for 2% of protein at the peak of postprandial lipaemia). A 
faint apoBlOO band was often observed in the apoB48 (unbound) fraction and this 
contamination was noted, but to proceed with additional chromatography would 
adversely affect recovery of the initial TRL added to the immunoaffinity gel. The 
modified method using Sepharose bound LDL A4 monoclonal antibody in Eppendorf 
tubes, based on the technique of Cohn et al (1993) provided a highly significant increase 
in recovery to 89 ±  7% compared to the original method of eluting fractions from the 
immunoaffinity chromatography column (58 + 17%). The method has been thoroughly 
tested and has produced satisfactory results, it provided a much improved recovery of 
the apoB48 TRL species, although visualisation of the apoB48 protein band in the 
apoB48 (unbound) fraction by SDS gel electrophoresis could be further improved. The 
LDL A4 monoclonal antibody coupled to the gel binds VLDL and not chylomicrons, 
giving a clean separation of the apoBlOO TRL species from the apoB48 TRL species. 
The contamination of the apoB48 (unbound) fraction with apoBlOO protein was noted, 
this would lead to a small underestimation of apoBlOO TRL lipid concentrations but this 
underestimation would only increase the contribution of apoBlOO TRL and as such 
enhance the results which would thus be representative of what was actually happening 
to VLDL postprandially. In Eppendorfs recovery at 89% is virtually complete. The 
inability to recover 100% of triglyceride is due in part to manipulation loses and the 
measurement of low concentrations of triglyceride in the washings but mainlyto the fact 
that there is a void volume around the gel that accounts for appoximately 10% of 
starting volume. Washing the gel reduced this soucre of contamination to 5 %.
This methodology was used to study the effect of postprandial chylomicronaemia 
of the metabolism of VLDL subfractions after an oral fat load in two different subject 
groups; normals and diabetics (see chapters VI and VII).
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Figure 3.1: A Western blot showing the binding specificities
o f the tested polyclonal sheep and rabbit 
antibodies and the mouse monoclonal LDL A4 
antibody to apoB.
*---------------  *-x-----------------4*------ 4
Primary sheep rabbit mouse
antibody polyclonal polyclonal monoclonal
LDLA4
B100
B48
Secondary Anti-sheep HRP Anti-rabbit HRP Anti-mouse HRP 
antibody
Figure 3.2: Ponceau S stain o f apoB Western blot. it shows the
presence o f  all proteins with a sensitivity o f  l-2pg. ApoB48 and 
apoBlOO can be clearly seen in the chylomicron and VLDL 
fractions respectively.
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Figure 3.3: Western blot o f  apoB. H alf o f  the b lot was incubated
with the mouse monoclonal antibody LDL A4 and the other half 
with the rabbit po ly  cloned apo B antibody (used as a control).
There is a total absence o f  an apoB48 band in the chylomicron 
fraction after incubation with LDL A4, but an apoBlOO band is 
present in the VLDL fraction . There are apoB48 and apoBlOO 
bands present in the chylomicron fraction , and an apoBlOO band 
present in the VLDL fraction  after incubation with the 
rabbit polyclonal antibody. It was concluded that only the mouse 
m onoclonal antibody LDL A4 shows a binding that is specific to 
apoBlOO and not apoB48.
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Figure 3.4: Elution profiles for dissociation o f VLDL from
an LDL A4 monoclonal antibody im munoaffinity 
Column. Testing a series o f  agents: 0.5M and 1M NaCl, 
Glycine buffer pH 10.3 and 1M NaSCN buffer, absorbance 
measured at 280nm.
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Figure 3.5: Elution profile o f VLDL and LDL. Lipoprotein
samples were prepared from a fasted plasma sample by 
ultracentrifugation, followed by elution from an LDL A4 
monoclonal antibody immunoaffinity column, with absorbance 
measured at 280nm.
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Figure 3.6: Elution profile o f VLDL and LDL. Lipoprotein
samples were prepared from a fasted plasma sample by 
ultracentrifugation, followed by elution from an LDL A4 
monoclonal antibody immunoaffinity column, with absorbance 
measured at 500nm.
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Figure 3.7: SDS gel electrophoresis o f VLDL. v l d l  samples
were prepared by ultracentrifugation followed by elution from  an 
LDL A4 monoclonal antibody immunoaffinity column using 1M 
NaSCN, showing the presence o f  an apoB 100 protein band in the 
apoBlOO (bound) fraction.
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Figure 3,8: SDS gel elecirophoresis o f LDL . l d l  samples were 
prepared by ultracentrifagation followed by elution from an LDL 
A4 monoclonal antibody imrnunoaffinity column using iM  NaSCN, 
showing the presence o f  an apoBlOO protein band in the apoBlOO 
(bound) fraction.
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Figure 3.9:
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Elution profile fo r the separation o f 
chylomicrons and VLDL from a postprandial 
plasma sample. Lipoprotein samples were prepared by a 
single ultracentrifugation step, followed by elution using an LDL 
A4 monoclonal antibody immunoaffinity chromatography column, 
with absorbance measured at 280nm.
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Figure 3.10: Elution profile for chylomicrons. Lipoprotein samples
were prepared from a postprandial plasma sample by 
ultracentrifugation, followed by elution from an LDL A4 
monoclonal antibody immunoaffinity column, with absorbance 
measured at 280nm.
2 . 5
1 . 5  I-
0 . 5
I ;
I
, .
* a**<5
I
1©
£
— i—  
10 20 3 0 4 0  5 0  6 0
Fraction num ber
V .
7 0  8 0 9 0 100
3s*C>
603
§
101
s
.s.
■j
g
V.
S'Cv.
o«a
CJ.<3
s
•§,3^
f t
s
ha fe. "3 S 5
<Ts
Sa
•Sf£
jaffnq *m ds°M
o  o  o  
juiuoaz) aousqjosqv
A
bs
or
ba
nc
e 
(2
80
nm
)
102
Figure 3.12: Elution profile for the chylomicron and VLDL
mixed fraction (TRL (d< 1.006g/ml)). Lipoprotein 
samples were prepared from a postprandial plasma sample by 
ultracentrifugation, followed by elution from an LDL A4 
monoclonal antibody immunoaffinity column, with absorbance 
measured at 280nm.
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figure 3,13: SDS gel electrophoresis o f chylomicrons and
VLDL,. The lipoprotein fractions were prepared together by a 
single ultracentrifugation step fo llow ed  by the separation into 
apoB48 and apoBlOO TRL fractions by a Sepharose bound LDL 
A4 monoclonal antibody in Eppendorf tubes , showing the 
presence o f  an apoBlOO protein band in the apoBlOO (bound) 
fraction  and a fa in t apoB48 protein band in the apoB48 (unbound) 
fraction There were also fa in t apoBlOO bands present in the 
apoB48 (unbound) fraction.
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The effect o f the duration o f the initial 
incubation step on the binding o f VLDL. v l d l
sam ples were isolated from  a postprandial plasm a sam ple by 
ultracentrifiigation, and loaded onto an LDL A4 monoclonal 
antibody immunoaffinity gel in E ppendorf tubes.
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Figure 3,16: A saturation curve fo r  the binding o f various
concentrations o f  VLDL. VLDL sam ples were isolated  
from a fa sted  plasm a sample by ultracentrifugation, and loaded  
onto an LDL A4 m onoclonal antibody immunoaffinity gel in
Eppendorf tubes.
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Chapter IV Inhibition of adipocyte lipolysis.
1 Introduction.
Fatty acid metabolism (Amer 1990) plays a key role in the regulation of the 
energy balance of mammals. The major pathways for FFA metabolism are mobilisation 
through lipolysis at a time of energy deficit, and esterification of both exogenous and 
endogenous fatty acids to triglycerides when energy needs are met. In anabolic 
situations fatty acids are stored in various tissues as triglyceride. During prolonged 
physical work or in catabolic states, fatty acids are mobilised by the action of HSL 
(Frayn et al 1995) and used as fuel. Disturbances in fatty acid metabolism are involved 
in the pathogenesis of common diseases such as obesity, diabetes (Boden 1996, 
Durrington 1996, Lewis and Steiner 1996) and atherosclerosis (Frayn, Williams and 
Am er 1996). Some FFA never leave the fat cells, instead they are re-esterified to 
triglyceride. FFA can be taken up by the fat cell directly from the albumin bound fatty 
acids in the blood stream or from lipoprotein triglyceride which is hydrolysed outside 
the fat cell through the action of LPL (Goldberg 1996). FFA can also be produced 
through de novo synthesis from carbohydrates and used for esterification to triglyceride 
(Saloranta and Groop 1996).
Adipocyte lipolysis (Coppack, Jensen and Miles 1994) is regulated through a 
signal transduction pathway (Yeaman 1990, Yeaman et al 1994) (chapter I, figure 1.8) 
and proceeds by the action of 2 enzymes, HSL (hydrolysis of triacylglycerol (TAG) to 
diacylglycerol (DAG)) and monoacylglycerol lipase (hydrolysis of DAG to 
monoacylglycerol (MAG)). It is HSL that regulates the mobilisation of fatty acids from 
adipose tissue (Fredrickson et al 1981, Yeaman 1990, Frayn 1993 and Yeaman et al 
1994). In the short term, activity of the enzyme is controlled via reversible 
phosphorylation, involving a signal transduction pathway. HSL is phosphorylated and 
activated in response to a variety of lipolytic hormones (Yeaman 1990), with insulin 
(Egan et al 1990) exerting a major antilipolytic action. Activation by catecholamines 
occurs through an increase in cAMP levels and results in phosphorylation of HSL by 
cAMP dependent protein kinase on a single serine residue, termed the regulatory site 
(serine 563). In more detail, HSL lipolysis is under neural and hormonal control and 
stimulatory or inhibitory agents exert their effects via the adenylate cyclase-A-kinase
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signal transduction pathway (chapter I, figure 1.8). The stimulatory/ inhibitory 
compounds bind to receptors on the adipocyte cell membrane. These receptors are 
coupled to either stimulatory (Gs) or inhibitory (Gj) G proteins which in turn activate/ 
inhibit adenylate cyclase. HSL phosphorylation is paralleled by an enhanced 
triglyceride lipase activity (Fredrickson et al 1981). Two serine residues are 
phosphorylated on HSL. Phosphorylation on the basal site (serine 565) has no apparent 
direct effect on the enzyme activity but inhibits subsequent phosphorylation of the 
regulatory site (ser 563). The basal site is phosphorylated by 5 'AMP activated protein 
kinase (Gorton and Yeaman 1990, Hardie 1992) under basal conditions of lipolysis 
(Okuda, Morimoto and Tsujita 1994). These two phosphorylations on the regulatory 
(serine 563) and basal (serine 565) sites are mutually exclusive (Gorton et al 1989) 
meaning that phosphorylation by AMP kinase on the basal site would prevent further 
phosphorylation on the regulatory site and HSL activation.
The antilipolytic effect of insulin (Yeaman 1990) involves the dephosphorylation 
and hence inactivation of HSL in adipocytes. This action has been attributed to protein 
phosphatases (Wood et al 1993). Protein phosphatases (PP2A and 2C) are the only 
protein phosphatases to display activity towards HSL phosphorylated at the regulatory 
site and PP1, PP2A and PP2C have been detected within rat adipocytes at significant 
levels.
Rat HSL preferentially releases polyunsaturated fatty acids from triglycerides 
(Gavino and Gavino 1992). Rat HSL (Fredrickson et al 1981, Smith et al 1993) 
structure has been elucidated recently (Gabriele et al 1993). It is an 84 kDa polypeptide 
of 768 amino acids, with an active site at serine 423. After fasting (prolonged), HSL 
activity in adipose tissue increases (Sztalryd and Kraemer 1994 a).
1.1 In vitro stimulation of lipolvsis.
Lipolysis can be stimulated experimentally by incubating rat adipocytes with 
either adenosine deaminase (ADA)/ 3-isobutyl-1-methylxanthine (IBMX), forskolin or 
isoprenaline (chapter I, figure 1.8).
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ADA/IBMX stimulated lipolysis.
ADA is an enzyme which converts adenosine to inosine. Inosine is inactive at 
the adenosine A \  receptor; ADA thus removes the inhibition of adenylate cyclase caused 
by any endogenously released adenosine. IBMX is a purine analogue, and as such is a 
phosphodiesterase inhibitor, which prevents the breakdown of cAMP to AMP. With no 
breakdown of cAMP, HSL can be repeatedly phosphorylated and therefore activated. 
Using ADA and IBMX in combination means that HSL is constantly being activated, so 
if any inhibition of HSL activity occurs it is most probably due to the antilipolytic action 
of the drug present in the incubate.
Forskolin stimulated lipolysis. (Allen, Ahmed and Naseer 1986)
Forskolin activates adenylate cyclase directly, leading to an increase in 
intracellular levels of cAMP, phosphorylation and activation of HSL.
Isoprenaline stimulated lipolysis.
Isoprenaline binds to the 6-receptor which is coupled to the Gs protein which 
results in the activation of adenylate cyclase, increasing intracellular levels of cAMP 
leading to the activation of HSL. Glycerol is a better indicator of lipolysis than FFAs 
since glycerol can be re-utilised by fat cells only to a minor extent because of low 
glycerol kinase activity in these cells.
1.2 Aim.
The objective of the present study was to investigate the effect and mechanism of 
action of a number of agents - nicotinic acid (and analogues: acipimox, 3-methyl-5- 
pyrazole carboxylic acid (3M5P), 3-pyridyl acetic acid hydrochloride (3PAA)), 
clofibrate, a thiazolidione (TZD), 5-amino-4-imidazole carboximide ribonucleoside 
(AICAR), a 63 agonist, phenyl isopropyl adenosine (PIA), acifran, insulin and p- 
nitrophenylethylhexyl phosphonate (304205) - on HSL activity and adipocyte lipolysis in 
isolated rat adipocytes from fasted male Alderley Park rats. Figure 4.1 shows their 
structures. The overall aim was to understand how control of HSL activity by drugs 
could effect the flux of triglyceride postprandially and change the liver-adipose tissue 
relationship in fatty acid metabolism.
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2 Methods.
Male Alderley Park rats (150 - 200 grams) were fasted overnight and killed by 
exsanguination, before the immediate removal of the epididymal fat pads (Sztalryd and 
Kraemer 1994 b) for isolation of adipocytes by collagenase digestion.
2.1 Isolation of primary rat adipocytes from the epididvmal fat pads of Alderlev
Park rats.
Primary rat adipocytes were isolated from the epididymal fat pads of fasted male 
Alderley Park rats. The cells were liberated by collagenase digestion (1 mg/ml, 120 
rpm, 60 minutes, 37°C) (Worthington Biochemical Corp.) (Rodbell 1964), washed, 
diluted and resuspended (cell density =  4.7x10^ cells/ml) in 1% bovine serum albumin 
(BSA) (Sigma A7030) pH 7.4 - 7.5 in polyethylene tubes.
2.2 Preparation of compounds.
Test compounds were dissolved in neat dimethyl sulphoxide (DMSO) to give a 5 
mM stock solution, then serially diluted (see appendix 2) to give a final concentration 
range in the incubation media of 100 fiM - 3x10"^ /xM, with the exception of AICAR 
and insulin. AICAR was dissolved in neat DMSO to give a stock solution of 250 mM 
and serially diluted as for all other agents, to give a final concentration range in the 
incubation media of 5x10^ ^M - 1.5x10"^ jxM. Insulin was prepared as follows; 1.0 
mg insulin was dissolved in 1.0 ml 0.03 M HC1. The solution was made up to 3.0 ml 
with de-ionised H2O, 100 /xl was diluted to 5 ml with 1 % BSA buffer. This gives a 
stock solution of insulin of 1 /xM and after serial dilution a final concentration range in 
the incubation media of 2x10"^ M - 6x10“^  /xM.
2.3 Measurement of lipolysis.
Lipolysis was measured by quantitative enzymatic determination of glycerol 
(Sigma GPO-Trinder Reagent A kit) and non-esterified fatty acids (NEFA) (enzymatic 
colorimetric method) (Wako NEFA C kit). Concentrations of glycerol were determined 
spectrophotometrically at a wavelength of 540 nm with reference to a standard curve 
over a range 0 - 1.25 mg/ml. The assay was performed in triplicate. Concentrations of 
NEFA were also determined spectrophotometrically at a wavelength of 540 nm with 
reference to a standard calibration curve using oleic acid over a range 0 - 1  mEq/L (1 
mmol/L = 1 mEq/L). The assay was performed in triplicate.
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2.4 HSL assay in isolated rat adipocytes.
Triplicate aliquots of adipocytes were pre-incubated for 10 minutes at 37°C, 
(AICAR was preincubated with the adipocytes for 1 hour instead of 10 minutes, as it is 
an inactive cell permeable precursor of 5-amino-4-imidazolecarboxamide ribotide 
(ZMP)) with compounds (concentration range of 100 /xM - 3x10“^  jxM, 5x10^ /xM - 
1.5x10'4 jxM for AICAR and 2x10"^ /xM - 6x10"^ fiM for insulin). One percent (1%) 
BSA containing ADA/IBMX (2 /xM) was then added and adipocytes incubated for a 
further 2 hours at 37°C, 65 rpm. After the incubation was complete, an aliquot of 
medium was removed and assayed for glycerol and NEFA (chapter IV, section 2.3).
2.5 Alternative preparation of stimulatory buffers.
Adipocyte lipolysis was stimulated experimentally by either ADA/IBMX (2 jtM), 
forskolin (10 jttM) (Sigma F 6886) or isoprenaline (10 and 100 nM) in 1% BSA buffer 
pH 7.4 - 7.5 to study lipolysis (chapter IV, section 2.3) and HSL activity (chapter IV, 
section 2.6).
2.6 HSL assay in isolated primary rat adipocytes using ^H MOME as a
triglyceride substrate.
Monoacyl monoalkylglycerol (MOME) or l(3)oleoyl-(2)-oleyl-glycerol (figure 
4.2) is a triglyceride analogue specific for the conversion of DAG to MAG, and was 
therefore used to measure HSL activity. A radioactive emulsion was prepared, 5 mg 
cold MOME (Servicon) was added to 62 mg/ml ^H MOME (Servicon) and evaporated 
using N2 gas. Two ml of ice cold gum arabic (5 mg/ml) (Sigma G 9752) was added 
and the mixture sonicated for 5 minutes (10x30 secs) using a MSE soniprep 150 at 
maximum amplitude. The preparation was used and could be stored for up to 2 - 3 
hours at 4°C. MOME was diluted 1:7 with 72 mM sodium phosphate pH 6.8 (plus 
1.43 mM EDTA, 115 mM KC1, 29 mM NaCl, 67 mg/ml BSA).
Triplicate aliquots of adipocytes (prepared in section 2.1), compounds and 1% 
BSA buffer containing ADA/IBMX (2 /xM) (all BSA buffers contained 0.005% 
adenosine (Sigma A 9876) were incubated (2 hours, 37°C, 65 rpm) and the medium was 
removed and assayed for glycerol and NEFA levels. ^H MOME substrate emulsion was 
prepared and added directly to the adipocytes, which were vortexed and incubated (10 
minutes, 37°C). The reaction was stopped by the addition of stop solution (methanol: 
chloroform: heptane (1.41: 1.25: 1.00)) and the tubes again vortexed. Carrier oleate
I l l
(200 fig, from a 20 mg/ml stock solution stored at -20°C) and 0.1 M sodium carbonate, 
pH 10.5, were added and tubes centrifuged (5 minutes, 13500 rpm). The top aqueous 
layer was aspirated and dpm counted.
2.7 In vitro HSL assay using isolated, partially purified HSL.
Partially purified HSL was prepared by Mr Robert Forder of Zeneca 
Pharmaceuticals (Egan et al 1992).
The compounds, ^H MOME emulsion and partially purified HSL preparation (at 
a concentration to allow 5% hydrolysis of ^H MOME) (Egan et al 1992) were incubated 
in a glass tube (60 minutes, 30°C). The reaction was terminated by the addition of stop 
solution, with 200 fig carrier oleate and 0.1 M sodium carbonate, pH 10.5, also added. 
The tubes were vortexed and centrifuged (2000 rpm, 15 minutes) and the upper aqueous 
layer removed and counted for ^H dpm. Blank tubes received enzyme diluent (50 mM 
Tris pH 7, 2 mM EDTA, 0.2 mM benzamidine diluted 50: 50 with ethylene glycol).
2.8 Statistical analysis.
Statistical analysis was not performed on the data presented in the results section 
as experiments were performed only once or twice and only used triple replicates. The 
results presented in sections 3 and 3.1 were confirmed by the experiments whose results 
are presented in section 3.2.
3 Results.
Direct inhibition of HSL.
Compound 304205 was the only agent to inhibit the activity of partially purified 
isolated HSL in vitro. The other compounds showed no inhibitory effects suggesting 
their antilipolytic mechanism of action is exerted on the adipocyte signal transduction 
pathway.
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3.1 Effects of selected agents on lipolysis and HSL activity in ADA/IBMX
stimulated primary rat adipocytes.
Adipocytes were incubated with selected agents over the previously stated 
concentration ranges. NEFA and glycerol dose response curves were constructed for 
each agent. A characteristic dose response curve for nicotinic acid is shown in figure 
4.3.
The agents inhibited ADA/IBMX stimulated adipocyte lipolysis in a 
concentration dependent manner, with NEFA and glycerol concentrations reaching basal 
levels or below at 3 /xM for nicotinic acid, 3 /iM for compound 304205, 5000 /xM for 
AICAR, 10 /xM for acipimox, 0.003 /xM for PIA, 30 fiM  for 3PAA, 10 /xM for 3M5P, 
6x10“4 for insulin and 10 /xM for acifran.
Nicotinic acid (and analogues; acipimox, 3M5P, 3PAA), acifran, PIA, insulin, 
AICAR and 304205 all inhibited ADA/IBMX stimulated lipolysis in the isolated rat 
adipocyte. NEFA and glycerol IC50 concentrations were estimated for each agent (table 
4.1) from the dose response curves. Insulin was the most potent antilipolytic agent 
(IC50 = 5x10"5 fiM). The order of potency was determined as (most potent first) 
insulin > PIA > 304205 > 3M5P > acifran/ nicotinic acid/ acipimox > 3PAA > 
AICAR.
TZD, clofibrate and the 63 agonist failed to inhibit both ADA/IBMX stimulated 
lipolysis and HSL activity in isolated primary rat epididymal adipocytes.
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Table 4.1: NEFA and glycerol IC^q values (pM) fo r  selected agents determined as
a result o f their antilipolytic mechanism o f action in ADA/IBMX 
stimulated primary rat adipocytes isolated from fasted male Alderley 
Park rats.
Name NEFA 
IC50 ifiM)
Glycerol
IC50 (AtM)
Nicotinic acid 2 2
Acipimox 4 2
Acifran 2 1.38
3-pyridyl acetic 
acid hydrochloride 
(3PAA)
9 4
3-methyI-5-pyrazole 
carboxylic acid (3M5P)
0.74 1
Phenyl
isopropyl adenosine 
(PIA)
1.5xl0"3 2.7xl0"3
Insulin 5.8xl0"5 5 .4x l0 '5
AICAR 950 700
p-nitrophenylethyl
hexylphosphonate
(304205)
0.16 0.39
TZD (263423) Non active Non active
Clofibrate Non active Non active
B3 agonist (190483) Non active Non active
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Table 4.2: Effect o f  agents on HSL activity (% inhibition) in ADA/IBM X
stimulated rat adipocytes using MOME.
Agent Concentration (pM) Inhibition of HSL activity 
(%)
Nicotinic acid 100 41
30 37
3 43
Acipimox 100 36
10 32
1 21
Acifran 100 13
10 59
3 36
3PAA 100 6
30 24
3 9
3M5P 30 16
10 17
1 16
PIA 1 24
0.03 42
0.003 26
Insulin 6x10-3 7
6x l0"4 7
o\ X O 1 1
AICAR 5000 37
500 28
304205 30 99
3 89
0.3 44
TZD 100 -21
(263423) 0.003 -40
Clofibrate 100 16
0.003 -28
O3 agonist 0.3 -142
(190483) 0.0003 -73
3x10-6 -30
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Using the foregoing dose response data, the concentration of agents closest to the 
estimated ED95 and IC50 concentrations were selected for incubation with ADA/IBMX 
stimulated rat adipocytes and MOME substrate emulsion was used for the 
measurement of HSL activity.
Inhibition of HSL activity was concentration dependent for compound 304205 
(table 4.2). Compound 304205 inhibited HSL activity >90% at concentrations > 3  /xM 
with the other agents also inhibiting HSL activity: 40% at concentrations > 3  /xM 
nicotinic acid, 37% at 5000 (xM AICAR, 32 - 36% at concentrations >10  /xM 
acipimox, 24 - 42% at concentrations >0.003 /xM PIA, 24% for concentrations above 
30 /xM for 3PAA, 16 - 17% for concentrations >  10 /xM 3M5P, 7% for concentrations 
>6x10"4 /xM insulin and 13-59%  at concentrations > 10 /xM acifran (table 4.2), yet in 
contrast NEFA and glycerol levels were inhibited to basal levels at these concentrations. 
Thus inhibition of HSL activity did not appear to be concentration dependent and 
lipolysis measurements indicated almost total inhibition of triglyceride hydrolysis, yet 
levels of HSL inhibition appeared to be lower than that expected.
3.2 Effects of selected agents on lipolysis and HSL activity in ADA/IBMK.
forskolin and isoprenaline stimulated ra t adipocytes.
Compound 304205, nicotinic acid and AICAR all inhibited lipolysis (both NEFA 
and glycerol levels) in ADA/IBMX stimulated primary rat epididymal adipocytes. Only 
AICAR and 304205 also inhibited lipolysis in forskolin and isoprenaline stimulated rat 
adipocytes. Both concentrations of isoprenaline (100 and 10 nM) gave identical results. 
Nicotinic acid failed to inhibit lipolysis in forskolin and isoprenaline stimulated rat 
adipocytes, even at the maximal concentration of 100 fxM. Where inhibition of 
adipocyte lipolysis (by either of the stimulatory agents) was observed, NEFA and 
glycerol levels reached near basal levels at 3 /xM for 304205, 3 fxM for nicotinic acid 
and 5000 /xM for AICAR as seen previously in section 3.1.
Compound 304205 inhibited HSL activity >90% under all modes of lipolytic 
stimulation. Inhibition of HSL activity by 304205 appears to be concentration 
dependent. Nicotinic acid inhibited HSL activity only in ADA/IBMX stimulated rat 
adipocytes. AICAR, like compound 304205, inhibited HSL acitivity under all modes of 
stimulation. Nicotinic acid and AICAR appeared to inhibit HSL activity in a non- 
concentration dependent manner (table 4.3). NEFA and glycerol measurements 
indicated almost total inhibition of triglyceride hydrolysis but the levels of inhibition of
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HSL activity observed were lower than expected, confirming the results of previous 
sections.
Table 4.3: Effect o f selected agents on HSL activity (% inhibition) in ADA/IBMX
(2 iiM), forskolin (10 fiM) and isoprenaline (100 and 10 nM) stimulated 
rat adipocytes.
Agent Concentration
0*M)
ADA/
IBMX
(2 MM)
Forskolin 
(10 /iM)
Isoprenaline 
(100 nM)
Isoprenaline 
(10 nM)
304205 30 99% 99% 99% 99%
0.3 79% 49% 60% 38%
Nicotinic 100 52% - - -
acid 3 38% - - -
AICAR 5000 27% 36% 41% 44%
500 25% 28% 40% 19%
3.3 Effects of different lipolytic stimuli on the NEFA: glycerol ratio.
Throughout these experiments it was noted that the ratio of NEFA: glycerol was 
not the expected theoretical 3:1, but instead approximately 1:5. The NEFA: glycerol 
ratio was calculated in ADA/IBMX, forskolin and isoprenaline stimulated rat adipocytes 
in the absence of any antilipolytic agents. Results indicate no significant differences in 
NEFA: glycerol ratios (table 4.4) between the different methods of lipolytic stimulation 
of adipocyte lipolysis. The ratio remains largely unaltered in the presence of 
antilipolytic agents. The explanation for these findings is unclear requiring further 
investigation however these results suggest that there may be some re-esterification of 
NEFAs by the adipocyte. BSA, present in the incubation medium, can bind NEFAs 
released into the incubation medium by lipolysis making them less available for reuptake 
and re-esterification. If the concentration of BSA (1%) is too low and not all NEFAs 
are bound by it, then they are more likely to be taken up and re-esterified by the 
adipocyte. BSA concentration, cell concentration and variable removal of adenosine 
during isolation of adipocytes may have affected the 'basal' rate of lipolysis and the 
NEFA:glycerol ratio.
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Table 4,4: The effects o f different lipolytic stimuli on the NEFA: glycerol ratio in
isolated primary rat adipocytes from fasted male Alderley Park rats.
Condition NEFA: glycerol 
ratio
ADA/IBMX 0.152 ±  0.033
Forskolin 0.150 ±  0.017
Isoprenaline 0.165 ±  0.007
Basal 0.170 ±  0.022
4 Discussion.
In the present study, the antilipolytic mechanism of action of selected agents on 
rat adipose tissue lipolysis and HSL activity was investigated under three experimental 
conditions. Firstly it was tested in the presence of ADA/IBMX, secondly with forskolin 
a direct activator of adenylate cyclase and thirdly in the presence of the non-selective 15- 
ad renoreceptor agonist, isoprenaline.
Three agents, clofibrate, TZD and a 153 agonist failed to inhibit both lipolysis 
and HSL activity in ADA/IBMX stimulated rat adipocytes. All other compounds 
inhibited lipolysis and HSL activity in this model system.
TZDs act as insulin sensitisers (Bressler and Johnson 1992, Hofmann and Colca 
1992) with adipose tissue being one of its target tissues. Studies in Zucker rats 
(Fujiwara et al 1988) show a lowering of FFA levels from adipose tissue which may be 
due to the antilipolytic action of insulin as a result of TZD increasing insulin sensitivity 
in the adipose tissue. Studies in NIDDM subjects (Suter et al 1992) show compound 
CS-045 (a TZD) improves insulin resistance, although the mechanism of action of TZDs 
remains unknown and from the results of the present study does not seem to involve the 
signal transduction pathway for HSL.
Lipolysis in the ADA/IBMX stimulated rat adipocytes was inhibited in a 
concentration dependent manner with NEFA and glycerol concentrations reaching basal
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levels of lipolysis at 3 /xM for nicotinic acid, 3 /xM for compound 304205, 5000 /xM for 
AICAR, 10 /xM for acipimox (Christie et al 1996), 0.003 jxM for PIA, 30 /xM for 
3PAA, 10 /xM for 3M5P, 6x10“^  /xM for insulin and 10 jxM for acifran. NEFA and 
glycerol IC50 concentrations were established for each agent allowing an order of 
potency for inhibition of adipocyte lipolysis in ADA/IBMX stimulated rat adipocytes to 
be determined. Most of the agents demonstrated equal potencies on both NEFA and 
glycerol concentrations. Insulin the physiological hormone was the most potent. The 
order of potency was insulin >  PIA > 304205 >  3M5P > acifran/ nicotinic acid/ 
acipimox > 3PAA > AICAR.
In vitro studies showed only compound 304205 inhibited HSL activity. This 
suggests that while 304205 is a direct inhibitor of HSL and acts possibly by binding 
directly to the enzyme, the other agents exert their antilipolytic effect via the signal 
transduction pathway for HSL. Compound 304205 inhibits HSL activity in a 
concentration dependent manner. With the exception of compound 304205, inhibition 
of HSL activity in ADA/IBMX stimulated rat adipocytes seemed not to be concentration 
dependent and the levels of inhibition of HSL observed appeared to be lower in all 
experiments than that expected, since both NEFA and glycerol concentrations were 
reduced to basal levels i.e. NEFA and glycerol results suggest complete inhibition of 
triglyceride hydrolysis.
We hypothesise that there could be two forms of HSL present in the adipocyte; 
an active phosphorylated form and a basal unphosphorylated form. The basal 
unphosphorylated form may not have been translocated from the lipid droplet to its site 
of action and it is only when the adipocyte is lysed during the HSL assay that the 
unphosphorylated HSL can act on the ^H MOME substrate, a triglyceride analogue, 
which it can freely hydrolyse. This would explain the results observed in the present 
study. The levels of inhibition of HSL activity produced by the agents is representative 
of 100% inhibition of the active phosphorylated form of HSL accounting for the 
observed inhibition of NEFA and glycerol concentrations to basal levels. Compound 
304205, the direct inhibitor of HSL, binds to the active site on HSL thus inhibiting 
activity of all forms of HSL present within the adipocyte and so produces >90% 
inhibition of HSL activity. This increased level of inhibition of HSL activity is not 
observed with the other agents, which require the signal transduction pathway to inhibit 
HSL activity, suggesting that it is possibly binding to both the active and basal forms of 
HSL.
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The antilipolytic mechanism of action of selected agents on HSL activity and on 
rat adipose tissue lipolysis was investigated using three experimental conditions in the 
presence of ADA/IBMX (2 /xM), forskolin (10 /xM) and isoprenaline (100 nM/ 10 nM).
Compound 304205 and AICAR were found to inhibit HSL activity and adipocyte 
lipolysis under all modes of stimulation. Nicotinic acid inhibited HSL activity and 
lipolysis in ADA/IBMX stimulated rat adipocytes but failed to do so in forskolin and 
isoprenaline stimulated rat adipocytes. As shown by the in vitro assay, compound 
304205 is a direct inhibitor of HSL and as such its antilipolytic mechanism of action is 
not dependent on the stimulatory conditions present for adipocytes. Therefore as 
expected 304205 inhibits HSL activity and lipolysis under all of the modes of 
stimulation.
AICAR, the cell permeable precursor of ZMP has been shown by Sullivan et al 
(1994) to activate AMP kinase intracellularly in primary rat adipocytes resulting in the 
inhibition of lipolysis and HSL activity. Phosphorylation of HSL in intact rat 
adipocytes occurs on 2 distinct sites termed the regulatory and basal sites, although the 
physiological role of the basal site is not clear. Nevertheless, it has been proposed that 
by phosphorylating the basal site, AMP kinase plays an antilipolytic role in vivo (Garton 
et al 1989). This is the mechanism by which AICAR exerts its antilipolytic action upon 
HSL activity and lipolysis. Therefore, as expected its antilipolytic mechanism of action, 
like compound 304205, is not dependent on the stimulatory conditions present therefore 
AICAR, inhibits HSL activity and lipolysis under all of the modes of stimulation. 
Sullivan et al (1994) also showed AICAR to profoundly inhibit lipogenesis through 
increased phosphorylation of acetyl CoA-carboxylase (ACC). It appears that in addition 
to regulating lipogenesis, AMP kinase also plays an important antilipolytic role by 
regulating HSL in rat adipocytes.
Nicotinic acid inhibits lipolysis and HSL activity in ADA/IBMX stimulated rat 
adipocytes but failed to inhibit lipolysis and HSL activity in forskolin and isoprenaline 
stimulated rat adipocytes. An inherent part of ADA stimulated lipolysis involves the 
removal of adenosine. ADA converts adenosine to inosine. Inosine is inactive at the 
adenylate cyclase linked Gj protein complex (adenosine A \ receptor) thus removing the 
inhibition of adenylate cyclase and HSL activation caused by any endogenously released 
adenosine. However where adipocytes were stimulated with either forskolin or 
isoprenaline, ADA was not present in the incubation media, thus allowing endogenous 
and exogenous adenosine to accumulate. It is suggested that nicotinic acid (and 
analogues: acipimox, 3PAA, 3M5P which are pharmacologically related) and acifran
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are Gj receptor linked agonists, depending on adenosine removal to exert their 
antilipolytic effect, resulting in suppression of cAMP levels through inhibition of 
adenylate cyclase (Butcher 1971, Aktories, Jakobs and Schultz 1980, Christie et al 
1996). This would also be true of the adenosine analogue PIA (an A j agonist) which 
appears to require identical conditions for the inhibition of HSL (Aktories, Schultz and 
Jakobs 1980). In ADA/IBMX stimulated lipolysis, the adenylate cyclase linked Gj 
protein complex would be susceptible to inhibition whereas accumulation of endogenous 
and exogenous adenosine in forskolin and isoprenaline stimulated rat adipocytes may 
leave the adenylate cyclase linked Gj protein complex unresponsive to Gi linked agonists 
as the Gi protein complex is fully functioning and cannot be further activated by these 
agents. The dependence of nicotinic acid (and analogues) upon the removal of 
adenosine suggests that the antilipolytic mechanism used by adenosine may be similar to 
that of nicotinic acid. It is proposed that nicotinic acid initiates an antilipolytic effect 
via binding to a distinct Gi linked receptor on the plasma membrane of adipocytes.
The most important and potent antilipolytic agent is insulin. The mechanism of 
action of this hormone remains unclear but it is thought to exert its antilipolytic effect 
via a decrease in phosphorylation of HSL by inhibiting the action of protein 
phosphatases (Wood et al 1993) on HSL.
Independent of the incubation conditions of rat adipocytes, the NEFA: glycerol
ratio remained largely unaltered. Glycerol was used as an index of lipolysis since it
cannot be re-utilised by the adipocyte. The hypothesis is that re-esterification of NEFAs 
is occurring, with the possibility that the rate of cycling of the futile cycle is being 
increased in an attempt to increase the sensitivity of the metabolic system due to an 
artificial environment or to the presence of the inhibitory agents. Another possibility 
may be that Alderley Park rats over-express acyl coA-synthetase and as a result have 
increased levels of NEFA re-esterification. It would be of interest to study another 
breed of rats to see if this hypothesis was correct. Experiments using radiolabelled fatty 
acids could also be performed to detect if NEFA re-esterification is occurring.
A schematic representation of the antilipolytic action of agents upon HSL 
activity, which includes information derived from this study, is illustrated in figure 4.4.
The main findings of this study were clofibrate, TZD and H3 agonist failed to
inhibit both lipolysis and HSL activity in ADA/IBMX stimulated rat adipocytes. All
other compounds inhibited ADA/IBMX stimulated lipolysis, with insulin, the 
physiological hormone, being the most potent. Compound 304205 is a direct inhibitor
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of HSL and inhibits HSL acitivity by binding directly to the enzyme, while the other 
agents exert their antilipolytic effect via the signal transduction pathway for HSL. It is 
proposed that nicotinic acid (and its analogues) initiates its antilipolytic effect via 
binding to a distinct Gj linked receptor on the plasma membrane of the rat adipocytes.
It is suggested that HSL is present in the isolated rat adipocyte in both an active 
phosphorylated form and a basal unphosphorylated form, with antilipolytic agents 
exerting their inhibitory effect upon the active form of HSL.
Figure 4.1: Structures o f selected agents used to investigate
lipolysis and HSL activity in isolated rat 
epididymal adipocytes.
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Figure 4.2: The structure o f  the triglyceride analogue, 3 fj
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Figure 4.3: Dose response curve fo r  nicotinic acid in AD A /
1BMX stimulated rat epididymal adipocytes.
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Figure 4.4: The adipocyte signal tranduction pathway.
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Chapter V The Zucker rat: preliminary studies 
with nicotinic acid.
1 Introduction.
1.1 The Zucker rat.
The Zucker rat inherits obesity as an autosomal Mendelian recessive trait (Bray 
1977)\ this characteristic obesity is linked to an allele termed fa  which has been mapped 
to chromosome 5. The genetically obese Zucker (fa/fa) rat was first described by 
Zucker and Zucker in 1961 and is frequently used as a model of early onset human 
obesity and NIDDM. An increase in plasma triglyceride and lipoproteins is one of the 
earliest abnormalites described in the Zucker rat (Barry and Bray 1969). The model 
displays hyperinsulinaemia and hyperlipidaemia but in contrast blood glucose levels are 
normal. Schonfeld et al (1974 b) and Wang et al (1984) suggested that the 
hypertriglyceridaemia which characterises these animals is due to hypersecretion of 
hepatic VLDL; plasma levels of all lipids are elevated including VLDL, LDL, HDL and 
FFA. The accumulation of large VLDL in plasma probably reflects increased hepatic 
production without any defect in clearance (Bray 1977). Cleary et al (1987) and Fukuda 
et al (1982) have suggested that altered hepatic metabolism of FFA in this strain of rat 
could be an underlying factor in the hypersecretion of VLDL by the liver. The 
increased flux in FFA may come from the adipose tissue as these rats are 
hyperinsulinaemic, so conceivably HSL activity in the adipose tissue may be elevated. 
Bray et al (1970) showed that mobilisation of FFA from the adipose tissue was normal
or increased both in vivo and in vitro in Zucker rats. In a recent study (Kasim et al
1992) it was shown that in the Zucker rat model, HMG CoA-reductase inhibitors can 
reduce the rate of secretion of VLDL.
Nicotinic acid (vitamin B3) (Hotz 1983, Shepherd 1991) (chapter IV, figure 4.1) 
is unique among the hypolipidaemic drugs in that it is also an important component of a 
healthy diet. Nicotinic acid plays a number of roles in metabolism as an essential 
component of the pyrimidine nucleotides, and as an electron acceptor in a variety of 
oxidative reactions during the dehydrogenation of specific substrates in fatty acid
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oxidation, the pentose phosphate pathway and the tricarboxylic acid cycle. The 
pharmacological effects of nicotinic acid only manifest at high doses with no effect on 
lipoprotein metabolism at its recommended daily allowance of approximately 14 mg.
Nicotinic acid and its analogues have been used to treat both 
hypercholesterolaemia and hypertriglyceridaemia (Gotto et al 1996). Their clinical 
efficacy was first noted by Altshul, Hoffer and Stephen (1955) and they have since been 
used with varying success in the management of all forms of hyperlipidaemia. 
Treatment with nicotinic acid has not been widespread due to its unpleasant side effects, 
namely flushing and gastrointestinal irritation.
Nicotinic acid inhibits lipolysis of triglyceride by HSL in the adipose tissue, thus 
diminishing the supply of FFA and the synthesis of VLDL. It is thought that nicotinic 
acid mediates its antilipolytic effect through its agonist action at the Gi coupled receptor 
resulting in a decrease in the level of intracellular cAMP, mainly due to the inhibition of 
adenylate cyclase (chapter IV). The direct consequence of the reduced cAMP 
concentration in the adipose tissue is a reduction in the activity of HSL. This is 
associated with a reduced enzymatic cleavage of triglycerides into fatty acids, thereby 
lowering the flux of plasma FFA levels to the liver and diminishing production of 
VLDL. This leads to alterations in LDL and HDL metabolism: LDL synthesis appears 
to be inhibited and HDL cholesterol concentrations increase.
1.2 Aim.
To investigate the antilipolytic effect of nicotinic acid on adipose tissue lipolysis 
primarily in fasted and fed Zucker rats; by measurement of plasma FFA concentrations, 
free glycerol, true triglyceride and total triglyceride concentrations.
2 Methods.
2.1 Animals.
Fasted male Alderley Park (Wistar-derived) rats (200 - 300 grams) were kept in 
reverse phase lighting conditions (figure 5.1) for 1 week to acclimatise to conditions, 
then fasted for 18 - 20 hours prior to commencing the experiment. Two dose response 
curves were constructed; over dose ranges of 5 - 200 mg/kg and 1 5 - 6 0  mg/kg nicotinic 
acid (appendix 3). Groups of six rats were used.
127
Dose response 1: 5 - 200 mg/kg nicotinic acid.
Group 1 - Control - receiving excipient only (0.5% polysorbate). 
Group 2 - one dose of nicotinic acid 5 mg/kg.
Group 3 - one dose of nicotinic acid 10 mg/kg.
Group 4 - one dose of nicotinic acid 25 mg/kg.
Group 5 - one dose of nicotinic acid 50 mg/kg.
Group 6 - one dose of nicotinic acid 100 mg/kg.
Group 7 - one dose of nicotinic acid 200 mg/kg.
Bleeding for all groups was 2 hours post dose. 
Dose response 2: 15 - 60  mg/kg nicotinic acid.
Group 1 - Control - receiving excipient only (0.5% polysorbate). 
Group 2 - one dose of nicotinic acid 15 mg/kg.
Group 3 - one dose of nicotinic acid 30 mg/kg.
Group 4 - one dose of nicotinic acid 45 mg/kg.
Group 5 - one dose of nicotinic acid 60 mg/kg.
Bleeding for all groups was 2 hours post dose.
Fasted male obese Zucker (fa/fa) rats (500 - 600 grams) (appendix 4, 5) were 
kept in reverse phase lighting (figure 5.1) and fasted for 18 - 20 hours prior to 
experimentation. Two dose response curves were constructed; over dose ranges of 10 - 
200 mg/kg and 1.25 - 25 mg/kg nicotinic acid. Groups of six rats were used.
Dose response 1; 10 - 200 mg/kg nicotinic acid.
Group 1 - Control - receiving excipient only (0.5% polysorbate). 
Group 2 - one dose of nicotinic acid 10 mg/kg.
Group 3 - one dose of nicotinic acid 25 mg/kg.
Group 4 - one dose of nicotinic acid 50 mg/kg.
Group 5 - one dose of nicotinic acid 100 mg/kg.
Group 6 - one dose of nicotinic acid 200 mg/kg.
Bleeding for all groups was 90 minutes post dose.
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Dose response 2: 1.25 -25  mg/kg nicotinic acid.
Group 1 - Control - receiving excipient only (0.5% polysorbate).
Group 2 - one dose of nicotinic acid 1.25 mg/kg.
Group 3 - one dose of nicotinic acid 2.5 mg/kg.
Group 4 - one dose of nicotinic acid 5 mg/kg.
Group 5 - one dose of nicotinic acid 10 mg/kg.
Group 6 - one dose of nicotinic acid 25 mg/kg.
Bleeding for all groups was 90 minutes post dose.
Female Zucker rats were also used for one experiment (1.25 - 25 mg/kg 
nicotinic acid) and kept in the same conditions as their male counterparts.
The rats were allowed to acclimatise to their altered lighting conditions for one 
week before commencing experimentation. There are several advantages to keeping the 
rats in reverse phase lighting prior to and during the experiment: the rats were allowed 
to sleep uninterrupted by the working day's activities, the rats would be truly overnight 
fasted; under normal lighting conditions the rats are fasting during their active period, 
there is greater control over the fasting period (<  24 hours) and immediate postprandial 
experiments can be done during working hours.
Nicotinic acid was administered orally. A 200 mg/kg stock solution of nicotinic 
acid (Sigma N4126) (40 mg/ ml/ 200 gram rat) was prepared and serially diluted with 
excipient (0.5% polysorbate) to produce solutions for the dose response experiments in 
the Alderley Park (5 - 200 mg/kg and 1 5 - 6 0  mg/kg nicotinic acid) and Zucker rats (10 
- 200 mg/kg and 1.25 - 25 mg/kg nicotinic acid) (appendix 3).
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Both Alderley Park and Zucker rats were anaesthetised by inhalation of fluothane 
and bled 2 hours post dose for the Alderley Park rats and 90 minutes post dose for the 
Zucker rats. The Zucker rats were anaesthetised earlier due to the excessive length of 
time taken for them to be anaesthetised as a consequence of their size and fat content. 
Blood samples (5 ml) were obtained by aortic bleeding and collected into Na2EDTA 
tubes (final concentration of 1 mg/ml).
Rats were killed by exsanguination and disposed of by the animal unit at Zeneca 
Pharmaceuticals, Macclesfield.
2.2 Laboratory methods.
Plasma was harvested by centrifugation (1800 rpm, 15 minutes, 4°C) and frozen 
at -20°C until analysis. Lipolysis was measured primarily by quantitative enzymatic 
determination of plasma FFA (Wako NEFA C Kit), and plasma free glycerol (Sigma 
GPO-Trinder Kit). True triglyceride (total triglyceride minus free glycerol) and total 
triglyceride concentrations (Sigma GPO-Trinder Kit) were also determined. This kit 
releases glycerol from triglyceride and measures total glycerol concentrations present 
(including any free glycerol)). Concentrations of each variable were determined 
spectrophotometrically at 540 nm, with reference to standard curves. Coefficient of 
variation was < 3 %, for each variable. Assays were performed in triplicate.
Only plasma FFA levels were measured in the Alderley Park rats. Plasma FFA, 
free glycerol, true triglyceride and total triglyceride concentrations were determined in 
the Zucker rats. FFA IC5Q values for nicotinic acid, were calculated for both the 
Alderley Park and Zucker rats. Glycerol IC50 values were calculated for the Zucker 
rats.
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2.3 Data analysis.
The mean and standard deviation of means (before log transformation) for each 
variable were reported. Due to large variations in plasma FFA, free glycerol, true 
triglyceride and total triglyceride concentrations an Anderson-Darling test for normal 
distribution was carried out on the data. Data was not found to be normally distributed 
and was thus log transformed. Analysis of variance (ANOVA) was performed (on the 
log transformed data) to see if there were any significant differences in the 
concentrations of plasma FFA, free glycerol, true triglyceride and total triglyceride 
concentrations in rats who were given nicotinic acid compared to the control group of 
rats. The significance level was set at p< 0.05 . When overall significant differences 
were observed, a Fisher's pairwise comparison was carried out to identify the groups 
that contributed to the significant difference.
3 Results.
Two experiments were carried out to establish a dose response for nicotinic acid 
in Alderley Park rats: the first over a wide concentration range of 5 - 200 mg/kg 
nicotinic acid and the second over a more specific range 1 5 - 6 0  mg/kg. The mean 
plasma FFA concentrations from both experiments were pooled and a dose response 
curve plotted from which the FFA IC50 value was determined. These results were used 
to establish a preliminary concentration range for administration of nicotinic acid to the 
Zucker rats. Similarly, two experiments were carried out to establish a dose response 
for nicotinic acid in the Zucker rats: the first over a wide concentration range of 10 - 
200 mg/kg of nicotinic acid and the second over a more specific range 1.25 - 25 mg/kg 
of nicotinic acid. The results from both experiments were used together to produce dose 
response curves for plasma FFA and free glycerol from which the FFA and free 
glycerol IC50 values were determined. Free glycerol, true triglyceride and total 
triglyceride concentrations were measured in the Zucker rats.
3.1 Effect of administration of nicotinic acid (5 - 200 mg/kg) in fasted male
Alderlev Park rats.
In the fasted male Alderley Park rats, administration of nicotinic acid produced 
an overall significant decrease (p<0.001) in plasma FFA levels compared to the control 
rats. Fisher's pairwise comparison showed that administration of doses of 25 mg/kg of 
nicotinic acid and above produced significant differences (p<0.05) in plasma FFA 
levels from the control rats thus contributing to the overall significant decrease in
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plasma FFA levels (table 5.1). Administration of a dose of nicotinic acid as low as 25 
mg/kg produces more than 50% inhibition of plasma FFA levels, with doses of 100 and 
200 mg/kg nicotinic acid producing almost complete inhibition of plasma FFA levels 
compared to the control rats, suggesting almost complete inhibition of adipocyte 
lipolysis.
Table 5.1: Mean plasma FFA concentrations in Alderley Park rats after
administration o f  nicotinic acid over doses 5 - 200 mg/kg. Significantly 
different from control group as assessed by ANOVA and Fisher's pairwise 
comparison.
Nicotinic acid dose FFA p  value when
(mg/kg) Mean ±  SD 0imol/L) log transformed
control 1210 +  184 -
5 1180 + 168 NS
10 1268 ±  212 NS
25 592 ±  575 <0.05
50 369 ±  441 <0.05
100 9.80 ±  0.40 <0.05
200 22.30 ±  19.40 <0.05
* Doses o f  nicotinic acid (mg/kg) administered to the rat are very large compared to 
those given to humans.
3.2 Effect of administration of nicotinic acid (15 - 60 mg/kg) in fasted male
Alderlev Park rats.
In the fasted male Alderley Park rats administration of nicotinic acid produced an 
overall significant decrease (p<0.001) in plasma FFA levels compared to the control 
rats. Fisher's pairwise comparison showed that after administration of nicotinic acid 
doses of 45 and 60 mg/kg, plasma FFA levels were significantly decreased compared to 
the control rats, thus contributing to the overall significant difference seen (table 5.2). 
Administration of 45 mg/kg nicotinic acid, produced approximately 44% inhibition of 
plasma FFA levels, as compared to the control rats, with almost complete inhibition 
(94%) produced by administration of 60 mg/kg of nicotinic acid compared to the control 
group.
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Table 5.2: Mean plasma FFA concentrations in Alderley Park rats after
administration o f  nicotinic acid over doses 1 5 - 6 0  mg/kg (before log 
transformation). Significantly different from control group as assessed 
by ANOVA and Fisher's pairwise comparison.
Nicotinic
acid dose (mg/kg)
FFA
Mean ±  SD (pmol/L)
p  value when log 
transformed
control 695 ±  112 -
15 753 ±  76 NS
30 691 ±  259 NS
45 387 ±  437 <0.05
60 40 ±  11 <0.05
The mean plasma FFA concentrations for the various doses of nicotinic acid 
administered from both experiments were pooled (using data before log transformation), 
and a dose response curve for nicotinic acid in Alderley Park rats was plotted (figure
5.3) and the FFA IC50 value was estimated to be approximately 45 mg/kg.
3.3 Effect of administration of nicotinic acid (10 - 200 mg/kg) in fasted male
Zucker rats.
Analysis using ANOVA (after log transformation) showed that after 
administration of nicotinic acid there was an overall significant decrease in plasma FFA, 
free glycerol, true triglyceride and total triglyceride levels compared to control rats 
(table 5.3).
Plasma FFA.
Administration of nicotinic acid produced an overall significant decrease 
{p<0.001) in plasma FFA concentrations compared to control rats. Fisher's pairwise 
analysis showed plasma FFA levels, for all doses of nicotinic acid administered, to be 
significantly decreased (p<0.05) contributing to the overall significant decrease 
achieved (table 5.3).
In the Zucker rats, plasma FFA concentrations were significantly decreased 
compared to controls, with administration of a dose of nicotinic acid as low as 10 mg/kg 
producing a 74% inhibition of plasma FFA concentration. The other doses of nicotinic
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acid, 25, 50, 100 and 200 mg/kg produced 77%, 81%, 78% and 81% inhibition of 
plasma FFA levels compared to the control rats.
Table 5.3: Mean plasma FFA, free glycerol, true triglyceride and total
triglyceride concentrations in Zucker rats after administration 
o f  nicotinic acid over doses 10 - 200 mg/kg (before log transformation).
Significantly different from control group (after log transformation) as 
assessed by ANOVA and Fisher's pairwise comparison; *p<0.05.
Nicotinic 
acid dose 
(mg/kg)
FFA
Mean±SD
(/tmol/L)
Free
glycerol
Mean±SD
(mmol/L)
True
triglyceride
Mean±SD
(mmol/L)
Total
triglyceride
Mean±SD
(mmol/L)
control 1037 ±  128 0.90 ±  0.18 2.55 ±  0.74 3.54 ±  0.805
10 270 ±  103* 0.28 ±  0.08* 2.06 ±  1.72 2.36 ±  1.76*
25 241 ±  41* 0.28 ±  0.04* 1.10 ±  0.31* 1.40 ±  0.34*
50 193 +  53* 0.41 ±  0.21* 2.19 + 1.64 2.62 ±  1.86
100 225 ±208* 0.25 + 0.13* 1.04 +  0.29* 1.31 +  0.42*
200 193 ±  75* 0.29 ±  0.03* 1.30 ±  0.41* 1.61 ±  0.43*
Overall 
significant 
difference 
(p value)
<0.001 <0.001 0.013 0.02
Plasma free glycerol.
Plasma free glycerol levels behaved in a similar manner as plasma FFAs (table
5.3). Analysis using ANOVA showed there to be an overall significant decrease 
(p< 0.001) in plasma free glycerol concentrations produced by administration of 
nicotinic acid over the dose range of 10 - 200 mg/kg compared to control group. 
Fisher's pairwise analysis showed that after administration of all doses of nicotinic acid 
administered, plasma free glycerol levels were significantly decreased (p<0.05) from 
the control rats contributing to the overall significance level of inhibition achieved. 
Plasma free glycerol concentrations were significantly decreased compared to controls, 
with administration of a dose of nicotinic acid as low as 10 mg/kg producing a 69% 
inhibition of plasma free glycerol levels. The other doses of nicotinic acid, 25, 50, 100 
and 200 mg/kg produced 69 %, 54 %, 72 %, and 68 % inhibition of plasma free glycerol 
levels compared to the control group.
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Plasma true triglyceride.
Analysis using ANOVA showed there to be an overall significant decrease 
ip =0.013) (table 5.3) in plasma true triglyceride levels after nicotinic acid 
administration over a dose range of 10 - 200 mg/kg, compared to the control group of 
rats. Fisher's pairwise analysis showed that after administration of nicotinic acid doses 
of 25, 100 and 200 mg/kg, plasma true triglyceride levels were significantly decreased 
(p<0.05) compared to the control group therefore contributing to the overall significant 
difference seen. The levels of inhibition of plasma true triglyceride concentrations were 
not as pronounced as those obtained for plasma FFAs. Plasma true triglyceride levels 
were inhibited by 19%, 57%, 14%, 59%, and 49% at the nicotinic acid doses of 10, 25, 
50, 100 and 200 mg/kg respectively.
3.4 Effect of administration of nicotinic acid (1.25 - 25 mg/kg) in fasted male
Zucker rats.
Analysis using ANOVA (after log transformation) showed that after 
administration of nicotinic acid (1.25 - 25 mg/kg), there was an overall significant 
decrease in plasma FFA, free glycerol and total triglyceride compared to control rats. 
True triglyceride levels showed no significant differences compared to the control rats 
(table 5.4).
Plasma FFA.
Administration of nicotinic acid (1.25 - 25 mg/kg) produced an overall 
significant decrease (p<0.001) in plasma FFA levels. Ten and 25 mg/kg doses of 
nicotinic acid caused a significant decrease (p<0.05) in levels of FFA, thus contributing 
to the overall significant decrease observed (table 5.4). In the Zucker rats, plasma FFA 
concentrations were significantly decreased compared to control rats with plasma FFA 
levels inhibited by 54% and 79% at doses as low as 10 mg/kg and 25 mg/kg of nicotinic 
acid, respectively. Doses of nicotinic acid lower than 10 mg/kg had no inhibitory effect 
on plasma FFA levels.
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Plasma free glycerol.
Analysis using ANOVA showed there to be an overall significant difference 
(p <0.001) in plasma free glycerol levels after nicotinic acid administration (1.25 - 25 
mg/kg), compared to the control group. Fisher's pairwise comparisons showed that 
after administration of nicotinic acid, 25 mg/kg was the only dose where the plasma free 
glycerol levels decreased significantly (p<0.05) compared to the control rats 
contributing to the overall significant decrease (p<0.001) seen (table 5.4). The levels 
of plasma free glycerol were inhibited by 17%, 9%, 17%, 40% and 84% compared to 
control rats at doses of 1.25, 2.5, 5, 10, and 25 mg/kg of nicotinic acid respectively.
Plasma true triglyceride.
Analysis using ANOVA showed there to be no overall significant difference in 
plasma true triglyceride levels (table 5.4) after administration of nicotinic acid (1.25 - 
25 mg/kg) compared to the control group of rats. Plasma true triglyceride levels were 
inhibited by 9%, 26%, 37%, 47%, and 29% at the nicotinic acid doses of 1.25, 2.5, 5, 
10 and 25 mg/kg respectively.
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Table 5.4: Mean plasma FFA, free glycerol, true triglyceride and total
triglyceride concentrations in Zucker rats after administration o f  
nicotinic acid overdoses 1.25 - 25 mg/kg (before log transformation).
Significantly different from control group (after log transformation) as 
assessed by ANOVA and Fisher's pairwise comparison; *p<0.05.
Nicotinic 
acid dose 
(mg/kg)
FFA
Mean ±  SD 
Oimol/L)
Free Glycerol 
Mean ±  SD 
(mmol/L)
True TG 
Mean ±  SD 
(mmol/L)
Total TG 
Mean ±  SD 
(mmol/L)
control 1217 ±  400 0.70 +  0.18 2.72 + 1.01 3.45 +  1.20
1.25 1184 ±  194 0.58+ 0.20 2.46 +  1.05 3.07 +  1.24
2.5 1324 ±  264 0.64 ±  0.15 2.02 ±  0.95 2.68 ±  1.06
5 1347 ±  219 0.58 ±  0.09 1.71 ±  0.39 2.31 +  0.43
10 557 ±  202* 0.42 +  0.12 1.44 +  0.26* 1.87 +  0.25*
25 256 ±  71* 0.11 ±  0.08* 1.93 ±  0.92 2.05 +  0.97*
Overall 
significant 
difference 
ip value)
<0.001 <0.001 0.102 0.035
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The mean plasma FFA concentrations for the various doses of nicotinic acid 
administered from both experiments were pooled (using data before log transformation), 
and a dose response curve for the effect of nicotinic acid on plasma FFA levels in 
Zucker rats was plotted (figure 5.3) and the FFA IC50 value was calculated by 
extrapolation at 50% control and was estimated to be approximately 10 mg/kg.
Similarly the mean plasma free glycerol concentrations for the various doses of 
nicotinic acid administered from both experiments were pooled (using data before log 
transformation), and a dose response curve for the effect of nicotinic acid on plasma free 
glycerol levels in Zucker rats was plotted (figure 5.4) and the free glycerol IC50 value 
was calculated by extrapolation at 50% control and was estimated to be approximately 
10 mg/kg.
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3.5 Effect of administration of nicotinic acid (1.25 - 25 mg/kg) in fasted female 
Zucker rats.
Female fasted Zucker rats were used for one experiment but there was no 
relationship between mean plasma FFA concentrations and dose of nicotinic acid given 
even after log transformation (table 5.6). It was decided not to use female Zucker rats 
for any further experiments: plasma FFA levels were too variable and unreliable thus 
not giving a clear representation of the effects of nicotinic acid on plasma FFAs.
Table 5.5: Mean plasma FFA concentrations in female Zucker rats after
administration o f  nicotinic acid over doses 1 . 2 5 - 2 5  mg/kg (before log 
transformation).
Nicotinic acid dose 
(mg/kg)
FFA Mean ±  SD 
(/imol/L)
% Inhibition of plasma 
NEFA levels
control 719 ±  295 0
1.25 733 ±  481 -1.8
2.5 543 ±  24 24
5 860 + 502 -20
10 326 ±  500 55
25 273 +  311 62
Overall significant 
differences (p value)
0.069 -
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4 Discussion.
It is widely believed that raised plasma FFA levels induce insulin resistance 
(hyperinsulinaemia) as seen for example in NIDDMs. The Zucker rat provides a good 
animal model of insulin resistance and if plasma FFA levels could be normalised with 
nicotinic acid for example over a 24 hour period, then perhaps insulin levels may also 
be reduced accordingly. Preliminary dose response studies were carried out in Alderley 
Park rats to establish a dosing range for nicotinic acid administration in the Zucker rats; 
FFA IC50 values were estimated for nicotinic acid in both Zucker and Alderley Park 
rats. It is known that plasma FFA levels are lower during the day when constant 
browsing will cause insulin to be released from the pancreas, which in turn will inhibit 
lipolysis and FFA production. During the evening and night however plasma FFA 
levels rise to almost fasting levels and it is at this time that nicotinic acid should be 
administered to keep FFAs low. Changing the lighting scheme should make it easier to 
accomplish this so experiments can be carried out in the fed state.
Nicotinic acid inhibits triglyceride lipolysis in adipose tissue, exerting its 
antilipolytic effect by inhibiting HSL stimulated adipocyte lipolysis. Work performed in 
the previous chapter using Alderley Park primary rat adipocytes isolated from fasted 
male rat epididymal fat pads, showed that the antilipolytic effect of nicotinic acid is 
exerted on the adipocyte signal transduction pathway for HSL activation (chapter I, 
figure 1.8). More precisely, nicotinic acid acts as a Gj-linked receptor agonist 
inhibiting adenylate cyclase via Gi coupled receptors and therefore decreasing 
intracellular cAMP levels. Plasma FFA levels were used merely as an indicator that 
nicotinic acid was inhibiting adipocyte lipolysis in vivo. Nicotinic acid clearly had an 
inhibitory, dose related effect in both male Alderley Park and Zucker rats. From the 
dose response curves for FFA and glycerol levels, fasted male Zucker rats seem to be 
more sensitive to nicotinic acid (FFA IC50 approximately 10 mg/kg) than their Alderley 
Park counterparts (FFA IC50 approximately 45 mg/kg) which could be due to either 
increased fasting levels of FFA in Zucker rats or a different HSL activation state. 
However it must be taken into account that the Zucker rats were bled 90 minutes post 
dose, due to the length of time taken to anaesthetise them due to their excessive amount 
of body fat, and to prevent excessive fasting for some of the animals, whereas the fasted 
male Alderley Park were bled 120 minutes post dose. The earlier bleeding of the 
Zucker rats would favour a lower IC50 value; this issue would therefore have to be 
resolved by repeating the Alderley Park rat dose response experiments and bleeding 
them 90 minutes post dose. In the fasted male Zucker rats the glycerol IC50 was 
estimated to be 10 mg/kg thus confirming the results seen in the previous chapter that
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nicotinic acid appears to inhibit FFA and glycerol levels to the same extent both in vivo 
and in vitro.
These preliminary studies with nicotinic acid in the Zucker rat were carried out 
with a long term aim towards acquiring a dose of nicotinic acid which would normalise 
insulin levels in the Zucker rat. This would be of great use, as Zucker rats are 
hyperinsulinaemic and develop marked hyperlipoproteinaemia as a result of over­
production of VLDL enriched in triglyceride similar to the situation in NIDDMs. It was 
hoped that by finding a dose of nicotinic acid that would suppress FFA levels (for 
example) for 24 hours or longer, this would normalise plasma insulin levels and maybe 
even start to correct some of the defects in the adipose tissue-liver relationship in Zucker 
rats.
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Figure 5.1: Reverse phase lighting conditions.
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Figure 5.2: Nicotinic acid dose response curves fo r  plasma
FFA levels in the fasted male Alderley Park rats 
(1C50=45 mg/kg) and Zucker rats 
(lCso=10 mg/kg).
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Figure 5.3: Nicotinic acid dose response curves fo r  plasma
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Chapter VI The regulation of intestinal and 
hepatic lipoprotein synthesis in 
normal patients after a fa t meal.
1 Introduction.
Triglyceride-rich lipoproteins (TRL) are a heterogeneous population of 
lipoprotein particles. VLDL are produced in the liver and contain apoBlOO and 
endogenous lipids. In contrast, ingestion of fat leads to the formation of chylomicrons 
containing apoB48 in the intestine which compete for a common lipolytic pathway with 
VLDL (Brunzell et al 1973). The lipoprotein species of primary interest in the 
postprandial phase are the intestinally derived chylomicrons. Also of recent interest is 
the effect of postprandial chylomicronaemia upon VLDL subfraction metabolism. 
Suprisingly, it has been shown that the postprandial increase in TRL particle numbers 
are mainly accounted for by VLDL, particularly large VLDL, VLDLj (Cohn et al 1988 
a and b, Karpe et al 1993, Schneeman et al 1993) whereas 80% of postprandial 
triglyceride is carried by lipoprotein particles containing apoB48. Most lipoprotein 
studies have been carried out in the fasting state, but humans spend most of their time in 
the postprandial phase. Investigations in the fed state require to be carried out, to 
understand the changes in lipoprotein metabolism postprandially. Traditionally these 
studies have been performed after subjects receive either an oral fat meal or an 
intravenous Intralipid infusion.
1.1 Quantification of postprandial lipoprotein metabolism.
In the past, several methods have been developed and used to study postprandial 
metabolism. Originally, postprandial lipoprotein metabolism was evaluated by 
measuring triglyceride concentrations in whole plasma and in TRL (d<  1.006g/ml) 
fractions after an oral fat load (Foger and Patsch 1993). Triglyceride is the chief 
component of chylomicrons (constituting 85%) (chapter I, table 1.2) and was used in 
this study to monitor chylomicron levels postprandially. Chylomicrons and VLDL were 
isolated together in the TRL (d<  1.006g/ml) fraction after a single sequential 
ultracentrifugation spin, following ingestion of an oral fat load. This yielded important
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insights into TRL metabolism but gave no indication or quantification of which 
lipoprotein fractions were responsible for changes in triglyceride levels in the 
d <  1.006g/ml fraction postprandially. Indeed it was assumed that all changes occurred 
in apoB48 particles, so other methods for quantification were required to be used to get 
a clearer picture of what was happening.
Postprandial triglyceridaemia predominately represents the presence in the 
plasma of large TRL, of both intestinal and hepatic origin. To determine the 
contribution of each of these species to postprandial triglyceridaemia several methods 
have been developed. These were either used separately or in combination to determine 
the contribution of both TRL species to postprandial triglyceridaemia. Both 
apolipoprotein (apoB48 and apoBlOO) determination and retinyl esters (RE) have been 
used for this purpose. RE (retinyl palmitate) have been employed as a marker of 
cholesteryl ester transport by chylomicrons and their remnants (Berr and Kern 1984). 
RE are incorporated into the core of chylomicrons in the intestine, following the 
absorption and esterification of vitamin A (Goodman et al 1966), the rationale (Berr and 
Kern 1984) for this approach is based on the concept that dietary vitamin A is esterified 
in the intestine and is incorporated into the core of chylomicron particles. These 
lipoproteins are secreted into intestinal lymph and their triglyceride component 
hydrolysed by LPL in the circulation. It is believed that the RE remain associated with 
chylomicrons during lipolysis and are taken up by the liver within chylomicron remnants 
via a receptor-mediated process. Evidence suggests that the liver does not re-secrete 
these RE and they are either stored or exported as unesterified retinol bound to retinal- 
binding protein. As plasma exchange between lipoproteins is believed to be minimal 
(Berr and Kern 1984) and RE are not re-secreted into the circulation, it was postulated 
that RE in plasma were appropriate markers for lipoproteins containing apoB48 of 
intestinal origin. Supplementation of test fat meals with vitamin A has therefore been 
commonly used as a means of quantifying lipoproteins of intestinal origin in the 
postprandial state (Simpson et al 1990, Karpe et al 1995). This method has been 
adopted by several groups in combination with other methods. However a recent study 
(Cohn et al 1993) found that RE within the TRL fraction were not always associated 
with the apoB48 containing lipoproteins and they are therefore not necessarily indicative 
of TRL of intestinal origin. RE were found to be regularly detected in apoBlOO TRL as 
well as in apoB48 samples. It was demonstrated that an increase in VLDL triglyceride 
accounts for approximately 20% of postprandial triglyceride. A significant portion of 
retinyl palmitate, up to 25% is bound to apoBlOO containing TRL at later time points, 
which suggests that it derives from transfer of core lipids between lipoproteins. Thus 
RE labelling of chylomicrons seems not to be a valid means over the longer term of
145
quantifying TRL particles of intestinal origin in the postprandial state but retinyl 
palmitate is a valid tracer substance of intestinal lipoproteins over the first few hours 
following ingestion of a fatty meal and as such, is useful in conjunction with other 
methods.
Concentrations of apoB48 and apoBlOO, the main structural components of TRL 
of both intestinal and hepatic origin respectively (Scott 1990) can be quantified after 
isolation of lipoproteins by ultracentrifugation, by SDS PAGE and subsequent 
densitometric scanning of protein bands stained with Coomassie Blue stain (chapter II, 
section 2.10.1) (Poapst et al 1987, Zilversmit and Shea 1989, Karpe and Hamsten 1994, 
Kotite, Bergeron and Havel 1995). One or two groups have already devised methods 
using monoclonal antibodies to separate TRL into apoB48 and apoBlOO TRL species, as 
described previously in chapter III. The methodology developed in chapter III allows 
the separation of apoB48 (chylomicrons) and apoBlOO (VLDL) TRL species, but goes 
on further to delineate the behaviour of VLDL subfractions (large and small VLDL, 
VLDLi and VLDL2) during postprandial lipaemia.
1.2 Aim.
This study was undertaken to delineate the behaviour of VLDL subfractions in 
both normal and diabetic patients (see chapter VII) during postprandial lipaemia. These 
lipoprotein particles were isolated by immunoaffinity chromatography and cumulative 
flotation.
2 Methods.
2.1 Patient selection, clinical measurements and oral fat tolerance tests.
Nine healthy subjects (6 males and 3 females) (table 6.1) were recruited from 
laboratory staff, friends and family. Initially a single fasting blood sample was taken to 
check plasma lipid levels were within the reference range (appendix 7). All were non- 
smokers.
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Table 6.1: Normal subject characteristics.
Subjects (n=9) Mean ( ± SD)
Age (years) 
BMI (kg/m2)
36 ±  10 
23.03 ± 1 . 1 9
Triglyceride (mmol/L) 1.11 ±  0.45
Cholesterol (mmol/L) 4.84 ±  0.72
VLDL cholesterol (mmol/L) 0.48 ±  0.17
LDL cholesterol (mmol/L) 2.91 ±  0.65
HDL cholesterol (mmol/L) 1.28 ±  0.34
Subjects were admitted at 8 am after an overnight fast, and a 22G venous 
cannula was placed in one forearm. Blood samples were taken through this during the 
day, the cannula being kept patent by flushing with normal saline (0.9%). A standard 
fat milkshake was prepared, containing 137 grams fat with a total energy content of 
1400 kcal (Warwick et al 1992). The oral fat load consisted of 280 ml double cream, 20 
grams sugar, 20 grams dried skimmed milk and 20 ml flavouring. After a 12 hour fast, 
subjects drank the milkshake within 15 minutes. The milkshake was well tolerated by 
all subjects. The subjects fasted for a further 11 hours, with free access to unlimited 
low calorie soft drinks.
A fasting blood sample was taken before intake of the fat meal, subsequent blood 
samples being drawn hourly for 11 hours after the ingestion of the fat meal. At 4 pm, 
the patients were given a low calorie fat free meal. In total, about 300 ml blood was 
taken during the turnover study. The bleeding schedule is given in appendix 8. Blood 
samples were collected into Na2EDTA tubes. For every time point, plasma was 
harvested by centrifugation (3000 rpm (1300 g), 15 minutes, 4°C) and stored at 4°C 
until analysis. For each time point, TRL (d<  1.006g/ml) were freshly isolated from 
plasma by sequential flotation ultracentrifugation (39000 rpm (108000 g), 15°C, 16 
hours) (chapter II, section 2.7) and subjected to immunoaffinity chromatography (using 
a Sepharose bound LDL A4 monoclonal antibody in Eppendorf tubes) (chapter III, 
section 3.6) in order to separate apoB48 and apoBlOO containing TRL, i.e. 
chylomicrons and VLDL, respectively. VLDL were further separated into large
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VLDLi and small VLDL2 subfractions by cumulative flotation (Lindgren and Jensen 
1972) (chapter II, section 2.8)
fl-Quantification of fasting lipids and lipoproteins, and apoE phenotyping were 
measured on the fasting plasma sample (0 hour). Plasma insulin concentrations were 
measured at 0 and 2 hours. ApoB and Al concentrations were measured in plasma and 
the TRL (d<  1.006g/ml) fractions at all time points. Triglyceride and cholesterol 
concentrations were measured in all plasma, TRL (d< 1.006g/ml), apoB48 (unbound), 
apoBlOO (bound), large VLDLi and small VLDL2 fractions at all time points. Plasma 
FFA concentrations were measured at all time points.
Bleeding of normal subjects was carried out by Dr. Vian Anber of the Lipid 
Research Group. The fat milkshakes were prepared on the morning of the oral fat loads 
by the hospital diet cooks, in the hospital kitchens.
2.2 Ethics approval.
Studies were approved by the Ethics Committee of Glasgow Royal Infirmary.
2.3 Statistical analysis.
Mean and standard deviation of means for plasma parameters were reported. 
Paired t-tests were used to determine the statistical significance for lipid, apoproteins 
and insulin, between measurements obtained from fasting (0 hour) and postprandial 
samples. Area measurements were expressed as mmol.hour. The Minitab 10 statistical 
package was used to calculate regression coefficients and p  values for correlations.
3 Results.
The B-Quantification measurements for the initial fasting plasma samples for 
each patient are shown in table 6.2. All fasting plasma lipid levels were within the 
acceptable reference range for the laboratory (appendix 7).
Triglyceride, cholesterol, apoB, and apoAI concentrations determined in the 
various lipoprotein fractions were adjusted back to plasma levels. Triglyceride 
concentration was used to study the metabolism of postprandial lipoproteins. Individual 
plasma, TRL (d<  1.006g/ml), apoB48, apoBlOO, VLDLj and VLDL2 triglyceride
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concentrations before and after ingestion of a fat load are shown in tables in the 
appendices (9 - 14). Individual plasma cholesterol, FFA, plasma and TRL 
(d<  1.006g/ml) apoB and AI concentrations before and after ingestion of a fat load are 
shown in tables in the appendices (15 - 20).
Table 6.2: fi-Quantification o f  lipids and lipoproteins and apoE phenotypes.
Lipid levels 
(mmol/L)
Subjects
BC MM BJ KE HA CN JM  IC AG
Plasma
triglyceride
1.20 0.95 0.85 1.15 1.00 1.30 0.50 0.90 2.11
Plasma
cholesterol
3.6 5.35 5.90 4.70 4.80 4.05 3.75 4.70 5.44
VLDL
cholesterol
0.40 0.50 0.50 0.35 0.35 0.45 0.90 0.35 0.60
LDL
cholesterol
2.35 3.35 4.10 2.65 2.95 2.40 2.10 2.70 3.60
HDL
cholesterol
0.85 1.50 1.30 1.70 1.50 1.20 0.75 1.65 1.05
ApoE
phenotype
4/3 3/3 3/3 3/2 3/3 4/3 3/3 4/3 3/2
Mean (±SD) plasma triglyceride concentrations before and after the ingestion of 
the fat load are shown in table 6.3 and figure 6.1. Mean plasma cholesterol 
concentrations did not change significantly during the course of the experiment. After 
the fat load, individual plasma triglyceride concentrations peaked between 3 - 7  hours 
postprandially, with triglyceride concentrations ranging from 1.75 - 6.04 mmol/L, and a 
mean peak of 3.45 ±  1.36 mmol/L (table 6.4). (Note table 6.3 shows mean 
triglyceride levels over the time course of the experiment while table 6.4 shows the 
mean maximal triglyceride value for subjects taken when their individual peaks 
occurred, usually at 4, 5, or 6 hours). When all individual plasma triglyceride response 
curves were combined, there was a peak at 5 hours postprandially with a mean 
triglyceride concentration of 2.84 +  1.33 mmol/L (table 6.3). The mean plasma 
triglyceride concentration was significantly elevated ip <0.05) above fasting 
concentration 1 - 8  hours postprandially (table 6.3, figure 6.1).
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Table 6.3: Postprandial changes in mean triglyceride concentrations
(mmol/L ±  SD) in plasma and all TRL fractions in normal subjects 
after an oral fa t load. Significantly different from fasting concentration 
by paired t-test *p < 0.05, **/? <0.01, ***p<0.005
Time
(hours)
Mean
Plasma
TG
(mmol/L 
±  SD)
Mean
TRL
(d< 1.006 
g/ml) TG 
(mmol/L 
± SD)
Mean 
ApoB48 
TRL TG 
(mmol/L 
±  SD)
Mean 
ApoBlOO 
TRL TG 
(mmol/L 
±  SD)
Mean
VLDLj
TG
(mmol/L 
±  SD)
Mean
VLDL2
TG
(mmol/L 
±  SD)
0 1.11 ±  
0.45
0.61 ±  
0.36
0.21 ±  
0.15
0.36 ±  
0.21
0.22 ±  
0.16
0.08 ±  
0.03
1 1.26 ±  
0.50**
0.75 ±  
0.43*
0.32 ±  
0.23*
0.38 ±  
0.25
0.23 ±  
0.17
0.07 ±  
0.3
2 1.94 ±  
0.84***
1.21 ±  
0.57***
0.64 +  
q 32***
0.47 ±  
q  23***
0.31 ±  
0 .2 0 ***
0.08 ±  
0.03
3 2.55 +
1 l g * * *
1.63 ±  
0.87***
0.98 ±  
0.59***
0.52 ±  
q 32***
0.35 ±  
0.25**
0.08 ±  
0.02
4 2.75 ±
j 34***
1.69 ±  
0.82***
1.05 +  
0.58***
0.50 ±  
0.30*
0.34 ±  
0 .21*
0.07 ±  
0.02
5 2.84 +  
1.33***
1.88 ±  
Q  ^ g * * *
1.29 ±  
0.83***
0.56 ±  
0.36*
0.37  ±  
0.29
0.07 ±  
0.03
6 2.78 ±  
1.68**
1.84 ±  
1.34*
1.20 ±  
1.03*
0.49 ±  
0.39
0.34 +  
0.32
0.07 ±  
0.03
7 2.43 ±  
1.31**
1.52 ±  
1.01*
0.91 ±  
0.65**
0.47 ±  
0.38
0.31 ±  
0.29
0.07 ±  
0.03
8 1.94 ±  
1.16*
1.21 +  
0.88
0.73 ±  
0.58*
0.39 ±  
0.31
0.23 ±  
0.22
0.058 +  
0.04
9 1.78 ±  
1.05
1.04 ±  
0.81
0.63 ±  
0.63
0.33 ±  
0.26
0.21 ±  
0.17
0.06 ±  
0.04
10 1.39 ±  
0.74
0.76 ±  
0.58
0.43 ±  
0.45
0.25 ±  
0.17
0.14 ±  
0.08
0.06 ±  
0.04
11 1.05 ±  
0.45
0.52 ±  
0.34
0.26 ±  
0.19
0.22 ±  
0.13
0.11 ±  
0.05
0.05 ±  
0.03
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TRL (d<  1.006g/ml) fractions were isolated from plasma by sequential flotation 
ultracentrifugation and were separated into apoB48 and apoBlOO TRL species by 
immunoaffinity chromatography. The apoBlOO TRL species were further separated into 
large and small VLDL subfractions (VLDLi and VLDL2 respectively) by cumulative 
flotation.
In the fasting state (time =  0 hour) the mean plasma triglyceride concentration 
was 1.11 ±  0.45 mmol/L (table 6.4) and mean TRL (d<  1.006g/ml), apoB48, 
apoBlOO, VLDLj and VLDL2 triglyceride concentrations were 0.61 ±  0.36 mmol/L, 
0.21 ±  0.15 mmol/L, 0.36 ±  0.21 mmol/L, 0.22 +  0.16 mmol/L and 0.08 ±  0.03 
mmol/L respectively.
Table 6.4; Mean o f maximal postprandial triglyceride levels fo r  individual subjects
after a fa t load when mean peaks occurredf usually at 4, 5 or 6 hours.
Lipoprotein
fraction
Mean fasting TG 
(mmol/L)
Mean individual 
peak TG (mmol/L)
Mean peak 
(hours)
Plasma 1.11 + 0.45 3.45 +  1.36 5
TRL (d < 1.006g/ml) 0.61 ±  0.36 1.88 ±  0.98 5
ApoB48 0.21 +  0.15 1.56 ±  0.80 5
ApoBlOO 0.36 +  0.21 0.63 + 0.35 5
VLDLi 0.22 ±  0.16 0.43 ±  0.29 5
VLDL2 0.08 ±  0.03 0.08 +  0.03 -
In the fed state at the time of maximal triglyceride increase (mean 5 hours 
postprandially for all lipoprotein fractions), there was a 68% increase in both mean 
plasma and mean TRL (d<  1.006g/ml) triglyceride concentrations. Mean apoB48 TRL 
triglyceride concentrations showed an 84% increase, with mean apoBlOO TRL 
triglyceride levels increasing by 36%. Mean large VLDLi and small VLDL2 
triglyceride levels increased by 41% and 4% respectively.
Table 6.3 shows mean TRL (d< 1.006g/ml) triglyceride concentrations after the 
ingestion of a fat meal. Individual TRL (d<  1.006g/ml) triglyceride concentrations 
peaked between 3 - 7  hours postprandially, with triglyceride concentrations ranging 
from 1.09 - 4.35 mmol/L; and a mean peak of 1.88 ±  0.98 mmol/L (table 6.4). When 
all the individual TRL (d<  1.006g/ml) triglyceride response curves were combined, 
there was a mean peak at 5 hours postprandially with a mean triglyceride concentration 
of 1.88 ±  0.98 mmol/L (table 6.3). The mean TRL (d<  1.006g/ml) triglyceride
151
concentrations were significantly elevated (p<0.05) above fasting concentrations 1 - 7  
hours postprandially, in accord with total plasma data (table 6.3).
The mean triglyceride concentrations of plasma, TRL (d<  1.006g/ml), apoB48 
and apoBlOO, VLDLi and VLDL2 fractions before and after the fat load are shown in 
figure 6.2. (Note significant differences from fasting triglyceride concentrations in 
plasma and TRL (d<  1.006g/ml) fractions before and after a fat load are shown in 
figure 6.2, while those for apoB48, apoBlOO, VLDLi and VLDL2 fractions are shown 
in figure 6.3) After the fat load, individual apoB48 triglyceride concentrations peaked 
between 3 - 8  hours postprandially, with triglyceride concentrations ranging from 0.67 -
3.00 mmol/L; and a mean peak of 1.56 ±  0.80 mmol/L (table 6.4). When all 
individual apoB48 triglyceride response curves were combined there was a mean peak at 
5 hours postprandially, with a mean triglyceride concentration of 1.29 ±  0.83 mmol/L 
(table 6.3). The mean apoB48 triglyceride concentration was significantly elevated 
above fasting concentrations 1 - 8  hours postprandially (table 6.3, figure 6.3). Again, 
the apoB48 results are in accord with plasma and TRL (d<  1.006g/ml) data. The 
majority of the postprandial increase in plasma triglyceride concentrations seems to be 
due to the increase in apoB48 triglyceride concentrations. A smaller but significant 
increase was observed in mean apoBlOO TRL triglyceride concentrations (table 6.3, 
figure 6.3). The individual apoBlOO triglyceride concentrations increased between 
hours 1 - 5 ,  peaking between 3 - 7  hours postprandially with triglyceride concentrations 
ranging from 0.3 - 1.44 mmol/L, and a mean peak of 0.63 ±  0.35 mmol/L (table 6.4). 
The mean apoBlOO triglyceride concentrations were significantly elevated above fasting 
concentrations between 2 - 5  hours (figure 6.3, table 6.3). After peaking, the 
triglyceride concentration decreases rapidly after 8 hours, with the decrease becoming 
significant after 11 hours.
Large VLDLi triglyceride concentrations increased between 1 - 5  hours (figure
6.4), peaking individually between 3 - 6  hours postprandially, with triglyceride 
concentrations ranging from 0.18 - 1.13 mmol/L; and a mean peak with a triglyceride 
concentration of 0.43 ±  0.29 mmol/L (table 6.4). Individual VLDLi triglyceride 
response curves peaked then decreased rapidly after 8 hours. When all the individual 
large VLDLi triglyceride response curves were combined, there was a mean peak at 5 
hours postprandially with a mean triglyceride concentration of 0.37 +  0.29 mmol/L 
(table 6.3). Individual (appendix 14) and mean VLDL2 triglyceride concentrations did 
not change significantly during the course of the experiment (figure 6.3, table 6.3), with 
triglyceride concentrations remaining relatively constant.
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The contribution of apoB48 and apoBlOO TRL fractions to the postprandial 
increase in TRL triglyceride and VLDLi VLDL2 fractions to the postprandial 
increase in total apoBlOO TRL triglyceride (table 6.5) was quantitated by measuring the 
area under individual triglyceride response curves (fasting 0 hour concentration was 
taken as baseline). Mean areas under the curve were calculated for plasma, TRL 
(d<  1.006g/ml), apoB48, apoBlOO, VLDLi and VLDL2 fractions (table 6.6). The 
increase in apoB48 TRL triglyceride was 5 times greater than the increase in apoBlOO 
TRL triglyceride (6.13 ±  4.28 mmol.hour vs 1.25 ±  1.06 mmol.hour). Seventy nine 
percent (±  8%) of the postprandial increase in TRL (d<  1.006g/ml) triglyceride was 
due to apoB48 TRL. The contribution of apoBlOO TRL accounted for 15% (±  8%) of 
the postprandial increase in TRL (d<  1.006g/ml) triglyceride. The increase in VLDLi 
triglyceride was 11 times greater than the increase in VLDL2 triglyceride (0.94 +  0.76 
mmol.hour vs 0.086 ±  0.077 mmol.hour). Seventy five percent (+  17%) of the 
postprandial increase in total apoBlOO triglyceride was due to VLDLi, with 10% (±  
10%) of the postprandial increase in total apoBlOO accounted for by VLDL2 .
Table 6.5: Contribution o f  apoB48 and apoBlOO TRL to postprandial increases in
TRL (d<1.006g/ml) triglyceride concentration, and o f  VLDLi and 
VLDL2 to postprandial increases in the apoBlOO TRL triglyceride 
concentration. Quantitated by the measurement o f area under the 
individual triglyceride response curves.
Fraction ApoB48 ApoBlOO VLDLi VLDL2
Triglyceride
(mmol.hour)
6.31 ±  4.28 
(79%)*
1.25 ±  1.06 
(15%)*
0.94 ±  0.76 
(75%)*
0.086 ±  0.077 
(10%)*
*Values in parentheses represent increases expressed as percentages o f  the total.
Mean cholesterol concentrations were also measured in the different TRL 
fractions and these results (mean cholesterol concentrations for each fraction) are shown 
in figure 6.5. A postprandial increase in total TRL (d<  1.006g/ml) cholesterol was 
observed in every subject, with mean TRL cholesterol concentrations increasing 
significantly 1 - 6 hours postprandially followed by a decrease in the mean TRL 
cholesterol to fasting concentrations. Mean apoB48 TRL cholesterol was significantly 
elevated 2 - 6  hours postprandially, returning to fasting concentrations 11 hours 
postprandially. There was no significant change in mean apoBlOO TRL cholesterol. 
Mean VLDLj TRL cholesterol levels were significantly increased 2 - 4  hours
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postprandially with no change in mean VLDL2 TRL cholesterol concentrations 
observed.
Table 6.6: Individual and mean areas under the curve (mmol.hour) to assess the
contribution o f apoB48 and apoBlOO TRL, VLDLi and VLDL2  to 
postprandial increases in the plasma concentration o f  triglyceride.
Subject Plasma
(mmol.hr)
TRL
(d<  1.006
g/ml)
(mmol.hr)
ApoB48
(mmol.hr)
ApoBlOO
(mmol.hr)
VLDLi
(mmol.hr)
VLDL2
(mmol.hr)
BC 23.42 18.48 15.73 1.80 0.78 0.08
MM 8.10 6.33 5.08 0.72 0.58 0.03
BJ 13.20 6.13 5.37 0.45 0.88 0.13
KE 11.94 8.71 5.27 2.82 2.08 0.067
HA 2.87 1.98 1.67 0.24 0.14 0
CN 3.65 2.72 2.13 0.30 0.24 0
JM 10.24 8.28 6.37 1.32 1.15 0.12
IC 9.17 6.41 5.13 0.60 0.37 0.25
AG 18.40 12.63 10.02 2.97 2.56 0.09
Mean 
(±  SD)
11.20 ±  
6.45
7.96 ±  
5.06
6.31 ±  
4.28
1.25 ±  
1.06
0.94 ±  
0.76
0.086 ±  
0.077
Mean plasma apoB, apoAI and TRL (d<  1.006g/ml) apoAI concentrations did 
not change significantly during the course of the experiment. Mean apoB TRL 
(d<  1.006g/ml) concentrations were significantly elevated above fasting concentrations 
2 - 5  hours postprandially (figure 6.6).
Plasma FFA concentrations were measured and the results (mean plasma FFA 
concentrations) are shown in figure 6.7. There was a consistent initial decrease in 
plasma FFA concentrations 1 - 2  hours after ingestion of the fat meal in virtually all 
subjects (appendix 15) followed by a subsequent rise in plasma FFA concentrations and 
a fall back towards baseline. Mean plasma FFA concentrations were significantly 
elevated (p<0.05) above fasting plasma levels 3 - 1 1  hours postprandially, with a mean 
peak at 6 hours, reaching a plateau and then a decrease after 10 hours (figure 6.7).
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Plasma insulin levels (table 6.7) were increased 2 hours after ingestion of the fat 
meal in virtually all subjects. Mean plasma insulin concentrations were significantly 
elevated (p=0.039) above fasting levels 2 hours postprandially.
Table 6.7: Postprandial changes in individual and mean plasma insulin
concentrations (mU/ L). Significantly different from fasting 
concentration by paired t-test: *p<0.05.
Subjects
Time (hours) 
0 hours 2 hours
Delta insulin
BC 7.00 14.10 7.10
MM 8.60 6.70 -1.90
BJ 6.20 8.40 2.20
KE 9.00 14.50 5.50
HA 8.40 10.00 1.60
CN 4.50 7.30 2.80
JM 2.50 11.70 9.20
IC 7.90 18.00 10.10
AG 10.60 38.90 28.30
Mean insulin 
(mU/L) ±  SD
7.19 ±  2.48 14.40 ±  9.91* 7.21 ±  8.50
Correlations between variables.
To examine the effect of fasting triglyceride concentrations on the measured 
parameters of postprandial lipaemia, the data for normal subjects was analysed. There 
was no significant correlation between log fasting triglyceride and the area under the 
curve for plasma (r=0.29, p=0.44), apoB48 (r=0.248, p= 0.52 ), apoBlOO (r=0.47, 
p=0.20), VLDLi (r=0.43, p=0.25) triglyceride or between log fasting triglyceride and 
area under the curve for VLDL2 triglyceride (r=-0.34, p=0.37).
To examine the effect of changes in insulin concentrations on the measured 
parameters of postprandial lipaemia, the data for normal subjects was analysed and 
revealed significant positive correlations between delta (/. e. a change in) insulin and the 
area under the curve for apoBlOO (r=0.67, p=0.045) and VLDLi (r=0.72, p=0.03 ) 
triglyceride. In addition, there was also positive significant correlations between delta 
insulin and the delta apoBlOO (r=0.70, p=0.03) and VLDLi (r=0.85, p —0.004) 
triglyceride concentrations (figure 6.8). A positive correlation, which failed to reach
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significance was observed between delta insulin and area under the curve for plasma 
(r=0.52, p=0.15), apoB48 (r=0.45, p= 0.22) and VLDL2 (r=0.33, p =0.39) 
triglyceride and between delta insulin and delta apoB48 (r=0.65, p = 0.059) and delta 
plasma (r=0.61, /?=0.081).
No correlations between delta insulin and FFA area under the curve (r=-0.093, 
p= 0.81 ) and delta insulin and delta FFA ( r= -0.002, p= 0.99 ), delta VLDL2 (r=-0.18, 
p=0.64) were observed.
4 Discussion.
A specific monoclonal antibody for apoBlOO, LDL A4, as described previously 
in chapter III, was used to isolate the apoB48 and apoBlOO containing TRL species from 
plasma obtained from normal subjects in the postprandial state. This allowed further 
examination of VLDL subfractions by cumulative flotation, from the apoBlOO 
containing TRL fraction isolated by immunoaffinity chromatography. In order to obtain 
reliable quantitative data with the antibodies, single sample aliquots in individual 
eppendorf tubes containing the antibody bound to sepharose were used, rather than 
eluting fractions from an immunoaffinity chromatographic column, as described 
previously in chapter III.
The individual and mean plasma triglyceride concentrations increased in all 
patients, with the individual plasma triglyceride response curves showing a large 
variation between subjects which appeared to be independent of their fasting triglyceride 
levels. Mean plasma cholesterol concentrations remained unchanged. Mean TRL 
(d<  1.006g/ml), apoB48, and VLDLj cholesterol concentrations were significantly 
elevated above fasting levels 1 - 6  hours in TRL (d<  1.006g/ml) fraction, 2 - 6  hours 
for apoB48 and 2 - 4  hours postprandially for VLDLi. Total apoBlOO and VLDL2 
cholesterol concentrations remained relatively constant throughout the duration of the 
experiment.
A consistent initial decrease in plasma FFA concentrations was observed 1 - 2  
hours postprandially in virtually all subjects followed by a subsequent rise in plasma 
FFA concentrations and a fall back to baseline. This phenomenon has previously been 
observed by others (Lewis et al 1991, O'Meara et al 1992) and is suggested to be 
related in timing to the early postprandial insulin rise. As seen in this study, plasma 
insulin concentrations increased significantly 2 hours postprandially. Plasma FFA 
concentrations were increased significantly above fasting levels 3 - 11 hours
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postprandially, peaking after 6 hours, presumably as a result of the hydrolysis of the 
apoB48 (chylomicron) and apoBlOO (VLDL) TRL associated triglyceride by LPL. It is 
likely that the capacity to incorporate FA into adipose tissue is exceeded.
Other investigators (Cohn et al 1988 a and b) have reported that the plasma 
concentration of apoB either does not change, or falls after a fat meal. In this study 
similar results were observed. Mean plasma apoB and Al and TRL (d<  1.006g/ml) 
apoAI concentrations did not alter during the postprandial period, while the TRL 
(d<  1.006g/ml) apoB concentrations were significantly elevated above fasting levels 2 - 
5 hours postprandially and then decreased as noted by Cohn.
The increase in plasma triglyceride concentration after an oral fat load is 
predominantly due to triglyceride contained within the apoB48 containing lipoproteins in 
the TRL fraction of plasma, with apoB48 TRL and apoBlOO TRL species accounting for 
approximately 79% and 15% of the postprandial increase in TRL triglyceride 
concentration, in agreement with earlier results, and VLDLi VLDL2 accounting for 
75% and 10% of the postprandial increase in total apoBlOO TRL triglyceride 
concentration. Although the increase in plasma triglyceride concentration in the fed 
state was predominantly due to an increase in apoB48 TRL triglyceride concentration, 
there was a significant increase in apoBlOO TRL triglyceride concentration above fasting 
levels over hours 2 - 5  representing a 36% increase in apoBlOO triglyceride 
concentration. It was also noted that triglyceride was present in the apoB48 (unbound) 
fraction at 0 hours. This may have been due to the presence of fasting chylomicrons or 
chylomicron remnants present in the plasma sample or to VLDL that failed to be 
retained by the antibody gel (see chapter III).
There may be several reasons for the increase in the concentration of apoBlOO 
triglyceride in postprandial plasma. The first may be that the plasma clearance of 
apoBlOO TRL is inhibited by the influx into plasma of postprandial chylomicrons. 
Second, the ingestion of a fat rich meal may stimulate the synthesis and secretion of 
apoBlOO TRL from the intestine. Third, hepatic apoBlOO TRL production may be 
enhanced postprandially in response to lipid of dietary origin reaching the liver via the 
portal vein or via chylomicron transport. The first possibility is supported by the studies 
of Brunzell (1973) who showed that chylomicrons and VLDL are catabolised by a 
common pathway. Triglycerides in both chylomicrons and VLDL are hydrolysed by 
LPL at the capillary endothelial surface and these lipoproteins can compete for enzyme 
mediated lipolysis. Reduced availability of lipolytic activity due to the postprandial 
presence of apoB48 containing chylomicrons could explain the observed increase in
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apoBlOO TRL triglyceride. An increase in the production of apoBlOO TRL is another 
equally plausible explanation. Cohn et al (1988 b) previously found that in the fed state 
there is an increase in the plasma concentration of apoBlOO in the TRL fraction, as well 
as an increase in the rate of production of apoBlOO TRL (Cohn et al 1990). They 
suggested that this represents a postprandial increase in synthesis and secretion of TRL 
by the liver, as it is normally assumed that apoBlOO in plasma is of hepatic origin.
In the normal subjects, positive significant correlations (Pearson) were seen 
between delta insulin and the area under the curve for apoBlOO and VLDLi 
triglyceride. In addition, there was also significant positive correlations between delta 
insulin and the delta apoBlOO and delta VLDLi triglyceride concentrations. A possible 
explanation may be that as insulin activates LPL activity, there is competition between 
chylomicrons and VLDL for lipolysis, chylomicrons are the preferred substrate and as 
such are hydrolysed. As a result VLDL accumulates due to decreased catabolism and 
continued synthesis. A possible explanation of the preferential lipolysis of chylomicrons 
compared to VLDL might be differences in apolipoprotein contents between these two 
TRL species. A delayed clearance of VLDL might be due to alterations in the 
apolipoprotein and lipid composition of VLDL particles. Bjorkegren et al (1997) 
observed that large and small VLDL were enriched in cholesterol, apoE and Cl, but 
depleted of apoCII, whereas the apoCIII, triglyceride and phospholipid contents were 
essentially unchanged in the postprandial state. ApoCII is necessary for the activation of 
LPL thus VLDL are poorly lipolysed possibly due to a lack of apoCII. Bjorkegren et al 
(1997) also noted an early transient increase in apoCIII contents of large VLDLj 
particles which may be implicated in the accumulation of this lipoprotein species during 
alimentary lipaemia (Karpe et al 1993). Theoretically, the early apoCIII accumulation 
and the depletion of apoCII of large VLDL could explain part of the preferential 
lipolysis of chylomicrons and the ensuing postprandial accumulation of large VLDL 
observed both by Bjorkegren et al (1996) and the present study.
Positive significant correlations (Pearson) (see chapter VII) were seen between 
log fasting triglyceride concentrations and individual area under the curve for plasma, 
apoB48, apoBlOO and VLDLj triglyceride response curves. This would indicate that 
fasting triglyceride concentrations have a bearing on postprandial triglyceride responses.
Other studies have suggested that the human intestine has the capacity to 
synthesise apoBlOO (Hoeg et al 1990), and it cannot be ruled out that in the fed state, 
apoBlOO TRL is partly of intestinal origin. The postprandial state has been postulated to 
be potentially atherogenic on the basis that intestinal chylomicrons and their remnants
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have the potential to cause lipid deposition in the cells of the artery wall (Zilversm.it 
1979). Postprandial apoBlOO may be of equal significance especially if it is the 
precursor of LDL which may be potentially atherogenic. The long term effects of 
repeated and prolonged alimentary lipaemia may be derangements in the metabolism of 
endogenous lipoproteins that are atherogenic.
The results from this study confirm the findings of both Karpe et al (1993) and 
Bjorkegren et al (1996). A 3 fold increase in plasma triglyceride levels was 
accompanied by an increase of large VLDLi triglyceride concentrations (between 1 - 5 
hours), in contrast VLDL2 triglyceride levels remain unaltered. Bjorkegren concluded 
that the most likely explanation for the rise in S f 60 - 400 VLDL is delayed lipolysis of 
the particle due to competition for the sites of LPL action. Recently Karpe and Hultin 
(1995) have shown that endogenous TRL accumulate in rat plasma due to a failure to 
compete for a common lipolytic pathway with a chylomicron-like emulsion. It was 
observed in most subjects that as the apoB48 TRL triglyceride level (figure 6.3) dropped 
to below 1 mmol/L at 7 - 8 hours, apoB48, apoBlOO and large VLDLj lipolysis levels 
became accelerated. Total apoBlOO and large VLDLj triglyceride levels dropped to 
below almost half that of fasting triglyceride levels (figure 6.3). In contrast small 
VLDL2 triglyceride levels remained relatively constant and unaffected by the levels of 
chylomicronaemia. It is suggested that this accelerated lipolysis is as a result of 
increased (excess) levels of LPL being present to hydrolyse the intestinal lipoproteins. 
As the levels of these decreases, LPL action over-compensates and lipolysis of the 
remaining lipoproteins becomes accelerated, with the result that the total apoBlOO and 
large VLDLi triglyceride concentrations drop to below fasting levels.
The fat load given, contained a supra-normal amount of fat (137 grams), in that 
the normal fat intake for women is approximately 75 grams/day and for men 99 
grams/day. This dose generated a clear response to the fat load, which was the 
objective of the study. In the literature alternative approaches have been taken for 
postprandial studies. These include a variety of either solid or liquid fat loads with 
either a constant dose of fat for all subjects or doses used as grams fat per kg body 
weight (ranging from 0.2 - 1.0 grams fat/ kg body weight) with meals containing from 
15 - 75 grams of fat. None of these approaches appear to be superior to the other and 
for reasons of simplicity we chose to use a constant dose of 137 grams of fat contained 
in a liquid fat load, used successfully in previous investigations in this laboratory 
(Warwick et al 1992).
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Figure 6.1: Postprandial changes in the mean plasma
triglyceride concentration. Significantly different from  
fasting concentration by pa ired  t-test: * p < 0 .0 5 , * * p < 0 .01, 
* * * p <  0.005.
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Figure 6.2: Postprandial changes in the mean triglyceride
concentration o f  plasma and all TRL fractions.
Significantly different from  fasting  concentration by pa ired  t-test:
fp <  0 .05 , * * p < 0 .0 l , * * * p <  0.005.
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Figure 6.3: Postprandial changes in the mean triglyceride
concentration o f  individual TRL fractions 
apoB48, apoBlOO, VLD Lj, VLDL2. Significantly 
different from  fasting  concentration by pa ired  t-test: * p < 0 .0 5 ,  
* * p < 0 .0 1 , * * * p <  0 .005.
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Figure 6.4: Increment in triglyceride concentrations in the
individual VLDLj TRL fractions (baseline at 
zero time subtracted).
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Figure 6.5: Postprandial changes in the mean cholesterol
concentrations in all the TRL fractions.
Significantly different from  fasting concentration by pa ired  t-test: 
* p < 0 .0 5 , * * p < 0 .0 1 , * * * p < 0.005.
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Figure 6.6: Postprandial changes in the mean plasma and 
mean TRL (d< 1.006g/ml) apoB and apoAI 
Concentrations. Significantly different from  fasting 
concentration by pa ired  t-test: * p <  0.05 , * * p <  0.01 .
* * * p <  0 .005.
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Postprandial changes in the mean plasma 
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Figure 6.8: Pearson correlations. Correlations between (a) delta
insulin and individual areas under the curve (mmol.hour) f o r  (i) 
apoBlOO and (ii) VLDLj and between (b) delta insulin and the 
increase, in (delta) (i) plasm a, (ii) apoBJOO and (iii) VLDLj 
triglyceride concentrations (mmol/L) f o r  normal patients.
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Chapter VII Metabolism of chylomicrons and 
VLDL in diabetic patients after a 
fat meal.
1 Introduction.
The current classification and diagnosis of diabetes was developed by the National 
Diabetes Data Group (NDDG) and published in 1979, who recognised 2 major forms of 
diabetes, which they termed insulin-dependent (IDDM) and non-insulin-dependent 
diabetes mellitus (NIDDM), now termed type 1 and type 2 diabetes respectively. It is 
now considered to be important to move away from a system that appears to base its 
classification of the disease, in large part, on the type of pharmacological treatment used 
in its managemant toward a system based on the disease etiology where possible. The 
vast majority of cases of diabetes fall into 2 broad categories. In one category (type 1 
diabetes), the cause is an absolute deficiency of insulin secretion resulting from a 
cellular-mediated autoimmune destruction of the 13-cells of the pancreas. In the other, 
(type 2 diabetes), the cause is a combination of resistance to insulin action and an 
inadequate compensatory insulin secretory response (relative insulin deficiency). The 
current expert committee (1997) have now proposed changes and modifications to the 
NDDG diagnosis and classification scheme (Report Committee 1997). The revised 
criteria for the diagnosis of diabetes mellitus are a casual plasma glucose (PG) (casual is 
defined as any time of the day without regard to time from last meal) concentration _> 
200 mg/dl (11.1 mmol/L, or a fasting (fasting defined as no calorie intake for 8 hours) 
PG _>_ 126 mg/dl (7.0 mmol/L) or a 2 hour PG J>200mg/dl during an OGTT (oral 
glucose tolerance test). This new criteria would not alter the status of the diabetic 
patients recruited here (appendix 35).
1.1 Lipid and lipoprotein abnormalities in NIDDM.
As previously discussed in chapter I, the basic dyslipidaemia that accompanies 
diabetes was described several years ago (Howard 1987). Recent work has focussed on 
abnormalities in lipoprotein alterations, composition and apolipoprotein content and the 
metabolic mechanisms that govern these changes.
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The most common abnormality of lipid metabolism in patients with diabetes is 
hypertriglyceridaemia due to an elevation in VLDL (Howard et al 1978, Mattock et al 
1979, Briones et al 1984, Bierman 1992, Laws 1996). This is accompanied by a 
decrease in HDL cholesterol concentrations. Abnormalities in both production (Abrams 
et al 1982, Kissebah et al 1982, Reaven 1987) and clearance (Abrams et al 1982, 
Kissebah et al 1982, Howard et al 1983, Taskinen et al 1986) of VLDL triglyceride 
have been reported in NIDDM (Type 2 diabetics). Kissebah et al (1982) also found that 
hypertriglyceridaemic diabetics had elevated rates of VLDL apoB production, a finding 
compatible with data in non-diabetics. There appear to be changes in the composition of 
VLDL (Schonfeld et al 1974 a, Taskinen et al 1986), which suggest that non-insulin 
dependent diabetics may have larger, triglyceride-rich VLDL as indicated by a higher 
triglyceride: apoB ratio. One of the general effects of NIDDM (Type 2 diabetics) on 
lipoprotein metabolism may be a relative decrease in LPL activity, consistent with the 
observed delayed clearance of VLDL.
The magnitude of postprandial lipaemia is known to be highly dependent on the 
fasting plasma triglyceride concentration (Patsch 1987)] since NIDDM (Type 2 
diabetics) patients generally have a higher fasting plasma triglyceride, a disturbed 
postprandial triglyceride metabolism would be expected. However it is not yet known 
in diabetics if the exaggerated lipaemia, often present towards the latter hours after a fat 
feed, is due to the persistance of VLDL or due to failure to clear either or both 
chylomicrons and VLDL. The only way to answer this question is to separate apoB48 
and apoBlOO TRL.
1.2 Aim.
This study was undertaken to delineate the behaviour of VLDL subfractions, in 
both normal (see chapter VI) and diabetic patients during postprandial lipaemia. These 
lipoprotein particles were isolated by immunoaffinity chromatography and cumulative
flotation. This is a novel study investigating mechanisms not previously examined in
diabetics.
2 Methods.
2.1 Patient selection, clinical measurements and oral fat tolerance tests.
As in chapter VI methods section.
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2.1.1 Diabetic subjects.
The diabetic subjects recruited were all attending the Diabetic clinic. All were 
well controlled Type 2 diabetics, and not on lipid treatment. All subjects were recruited 
by Dr Neil Bennett with the permission of Dr A. MacCuish. The patients were initially 
contacted by Dr Bennett during routine visits to the Diabetic clinic where he discussed 
the study with them and asked if they would consider taking part. If the patients agreed, 
an initial fasting blood sample was taken to check that lipid levels (table 7.1) were 
relatively normal (triglyceride approximately 2 mmol/L and cholesterol approximately 6 
mmol/L). Plasma apoB, apoAI and FFA levels were also measured. The subjects were 
given an information sheet (appendix 21) about the study. Suitable subjects were 
contacted by telephone and then by letter. All subjects gave signed informed consent 
before the study was started (appendix 22). Initially 25 diabetic subjects were screened 
and from those, 5 diabetic subjects (3 males and 2 females) agreed to take part in the fat 
feeding study. Their mean plasma lipid levels are given in table 7.1.
Table 7.1: Diabetic subject characteristics.
Subjects (n=5) Mean ( ±  SD)
Age (years) 61.8 ±  9.0
BMI (kg/m2) 31.2 ±  2.28
Triglyceride (mmol/L) 1.79 ±  1.15
Cholesterol (mmol/L) 5.04 ±  0.90
VLDL cholesterol (mmol/L) 0.68 ±  0.38
LDL cholesterol (mmol/L) 3.59 ±  0.65
HDL cholesterol (mmol/L) 0.70 ± 0.70
2.2 Statistical analysis.
Mean and standard deviation of means for plasma parameters were reported. 
Paired t-tests were used to determine the statistical significance between lipid, 
apoprotein and insulin measurements obtained from fasting (0 hour) and postprandial
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samples. Unpaired t-tests were used to determine statistical significance between fasting 
plasma lipids and lipoproteins and the triglyceride response curves and area under the 
curves obtained from normal and diabetic subjects, where the baseline was the fasting 0 
hour concentration. Area measurements were expressed as mmol.hour. The Minitab 10 
statistical package was used to calculate regression coefficients and p  values for 
correlations.
3 Results.
Plasma triglycerides, cholesterol, apoB, apoAI and FFA were studied in the 9 
normal and 25 diabetic patients recruited. Plasma triglyceride, cholesterol and apoB 
concentrations were found to be significantly increased (p <0.005) in the diabetic 
population, with no difference observed in the plasma FFA and apoAI concentrations 
(table 7.2).
Individual 13-Quantification measurements for the initial fasted plasma samples 
for each of the diabetic patients are shown in table 7.3. We were unable to obtain HDL 
cholesterol results for technical reasons from two of the diabetic patients.
All triglyceride, cholesterol, apoB and apoAI concentrations in the various 
isolated lipoprotein fractions were adjusted back to plasma levels. The triglyceride 
concentration was used as the index of postprandial lipoprotein metabolism.
Table 7.2: Comparison o f  lipid parameters in normal and diabetic populations.
Param eter Normals
(n=9)
(Mean ±  SD)
Diabetics
(n=25)
(Mean ±  SD)
Significance 
(p  value)
Triglyceride
(mmol/L)
1.22 ±  0.40 2.39 ±  1.12 0.0001
Cholesterol
(mmol/L)
4.62 ±  0.72 5.32 ±  0.84 0.028
ApoB
(g/L)
0.84 ±  0.18 1.16 ±  0.29 0.0008
ApoAI
(g/L)
1.32 ±  0.27 1.26 ±  0.22 0.59
FFA
(mmol/L)
0.32 ±  0.21 0.31 ±  0.22 0.83
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Table 7.3: Jl‘Quantification o f lipids and lipoproteins and apoE phenotypes in
individual diabetic subjects involved in fa t feeding studies.
Lipid
levels
(mmol/L)
Subjects
JC  SJ PF CE MH
Plasma
triglyceride
3.40 0.70 2.55 0.95 1.35
Plasma
cholesterol
4.90 5.15 6.35 3.80 5.00
VLDL
cholesterol
1.15 0.25 0.95 0.70 0.35
LDL
cholesterol
2.85 3.20 4.50 3.95 3.45
HDL
cholesterol
0.90 1.70 0.90 -
ApoE
phenotype
4/3 3/3 3/3 3/2 4/3
Individual plasma, TRL (d<  1.006g/ml), apoB48, apoBlOO, VLDLi ^  
VLDL2 triglyceride concentrations before and after ingestion of a fat load are shown in 
tables in appendices 23 - 28. Individual plasma FFA, cholesterol, plasma and TRL 
(d<  1.006g/ml) apoB and apoAI concentrations before and after a fat load are shown in 
tables in appendices 29 -34.
Mean (±  SD) plasma triglyceride concentrations before and after the ingestion of 
the fat load are shown in table 7.4 and figure 7.1. Mean plasma cholesterol 
concentrations did not change significantly during the course of the experiment. After 
the fat load, individual plasma triglyceride concentrations peaked between 5 - 6  hours 
postprandially, (figure 7.2) at triglyceride concentrations ranging from 2.31 - 10.23 
mmol/L, with a mean of 4.99 ±  3.07 mmol/L (table 7.5). Note table 7.4 shows mean 
triglyceride levels over the time course of the experiment, while table 7.5 shows the 
mean maximal triglyceride value for subjects taken when their individual peaks 
occurred, usually at 4, 5 or 6 hours. The mean plasma triglyceride concentration was 
significantly elevated (p < 0 .05) above fasting concentrations from 2 to 5 hours 
postprandially (table 7.4, figure 7.1).
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Table 7.4: Postprandial changes in mean triglyceride concentrations (mmol/L ±
SD) in plasma and all TRL fractions in diabetic patients after an oral 
fa t  load. Significantly different from fasting concentration by paired t- 
test: *p<0.05; **p<0.01.
Time
(hours)
Mean
Plasma
TG
(mmol/L 
± SD)
Mean
TRL
(d<  1.006 
g/ml) TG 
(mmol/L 
±  SD)
Mean 
ApoB48 
TRL TG 
(mmol/L 
±  SD)
Mean 
ApoBlOO 
TRL TG 
(mmol/L 
±  SD)
Mean
VLDLj
TG
(mmol/L 
±  SD)
Mean
VLDL2
TG
(mmol/L 
±  SD)
0 2.13 ±  
1.12
1.32 +  
0.77
0.41 ±  
0.26
0.71 ±  
0.44
0.43 ±  
0.27
0.11 ±  
0.06
1 2.23 ±  
1.08
1.44 ±  
0.83
0.52 ±  
0.30
0.75 ±  
0.46
0.43 ±  
0.29
0.11 ±  
0.07
2 2.77 ±  
1.18*
1.87 ±  
0.91*
0.83 + 
0.42*
0.86 ±  
0.49*
0.56 + 
0.30*
0.13 ±  
0.07
3 3.31 ±
I 49**
2.18 ±  
1.07*
1.09 ±  
0.55*
0.92 ±  
0.48**
0.59 +  
0.30*
0.14 ±  
0.07
4 4.03 ±  
2.11*
2.71 ±  
1.44*
1.55 ±  
0.93*
0.98 ±  
0.54**
0.73 ±  
0.43*
0.07 ±  
0.04
5 4.65 ±  
2.69*
3.17 ±  
1.89*
1.85 ±  
1.15*
1.09 ±  
0.62*
0.76 ±  
0.46*
0.08 ±  
0.03
6 4.87 +  
3.16
3.35 ±  
2.52
2.06 +  
1.55
1.07 ±  
0.67
0.76 +  
0.53
0.10 ±  
0.03
7 4.15 ±  
3.45
3.26 + 
1.88
1.97 ±  
1.30
1.06 ±  
0.57
0.70 ±  
0.43
0.12 +  
0.05
8 4.29 ±  
3.10
3.34 ±  
3.26
2.10 ±  
2.4
0.95 ±  
0.68
0.66 ±  
0.53
0.10 ±  
0.03
9 3.99 ±  
2.61
3.31 ±  
3.33
2.06 ±  
2.4
1.03 ±  
0.87
0.66 ±  
0.62
0.11 ±  
0.05
10 4.48 + 
3.73
3.34 ±  
3.00
1.86 ±  
2.29
0.98 + 
0.9
0.58 ±  
0.64
0.09 ±  
0.04
11 4.66 ±  
5.43
2.76 ±  
3.00
1.73 ±  
2.4
0.83 ±  
0.79
0.58 ±  
0.62
0.09 ±  
0.05
171
The plasma triglyceride concentrations in subjects JC, SJ, and PF began to 
increase again after the initial triglyceride peak at 10 hours postprandially but for the 
group as a whole this late increase was not significant compared to the baseline (0 hour) 
value (figure 7.2) (appendix 23).
In diabetic subjects, in the fasting state (time = 0 hour), the mean plasma 
triglyceride concentration was 2.13 ±  1.12 mmol/L (table 7.5) and mean TRL 
(d<  1.006g/ml), apoB48, apoBlOO, VLDLj and VLDL2 triglyceride concentrations 
were 1.32 ±  0.77 mmol/L, 0.41 ±  0.26 mmol/L, 0.71 ±  0.44 mmol/L, 0.43 ±  0.27 
mmol/L, and 0.11 ±  0.06 mmol/L respectively. These concentrations are significantly 
higher than those observed in normal subjects (with the exception of apoB48 and 
VLDL2 fasting triglyceride concentrations), who in the fasting state (time =  0 hour) 
had a mean plasma triglyceride concentration of 1.11 ± 0 . 4 5  mmol/L (chapter VI, table
6.4) and mean TRL, apoB48, apoBlOO, VLDLj and VLDL2 triglyceride concentrations 
of 0.61 ±  0.36 mmol/L, 0.21 ±  0.15 mmol/L, 0.36 ±  0.21 mmol/L, 0.22 ±  0.16 
mmol/L and 0.08 ±  0.03 mmol/L respectively.
In the fed state at the time of maximal triglyceride increase (mean 6 hours 
postprandially for plasma, TRL (d<  1.006g/ml) and apoB48 TRL fractions, and 5 hours 
for the apoBlOO TRL fractions: total ajx)B100, VLDLj, and VLDL2), there was a 57% 
increase in mean plasma triglyceride concentrations accompanied by a 64%, and an 81% 
increase in mean TRL (d<  1.006g/ml) and mean apoB48 TRL triglyceride 
concentrations, respectively. Mean apoBlOO TRL, VLDLj and VLDL2 triglyceride 
levels showed an increase of 37%, 38% and 57% respectively (table 7.5).
Table 7.5: Mean o f maximal postprandial triglyceride levels fo r  individual subjects
after a fa t load when mean peaks occurredf usually at 4, 5 or 6 hours.
Lipoprotein
fraction
Mean fasting TG 
(mmol/L)
Mean of individual 
peak TG (mmol/L)
M ean peak 
(hours)
Plasma 2.13 ±  1.12 4.99 ±  3.07 6
TRL(d <  1.006g/ml) 1.32 ±  0.77 3.64 ±  2.34 6
ApoB48 0.41 ±  0.26 2.18 ±  1.46 6
ApoBlOO 0.71 ±  0.44 1.12 ±  0.66 5
VLDLi 0.43 ±  0.27 0.69 ±  0.57 5
VLDLi 0.11 ±  0.06 0.26 ±  0.23 5
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Table 7.4 shows mean TRL (d<  1.006 g/ml) triglyceride concentrations after 
ingestion of a fat meal. Individual TRL triglyceride concentrations peaked between 5 - 
7 hours, with triglyceride concentrations ranging from 1.85 - 7.56 mmol/L; and a mean 
peak of 3.64 ±  2.34 mmol/L (table 7.5). When all individual TRL (d<  1.006g/ml) 
triglyceride response curves were combined, there was a mean peak at 6 hours with a 
mean triglyceride concentration of 3.35 ±  2.52 mmol/L (table 7.4). The mean TRL 
(d<  1.006g/ml) triglyceride concentration was significantly elevated ip <0.05) above 
fasting concentrations 2 - 5  hours postprandially, in accord with total plasma data.
The mean triglyceride concentrations of plasma, TRL (d<  1.006g/ml) and 
apoB48 are shown in figure 7.1 with the mean triglyceride concentrations of apoBlOO, 
VLDLj and VLDL2 fractions, before and during the fat load are shown in figure 7.3. 
After the fat load, individual apoB48 triglyceride concentrations peaked between 5 - 7  
hours, with triglyceride concentrations ranging from 1.17 - 4.75 mmol/L; and a mean 
peak of 2.18 ±  1.46 mmol/L (table 7.5). When all individual apoB48 triglyceride 
response curves were combined, there was a mean peak at 6 hours with a mean apoB48 
triglyceride concentration at the peak of 2.06 ±  1.55 mmol/L, followed by a later 
increase then decrease in triglyceride concentrations around 8 hours in some subjects 
(figure 7.1, table 7.4). The mean apoB48 triglyceride concentration was significantly 
elevated above fasting concentrations from 2 to 5 hours postprandially. Again the 
apoB48 results are in accord with plasma and TRL (d<  1.006g/ml) data.
A smaller but significant increase was observed in both individual and mean 
apoBlOO triglyceride concentrations (table 7.4, figure 7.3). The individual apoBlOO 
triglyceride concentrations peaked between 3 - 6  hours postprandially at 0.42 - 2.1 
mmol/L; with a mean peak value of 1.12 ±  0.66 mmol/L (table 7.5). When all 
individual apoBlOO triglyceride response curves were combined, triglyceride 
concentrations increased over 1 - 5 hours, with a mean peak at 5 hours and a mean 
apoBlOO triglyceride concentration at the peak of 1.09 ±  0.62 mmol/L (table 7.4). The 
mean apoBlOO triglyceride concentrations were significantly elevated above fasting 
concentrations 2 - 5  hours postprandially (figure 7.3, table 7.4). After peaking the 
apoBlOO triglyceride concentration remained elevated and appeared to reach a plateau.
Large VLDLj triglyceride concentrations increased between 1 - 5  hours 
postprandially (figure 7.4), peaking individually between 3 - 6  hours postprandially, 
with triglyceride concentrations ranging between 0.42 - 1.57 mmol/L (mean of 0.69 ± 
0.57 mmol/L (table 7.5)). The mean VLDLj triglyceride concentration was 
significantly elevated (p<0.05) above fasting concentrations 2 - 5  hours postprandially
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(table 7.4, figures 7.3, 7.4), in accord with total apoBlOO data. Some of the individual 
VLDL2 triglyceride concentrations increased during the course of the experiment 
(appendix 28, table 7.4), but overall mean VLDL2 triglyceride concentrations remained 
relatively constant during the course of the experiment (figure 7.3).
The contribution of apoB48 and apoBlOO TRL fractions to the postprandial 
response in TRL (d<  1.006g/ml) triglyceride (table 7.6) was quantified by measuring 
the area under the individual triglyceride response curves (fasting 0 hour concentration 
was taken as baseline). VLDLj and VLDL2 contributions to the postprandial increase 
in apoBlOO TRL was also quantitated by measuring the area under individual response 
curves (fasting 0 hour was taken as baseline) (table 7.6). The increase in apoB48 TRL 
triglyceride was almost 5 times greater than the increase in apoBlOO TRL triglyceride 
(13.3 ±  13.0 mmol.hour vs 2.9 ±  2.7 mmol.hour). Eighty three percent (±  9%) of 
the postprandial increase in TRL (d< 1.006 g/ml) triglyceride was due to apoB48 TRL 
(table 7.7). The contribution from apoBlOO TRL accounted for 16% (±  6 %) of the 
postprandial increase in TRL (d<  1.006g/ml) triglyceride. The increase in VLDLj 
triglyceride was 12 times greater than the increase in VLDL2 triglyceride (2.41 ±  2.00 
mmol.hour vs 0.20 ±  0.17 mmol.hour). Seventy three percent (±21% ) of the 
postprandial increase in total apoBlOO triglyceride was due to VLDLi, with 13% (±  
13%) of the postprandial increase in total apoBlOO accounted for by VLDL2 (table 7.7).
Table 7,6: Individual and mean areas under the curve (mmol.hour) to assess the
contribution o f apoB48 and apoBlOO TRLy VLDLj and VLDL2  to 
postprandial increases in the plasma concentration o f triglyceride in 
diabetics.
Subject Plasma
(mmol.hr)
TRL
(d<  1.006
g/ml)
(mmol.hr)
ApoB48
(mmol.hr)
ApoBlOO
(mmol.hr)
VLDLi
(mmol.hr)
VLDL2
(mmol.hr)
MH 12.1 7.9 7.1 1.2 0.81 0.2
CE 8.2 6.3 5.6 1.3 1.14 0.5
JC 55.4 48.1 37.9 7.5 7.57 0.07
SJ 11.0 9.1 6.2 1.6 0.72 0.2
PF 15.5 10.9 9.7 2.6 1.8 0.1
Mean 
(±  SD)
20.5 ± 
19.7
16.5 ± 
16.0
13.3 ±  
13.0
2.9 ±  2.7 2.41 ±  2.0 0.2 ±  0.17
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Table 7.7: Contribution o f apoB48 and apoBlOO TRL to postprandial increases in
the TRL (d<1.006g/ml) triglyceride concentration, and ofVLD Lj 
and VLDL2  to postprandial increases in the total apoBlOO 
triglyceride concentration. Quantitated by the measurement o f area 
under the individual triglyceride response curves.
Fraction ApoB48 ApoBlOO VLDLi VLDL2
Triglyceride
(mmol.hour)
13.3 ±  13.0 
(83%)*
2.9 ±  2.7 
(16%)*
2.4 +  2.0
(73%)*
0.20 ±  0.17 
(13%)*
* Values in parentheses represent increases expressed as percentages o f  the total 
triglyceride in lipoprotein fractions.
Mean cholesterol concentrations were also measured in the different TRL 
fractions. No significant increases in cholesterol concentrations were observed in the 
TRL (d<  1.006g/ml), apoBlOO, VLDLj or VLDL2 fractions. There was however a 
significant elevation in apoB48 cholesterol concentrations 3 - 5  hours postprandially.
Plasma and TRL (d<  1.006g/ml) apoB and apoAI concentrations were also 
measured. Mean plasma apoB, apoAI and mean TRL (d<  1.006g/ml) apoB and apoAI 
concentrations did not change significantly during the course of the experiment.
Plasma free fatty acid (FFA) concentrations are shown in figure 7.5. Mean 
plasma FFA concentrations were increased but not significantly by the fat meal (figure 
7.5).
Plasma insulin levels (table 7.8) increased 2 hours after ingestion of the fat mead 
in all subjects. Mean plasma insulin concentrations were significantly elevated 
(p=0.003) above fasting levels 2 hours postprandially.
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Table 7.8: Postprandial changes in individual and mean plasma insulin
concentrations (mU/L). Significantly different from fasting concentration 
by paired t-test: *p< 0.005.
Subjects
Time (hours) 
0 hours 2 hours
Delta insulin
JC 19.2 32.8 13.6
SJ 6.9 15.0 8.1
PF 37.2 49.3 12.1
CE 7.5 24.7 17.5
MH 10.2 17.4 7.2
Mean insulin 
(mU/L) (±  SI))
16.2 ±  12.7 27.8 +  13.8* 11.7 ±  4.2
Correlations between variables.
To examine the effect of fasting triglyceride concentrations on the measured 
parameters of postprandial lipaemia, potentially important correlations were examined. 
Log fasting triglyceride was not significantly correlated with plasma (r=0.51, 
p= 0.379 ), apoB48 (r=0.537, p=0.351), apoBlOO (r=0.555, p=0.332 ), VLDLj 
(r=0.60, p = 0.285) or VLDL2 (r=-0.03, p = 0.962) triglyceride areas under the curve. 
FFA area under the curve (r=0.709, p=0.18) and delta insulin (r=0.805, p=0.10) 
were positively correlated with log fasting triglyceride but these associations failed to 
reach significance.
A positive, significant correlation between areas under the curve for FFA and 
apoB48 (r=0.948, p=0.014) was observed (figure 7.6).
The effect of changes in insulin concentrations on the measured parameters of 
postprandial lipaemia was also examined by correlation analysis. This revealed no 
correlation between delta insulin and the area under the curve for plasma (r=0.196, 
p = 0 .752), apoB48 (r=0.232, p=0.707), apoBlOO (r=0.261, p=0.672 ), VLDLx 
(r=0.316, p=0.605), VLDL2 triglyceride (r=0.467, p —0.428) and FFA (r=0.494, 
p =0.398).
One of the diabetic patients (JC) produced exaggerated individual postprandial 
triglyceride responses for plasma, TRL (d<  1.006g/ml), apoB48, apoBlOO, VLDLi and 
VLDL2 fractions (appendices 23 - 28). This exaggerated response was observed
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particularly during the latter hours of lipaemia and was out of keeping with the rest of 
the diabetic patients. Triglyceride response curves for plasma, TRL (d<  1.006g/ml), 
apoB48, apoBlOO, VLDLj and VLDL2 were re-plotted excluding JC. This resulted in 
a lowering of all triglyceride response curves, particularly in the latter stages of 
postprandial lipaemia. However there were no significant differences in plasma, TRL 
(d<  1.006g/m]), apoB48, apoBlOO, VLDLj and VLDL2 results whether JC was 
included or not.
3.1 Comparison of normal and diabetic patients.
Normal subjects were compared with diabetics. Since JC had an aberrant 
postprandial response statistical analysis was performed with and without this subject. 
Several variables reached significance when he was excluded from the diabetic group, 
but inclusion or exclusion of JC did not affect overall interpretation of data.
Mean fasting plasma cholesterol concentrations were comparable in normals and 
diabetics (4.84 ±  0.72 mmol/L vs 5.48 ±  0.6 mmol/L respectively). No significant 
changes occurred between normal and diabetic groups in mean plasma cholesterol 
concentrations during the course of the experiment.
Mean plasma insulin concentrations were significantly different (p<0.05) 
between the normal and diabetic groups (fasting 7.19 ±  2.48 mU/L vs 16.2 ±  12.7 
mU/L and at 2 hours 14.40 ±  9.91 mU/L vs 27.8 ±  13.8 mU/L respectively).
Mean fasting FFA concentrations were significantly different between the 
groups, with the FFA concentration in the normal subjects being lower than that in 
diabetic subjects (0.32 +  0.21 mmol/L for normals, 0.62 ±0.19 mmol/L for diabetics 
ip =0.02) (Note this value differs from the data in table 7.2 probably because of patient 
selection). FFA concentrations in the normal subject group were also significantly 
decreased compared to diabetic groups at 1 hour post meal but thereafter the difference 
was lost. After the meal, there was a consistent initial decrease in FFA concentrations 
in both groups ( 0 - 2  hours in normals, 0 - 3  hours in the diabetic group). FFA 
concentrations subsequently rose to reach peak levels at 6 hours postprandially for 
normals and 7 - 1 0  hours postprandially for the diabetic group (figure 7.7). Thereafter, 
FFA levels started to fall in all groups. There was no significant difference in the mean 
area under the curve between the normal and diabetic subject groups (4.15 ±  1.67 
mmol.hour vs 2.91 ±  3.12 mmol.hour respectively).
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Mean fasting plasma apoAI and mean TRL (d<  1.006g/ml) apoB and apoAI 
concentrations were not significantly different between the normal and diabetic groups. 
During the course of the experiment there were no significant changes in the mean 
plasma apoAI and mean TRL (d<  1.006g/ml) apoB concentrations and response curves 
between the normal and diabetic groups. The mean TRL (d<  1.006g/ml) apoAI 
response curves were not significantly different between the normal and diabetic group, 
however exclusion of JC from the diabetic group allowed the differences at 2 - 5 and 7 - 
9 hours postprandially to reach significance, compared to the normal subject group. 
The mean fasting plasma apoB concentrations were significantly different between the 
normal and both diabetic groups (0.84 ± 0 . 1 8  g/L for normals vs 1.146 ±  0.24 g/L for 
diabetics (p=0.006)). The mean plasma apoB response curve concentrations in the 
diabetic groups remained significantly elevated above that of the normal subject group 
during the course of the experiment (0 - 1 1  hours postprandially), although levels did 
not change during the course of the experiment (figure 7.8).
Mean plasma triglycerides peaked at 5 hours after ingestion of the fat meal in the 
normal group, whereas the peak of mean plasma triglycerides seemed to occur 1 - 2  
hours later in the diabetic subject group (figure 7.9). Mean plasma triglyceride 
concentrations returned to fasting levels or even lower by 11 hours in the normal group, 
but remained elevated above the fasting levels even after 11 hours in the diabetic group. 
Seven to ten hours after the meal, mean plasma triglyceride response curves and 
concentrations in the normal subject group decreased significantly (p<0.05) compared 
to the diabetic group (figure 7.9). The mean areas under the plasma triglyceride 
response curves were not significantly different (11.2 ±  6.5 mmol.hour for normals; 
20.5 ±  19.7 mmol.hour for diabetics) between the groups.
Mean fasting and postprandial apoB48 triglyceride concentrations in the subject 
groups are shown in figure 7.10. Mean apoB48 triglycerides peaked at 5 hours 
postprandially in the normal group, whereas the peak for mean apoB48 triglycerides 
seemed to occur 1 - 2  hours later in the diabetic group (6 hours postprandially). Mean 
apoB48 triglyceride response curves and concentrations returned to fasting levels at 11 
hours postprandially in the normal subject group but remained elevated above fasting 
concentrations in the diabetic subject group, suggesting that there may be a problem 
with clearance of dietary triglyceride or chylomicrons. The mean apoB48 fasting 
triglyceride concentration was decreased in the normal subject group compared to the 
diabetic subject group, but did not reach significance (0.21 ±  0.15 mmol/L for normals 
compared to 0.41 ±  0.26 mmol/L for diabetics). Mean apoB48 triglyceride 
concentrations were significantly lower in the normal subject group compared to the
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diabetic subject group, when JC was excluded, at 7 (p<0.001), 10 and 11 (p<0.05) 
hours postprandially. This suggests that the diabetics may have delayed clearance of 
chylomicron triglyceride. The mean area under the apoB48 triglyceride curves was 
higher in diabetics, but not significantly (6.31 ±  4.28 mmol.hour for normals; 13.3 ±  
13.0 mmol.hour for diabetics).
Mean fasting and postprandial apoBlOO concentrations in the subject groups are 
shown in figure 7.11. Mean apoBlOO triglyceride concentrations peaked at 5 hours 
postprandially in both patient groups. Mean apoBlOO triglyceride response curves and 
concentrations returned to below fasting levels 11 hours postprandially in the normal 
group while remaining slightly elevated in the diabetic subject group. The mean 
apoBlOO triglyceride response curve concentrations in the diabetic group remained 
significantly elevated (p<0.05) above that of the normal subject group throughout the 
course of the experiment ( 0 - 1 1  hours postprandially) (figure 7.11). The mean 
apoBlOO triglyceride response curve concentrations in the diabetic group, if JC was 
excluded, were significantly elevated (p<0.05) above that of the normal subject group 
6, 7, 10, 11 hours postprandially. The mean area under the apoBlOO triglyceride curves 
was higher in diabetics, but not significantly (1.3 ±  1.1 mmol.hour for normals; 2.9 ±  
2.7 mmol/hour for diabetics).
Fasting and postprandial triglyceride concentrations of VLDLi and VLDL2 
subfractions in the subject groups are shown in figure 7.12. Mean VLDI4  triglyceride 
concentrations peaked at 5 hours postprandially in all subject groups, in accord with 
apoBlOO data. Mean VLDLj triglyceride response curves and concentrations returned 
to below fasting levels 11 hours postprandially in the normal while remaining slightly 
elevated in the diabetic group. The mean VLDLj triglyceride response curve and 
triglyceride concentrations in the diabetic group remained significantly elevated 
(p<0.05) above that of the normal subject group during the course of the experiment (0 
-1 1  hours postprandially) (figures 7.12). Exclusion of JC meant that this significance 
was lost. The mean areas under the VLDLj triglyceride curves were again higher in 
diabetics but showed no significant differences (0.94 ±  0.76 mmol.hour for normals; 
2.41 +  2.00 mmol.hour for diabetics). Mean VLDL2 triglyceride response 
concentrations remained relatively constant in normal subjects during the course of the 
experiment (figure 7.12). However, in the diabetic subject group, mean VLDL2 
triglyceride concentrations appeared to have a double peak postprandially and decreased 
to approximately baseline concentrations. The mean VLDL2 triglyceride response curve 
concentrations in the diabetic group were significantly elevated above that of the normal 
subject group 3 and 6 - 9  hours postprandially (p<0.05). As a result, the mean areas
179
under the curves were comparable between the normal and diabetic group (0.086 ±  
0.07 mmol.hour for normals compared to 0.20 ±  0.17 mmol.hour for diabetics) but the 
diabetic group was significantly different from the normal group when JC was excluded 
(0.086 ±  0.07 mmol.hour for normals compared to 0.24 ±  0.18 mmol.hour 
(p=0.OZ)).
Recovery of initial TRL added to the immunoaffinity gel was 88 ±  6 %, and 
comparable with the recoveries of 89 ±  10% obtained from normal patients, as 
estimated by measuring the recovered triglyceride in the apoBlOO (bound) and apoB48 
(unbound) fractions.
The distribution of apoE phenotypes was similar in normal and diabetic patient
groups.
3.2 Correlations between variables.
To examine the influence of variation in fasting triglyceride on postprandial 
lipoprotein metabolism, the combined data for all subjects was analysed. This revealed 
significant positive correlations between the log fasting plasma triglyceride concentration 
and the area under the curve for plasma (r=0.534, p = 0.049), apoB48 (r=0.549, 
p= 0.042 ), apoBlOO (r=0.623, p=0.017), VLDLj (r=0.618, p=0.019) triglyceride 
(figure 7.13), and with delta insulin (r=0.56, p=0.037) (figure 7.14). Log fasting 
triglyceride was not significantly correlated with VLDL2 (r=0.131, p =0.654) or FFA 
area under the curve (r= 0.325, p = 0.257).
A positive significant correlation between area under the curve for FFA and area 
under the curve for apoB48 (r=0.541, p=0.046) was observed (figure 7.15).
To examine the influence of changes in insulin concentrations on the measured 
parameters of postprandial lipaemia, the data for all subjects was analysed. No 
significant correlation between delta insulin and area under the curve was seen for 
plasma (r=0.342, p=0.231), apoB48 (r=0.324, p= 0.259 ), apoBlOO (r=0.461, 
p= 0 .097 ), VLDLi (r=0.42, p=0.135 ), or VLDL2 (r=0.385, p=0.174) triglyceride. 
Delta insulin was significantly correlated with delta VLDLj (r=0.610, p=0.021). No 
correlations were observed between area under the curve for delta insulin and FFA (r= - 
0.013, p=0.965) or between delta insulin and delta VLDL2 (r=-0.204, p=0.485).
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4 Discussion,
In this study an analysis of both chylomicron and VLDL subfraction metabolism 
in the postprandial state was undertaken in patients with NIDDM (Type 2 diabetes).
As in the previous chapter, a specific monoclonal antibody for apoBlOO was used 
to separate the apoB48 and apoBlOO containing TRL species from plasma obtained from 
diabetic subjects in a postprandial state. This allowed further isolation of VLDL 
subfractions, by cumulative flotation from the apoBlOO fraction isolated by 
immunoaffinity chromatography. Again, single sample aliquots in individual eppendorf 
tubes containing antibody bound to sepharose were used, rather than eluting fractions 
from an immunoaffinity column, to obtain reliable quantitative data. Adequacy of 
separation was controlled by monitoring the apolipoprotein composition of isolated 
fractions by SDS gel electrophoresis (chapter III).
This study demonstrates that the lipid and lipoprotein responses to a fat meal in 
normal and NIDDM (Type 2 diabetic) subjects depend on the fasting triglyceride level 
and not on the underlying diabetic state, as observed by others (Lewis et al 1991), 
although the fasting triglyceride concentration can reflect diabetic control. Significant 
positive correlations between fasting triglyceride (log) and lipid and lipoprotein 
responses to the fat meal were seen when the combined data for all subjects were 
analysed. These correlations lost significance when the data from the diabetic patients 
was analysed separately. NIDDM (Type 2 diabetic) patients with normal fasting 
triglyceride levels have postprandial responses that are similar to those of non-diabetic 
controls. By contrast, the NIDDM (Type 2 diabetic) patient (JC) with an increased 
fasting triglyceride level demonstrated several differences after ingestion of a fat meal; 
including greater and prolonged elevation of total plasma, TRL (d< 1.006g/ml), 
apoB48, apoBlOO, VLDLj and or VLDL2 triglyceride concentrations and plasma FFA 
concentrations. The triglyceride response curves were elevated and prolonged 
particularly in the latter stages of postprandial lipaemia, suggesting that there may be a 
problem with clearance of triglyceride (chylomicrons and their remnants) by this 
NIDDM (Type 2 diabetic) subject (JC), yet plasma cholesterol, apoB and apoAI 
concentrations remained normal and comparable to the normal subjects. Other 
investigators have demonstrated the association between fasting triglyceride 
concentration and postprandial triglyceride elevation in non-diabetic subjects (Cohn et al 
1988). The differences observed between normal and diabetic subjects in apoB48, 
apoBlOO, VLDLi and VLDL2 triglyceride concentrations occur as stated previously in 
the latter hours of lipaemia. These differences would not have been seen without the
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separation of these lipoprotein fractions by immunoaffinity chromatography and then 
cumulative flotation.
There were no significant differences between the normal and diabetic groups as 
regards mean plasma cholesterol, FFA and plasma apoAI concentrations and response 
curves. The mean areas under the triglyceride response curves were calculated for 
plasma, TRL (d<  1.006g/ml), apoB48 , apoBlOO, VLDLi and VLDL2 fractions. No 
significant differences in the areas under the curves were found between the both 
groups, suggesting that the overall production and clearance of each of these lipoprotein 
species occurs at the same rate in normal and NIDDM (Type 2 diabetic) patients. The 
exception was VLDL2 where the diabetics had a significantly greater area under the 
triglyceride response curve. This suggests that there may be a difference in the rate of 
production or clearance of VLDL2. However significant differences were noted in the 
plasma, TRL (d<  1.006g/ml) and apoB48 triglyceride response curves between the 
normal and diabetic (NIDDM) groups in the later hours of postprandial lipaemia ( 7 - 1 0  
hours postprandially). This indicates that although the differences in area under the 
curves did not reach significance, the differences seen in the triglyceride response 
curves may indicate a delayed rate of triglyceride clearance in NIDDM (Type 2 
diabetic) subjects, but in order to confirm this a larger NIDDM (Type 2 diabetic) patient 
population would be required.
Total apoBlOO and VLDLi mean triglyceride response curves were significantly 
elevated between 0 - 1 1  hours postprandially in the diabetic group compared to the 
normal subject group, and 6, 7, 10, and 11 hours postprandially when JC was excluded 
from the diabetic group compared to the normal subject group. This suggests increased 
VLDL 1 triglyceride concentrations and the possibility of a delayed clearance rate for 
total apoBlOO and VLDLi triglyceride. VLDL2 triglyceride response curves are 
relatively unchanged throughout the course of the experiment, although there are 
significant differences 3 and 6 - 9  hours postprandially in the diabetic subjects compared 
to normals. The differences in the response of VLDLi and VLDL2 subfractions to the 
fat meal may suggest independent regulation and separate synthesis pathways for the 
VLDL subfractions. This was a finding of a recent study by Malmstrom et al (1997 a). 
Possible explanations for elevated levels of VLDLi in normal subjects have been 
discussed in the previous chapter, however in NIDDM (Type 2 diabetic) patients the 
situation may be exacerbated because NIDDM (Type 2 diabetic) subjects are insulin 
resistant. In NIDDM (Type 2 diabetic) subjects the antilipolytic effects of insulin may 
be diminished and as a result, excess circulating fatty acids are released from adipose 
tissue resulting in increased hepatic triglyceride rich VLDL synthesis with reduced LPL
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activity impeding the removal of triglyceride from the circulation. This theory is 
compatible with the results of this study which show that there may be delayed clearance 
of chylomicrons and VLDL according to the triglyceride response curves although the 
differences in mean area under the curve data did not reach significance.
Plasma FFA concentrations increased but did not change significantly during the 
course of the experiment and were not significantly different among the groups. A 
consistent initial decrease in plasma FFA concentrations 1 - 3  hours after ingestion of 
the fat meal was observed in virtually all subjects in each group followed by a 
subsequent rise in plasma FFA concentrations. This phenomenon has previously been 
observed by others (Lewis et al 1991, O'Meara et al 1992) and is suggested to be 
related in timing to the early postprandial insulin rise as also seen in this study. The 
source of the plasma FFA in normal and diabetic subjects still requires to be clarified; in 
normals most of the FFA will be present in plasma as a result of the hydrolysis of 
chylomicron and VLDL triglyceride by LPL. In diabetics (NIDDM), the situation is 
slightly different, the FFA may arrive in plasma from different sources; i.e. NIDDM 
(Type 2 diabetics) who are insulin resistant may have FFA present in plasma as a result 
of the lack of inhibition of HSL in adipose tissue. HSL is normally suppressed by the 
action of insulin and LPL activated by it, therefore in subjects who are insulin resistant 
the HSL could be activated resulting in production of excess FFA from stored 
triglycerides from adipose tissue resulting in increased hepatic VLDL synthesis, LPL 
will not be properly activated and therefore there could be decreased hydrolysis of 
chylomicrons and VLDL triglyceride by LPL and removal of triglyceride from plasma.
Positive, significant correlations (Pearson) were seen between fasting triglyceride 
concentrations and individual areas under the curve for plasma, apoB48, apoBlOO and 
VLDLi triglyceride response curves, suggesting that the lipoprotein responses to a fat 
meal in normal and diabetic patients depends on the fasting triglyceride concentration 
and not necessarily the underlying diabetic state. In normal subjects, positive, 
significant correlations (Pearson) were seen between delta insulin and area under the 
curve for apoBlOO and VLDLi as we^ as between delta insulin and delta apoBlOO and 
delta VLDLi but these were not observed in the diabetic subject population. In the 
diabetic population and the subject group as a whole a positive, significant correlation 
(Pearson) was seen between area under the curve for FFA and area under the curve for 
apoB48 indicating that these two variables may be closely linked e.g. higher FFA may 
cause LPL loss from endothelial sites and impair apoB48 particle removal. The 
magnitude of postprandial lipaemia is known to be highly dependent on the fasting 
plasma triglyceride concentration (Patsch 1987), since NIDDM (Type 2 diabetic)
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patients generally have a higher fasting plasma triglyceride a disturbed postprandial 
triglyceride metabolism would be expected. However this study demonstrated NIDDM 
(Type 2 diabetic) patients with normal fasting plasma triglyceride concentrations had 
postprandial responses similar to those of non-diabetic controls.
The fact that there were differences in age and BMI between the diabetic and 
control subjects should be kept in mind when interpreting data from the postprandial 
studies. The type 2 diabetics recruited here were older and had a higher BMI compared 
to controls and therefore were probably less fit than controls. It has been shown that 
chylomicron removal decreases with age and that fitness may lead to an increase in LPL 
levels, enhancing chylomicron removal. Weight loss, increasing exercise and dietetic 
changes may all reduce postprandial hyperlipidaemia in the diabetic subjects The 
normal subjects recruited here may have been fitter and would also have had a different 
diet compared to the diabetic group. These differences should be considered before 
patient recruitment for future postprandial studies.
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Figure 7.1: Postprandial changes in the mean triglyceride
concentration o f plasma, TRL (d< 1.006g/ml)
and apoB4S fractions in diabetic subjects.
Significantly different from  fasting concentration by pa ired  t-test: 
* p < 0 .0 5 , * * p < 0 .0 1 .
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Figure 7.2: Postprandial changes in the individual plasma
concentration o f triglycerides in diabetic 
subjects.
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Figure 7.3: Postprandial changes in the mean triglyceride
concentration o f apoBlOO, VLDLj and VLDL2 
fractions in diabetic subjects. Significantly different 
from fasting concentration by paired  t-test: * p < 0 .0 5 , * * p < 0 .0 1 .
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Figure 7.4: Postprandial changes in triglyceride
concentrations in the individual VLDLj TRL 
fractions in diabetic subjects.
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Figure 7.5: Postprandial changes in the mean plasma
concentration o f  FFA in diabetic subjects.
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Figure 7.6 : Pearson correlation between FFA area under the
curve and apoB48 area under the curve in 
diabetic subjects.
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Figure 7.7: Postprandial changes in the mean plasma FFA
concentration fo r  normal and diabetic subjects,
with and without JC. Significantly differen t fro m  fasting
concentration by paired t-test: * p < 0 .0 5 .
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Figure 7.8: Postprandial changes in the mean plasma apoB
concentration fo r  normal and diabetic subjects, 
with and without JC. Significantly different from  fasting  
concentration by paired t-test: *p <  0.05.
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Figure 7.9: Postprandial changes in the mean plasma
triglyceride concentration fo r  normal and 
diabetic subjects, with and without JC. Significantly 
different from fasting concentration by paired  t-test: *p < 0 .0 5 .
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Figure 7.10: Postprandial changes in the mean apoB48
triglyceride concentrations fo r  normal and 
diabetic subjects, with and without JC. Significantly 
different from  fasting concentration by paired  t-test: *p <  0 .05; 
***/?< 0.005.
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Figure 7.11: Postprandial changes in the mean apoBlOO
triglyceride concentration fo r  normal and 
diabetic subjects, with and without JC. Significantly 
different from  fasting concentration by paired  t-test: * p < 0 .0 5 .
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Figure 7.12: Postprandial changes in the mean VLDL] and 
VLDL2 triglyceride concentration fo r  normal 
and diabetic subjects, with and without JC.
Significantly different from  fasting concentration by pa ired  t-test: 
*p <  0.05.
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Figure 7.13: Pearson correlations. Correlations between log fasting
triglyceride concentration (mmol/L) and individual areas under 
the curve (mmol.hour) f o r  (a) plasm a, (b) apoB48, (c) apoBlOO, 
(d) VLDL], (e) VLDL2 triglyceride and (f) FFA response curves, 
including all normal and diabetic subjects.
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Figure 7.14 Pearson correlation, including all subjects 
between log fasting plasma triglyceride and 
delta insulin.
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Figure 7.15: Pearson correlation between FFA area 
under the curve and apoB48 area under the 
curve fo r  all subjects.
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Chapter VIII Conclusions and future 
directions.
The aim of this thesis was to understand better the regulation of triglyceride 
metabolism in both mem and rat models, in which it is aberrant. This objective has 
largely been met, and further insight has been gained into the regulation of triglyceride 
metabolism in two inter-related areas. First, in postprandial lipid and lipoprotein 
metabolism and second in the regulation of HSL activity and adipocyte lipolysis. A 
schematic representation of triglyceride metabolism, which includes information derived 
from the present studies is illustrated in figure 8.1. What follows is a short discussion 
integrating the main findings relating to the regulation of triglyceride metabolism.
1 Postprandial studies.
Postprandial triglyceridaemia describes the presence, following a meal, in plasma 
of triglyceride-rich lipoprotein particles, a heterogeneous population of lipoprotein 
particles comprising chylomicrons and VLDL. In order to delineate the behaviour of 
VLDL and its subfractions during alimentary lipaemia (in normal subjects, chapter VI 
and in diabetic subjects, chapter VII) it is essential to separate chylomicrons (apoB48 
TRL) and VLDL (apoBlOO TRL) fractions using a reliable method. Immunoaffinity 
chromatography is the current method of choice and has been successfully used by other 
groups. Simple measurement of plasma triglyceride concentrations alone may mask a 
defect in diabetic chylomicron metabolism, as both chylomicron and VLDL accumulate 
postprandially (chapter VII). The abnormalities in postprandial lipaemia i.e. in diabetics 
which were attributed to chylomicrons (apoB48 TRL) could conceivably have been due 
to VLDL (apoBlOO TRL) accumulation, although it is true that the majority of 
triglyceride is present in chylomicrons. The exaggerated lipaemia, often present 
particularly towards the latter hours after a fat feed in diabetic subjects, could be due to 
the persistence of VLDL or failure to clear efficiently either or both chylomicrons and 
VLDL. Without the immunoaffinity chromatographic separation (using a Sepharose 
bound LDL A4 monoclonal antibody in Eppendorf tubes) of chylomicron and VLDL 
lipoprotein particles it would be impossible to study changes in the behaviour of 
VLDLj.
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The development of the methodology to separate chylomicrons and VLDL 
(chapter III), was based on that already published in the literature (Schneeman et al 
1993, Campos et al 1992, Milne et al 1984 and Cohn et al 1988, Bjorkegren et al 
1997), however we used a different monoclonal antibody and made some changes to the 
methodology from that used by Cohn et al (1993). Development and testing of the 
immunoaffinity chromatography methodology was, like the postprandial studies, labour 
intensive and time consuming. Acceptable recovery rates (85 - 95%) quoted by Cohn 
were reproduced by this methodology (89 ±  10%). Adequate separation of apoB48 
(chylomicrons) and apoBlOO (VLDL) TRL containing fractions for the purposes of the 
present study was achieved. Quality of separation was monitored by gel electrophoresis 
of the isolated fractions. Some contamination of apoB48 fractions was noted, leading to 
a small underestimation of apoBlOO TRL lipid concentrations. Additional 
chromatography was not carried out to remove contaminating apoBlOO material as this 
would adversely affect recovery. Thus in the interpretation of results it should be noted 
that while the retained fraction (apoBlOO bound) was demonstrated free of 
chylomicrons, the non-retained fraction (apoB48 unbound) had some apoBlOO 
containing lipoproteins present. Minor contamination of the unbound fraction was also 
noted by Cohn et al 1993 who also observed faint apoBlOO bands often present in the 
apoB48 fraction. There may be two reasons for this contamination, either the 
immunoaffinity gel was saturated or there is apoBlOO that fails to bind to the antibody. 
The latter is more likely to be the case, since part of the validation process for the 
immunoaffinity chromatography method involved preparation of a saturation curve. 
The small underestimation of apoBlOO TRL lipid concentrations, if taken into account, 
would only increase the contribution of apoBlOO TRL and enhance the significance of 
the present results. However to what extent does the presence of apoBlOO TRL 
confound the apoB48 TRL data. Since apoB48 TRL triglyceride accounts for 79% and 
83%, in normals and diabetics respectively, and apoBlOO for 15% and 16%, in normals 
and diabetics respectively, of the increase in TRL (d< 1.006g/ml) triglyceride 
concentrations after a fat meal, and with the vast majority of apoBlOO TRL retained in 
the immunoaffinity resin, the amount of triglyceride in apoBlOO particles contaminating 
the 'apoB48! unbound fraction by apoBlOO TRL is small. Therefore we cautiously label 
the unretained fraction 'apoB48 unbound' (chapters VI, VII). At present there is no 
method that we or others are aware of that can separate clearly apoBlOO containing 
lipoproteins from apoB48 containing lipoproteins. The use of immunoaffinity 
chromatography to isolate VLDL allowed subsequent separation of VLDL subfractions, 
into large VLDL^ and small VLDL2 by cumulative flotation. This allowed a clearer 
insight into what was happening to VLDL metabolism postprandially. In both normal 
and diabetic subjects, VLDLj accounted for the behaviour of the total
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VLDL TRL fraction with VLDL2 remaining essentially unchanged during alimentary 
lipaemia. VLDLi can viewed as the liver's chylomicron delivering FFAs as an 
energy source in the fasting state. Postprandially, the normal response to the increased 
availability of lipoprotein triglyceride in the form of chylomicrons is to reduce VLDLi 
release from the liver (Malmstrom et al 1997 a, b) and to suspend VLDLi lipolysis 
(chapter VI) (Karpe et al 1993, Bjorkegren et al 1996) thereby relieving postprandial 
competition between chylomicrons and VLDL via the same lipolytic pathway. Karpe 
demonstrated that the plasma concentration of large VLDLi (Sf 60 - 400) apoBlOO 
increases after an oral fat load both in healthy subjects and in normo- and 
hypertriglyceridaemic patients with CHD (Karpe et al 1993), and VLDL2 levels remain 
unchanged. Bjorkegren also concluded from a recent study that chylomicrons (and their 
remnants) impede the normal lipolytic degradation of VLDL and it may be that the most 
likely explanation for the rise in VLDLi (Sf60  - 400) is delayed lipolysis of the particle 
due to competition for the same lipolytic pathway involving LPL.
A number of observations can be made that add to current concepts of the 
regulation of triglyceride metabolism.
(1) The postprandial response of apoB48 lipoproteins in diabetics has not previously 
been studied, but it is clear from chapter VII that the triglyceride response curves were 
elevated and prolonged particularly in the latter stages of postprandial lipaemia 
indicating late clearance of chylomicrons and their remnants from the plasma. This also 
contributes to differences between normal and CHD patients (Simpson et al 1990) who 
develop exaggerated lipaemia when given a standard fat load test meal. Chylomicron 
remnants are removed from the circulation, by the liver via receptor-mediated 
endocytosis which is believed to involve both the LDL receptor (LDL-R) and the LDL 
receptor-related protein (LRP) (figure 8.1). Insulin resistance may impair this removal 
suggesting that insulin may have some control over the LRP.
(2) Also VLDLi lipolysis is virtually halted during the early part of alimentary 
lipaemia as seen in chapters VI and VII. VLDLi increases 2 fold in normal (and 1.6 
fold in diabetic) subjects over the first 5 hours after ingestion of the fat load, at a time 
when insulin suppresses the release of VLDLi (Malmstrom et al 1997 a) in normal 
subjects. It is possible that the relationship between VLDLi area under the curve and 
the increase in insulin are both reflections of insulin resistance. A rise in insulin 
postprandially is a reflection principally of insulin resistance and an rise in VLDLi 
maybe due to a failure of insulin to act to suppress the release of lipoproteins from the 
liver explaining the correlation observed in normal subjects between rise in insulin and
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VLDLi un(ter the curve. The lack of such a correlation in diabetics is a reflection 
that the group are inherently resistant to insulin action.
A delayed clearance of VLDL may be due to an altered apolipoprotein and lipid 
composition of VLDL particles (figure 8.1) thereby increasing their potential 
atherogenicity. Bjorkegren et al (1997) observed that large and small VLDL were 
enriched in cholesterol, apoE and Cl, but depleted of apoCII. The apoCIII, triglyceride 
and phospholipid contents were essentially unchanged in the postprandial state. 
Bjorkegren et al (1997) also noted an early transient increase in the apoCIII content of 
large VLDLi particles which may be implicated in the accumulation of this lipoprotein 
species during alimentary lipaemia (Karpe et al 1993). ApoCII is necessary for the 
activation of LPL thus VLDL are poorly lipolysed due to a lack of apoCII. 
Theoretically, the early apoCIII accumulation and the depletion of apoCII of large 
VLDL could explain part of the preferential lipolysis of chylomicrons and the ensuing 
postprandial accumulation of large VLDL observed both by Bjorkegren et al (1996) and 
the present study.
VLDLi metabolism gives rise to remnants in the VLDL2 and IDL ranges 
(Packard and Shepherd 1997) and small dense LDL (figure 8.1). Prolonged 
chylomicronaemia causes an increased residence time of VLDLi m circulation. 
CETP mediates the exchange of neutral lipid between lipoproteins with the result that 
when circulating levels of TRL (chylomicrons and VLDL) are high, a proportion of 
their core triglyceride is transferred to LDL (and HDL) and replaced with cholesteryl 
ester from the denser lipoprotein species (figure 8.1). Triglyceride-enriched LDL is 
then a substrate for endothelial-bound lipases and their action leads to the formation of 
smaller, lipid depleted particles. Inefficient clearance of chylomicrons may therefore 
lead to atherogenesis in an indirect way. That is if VLDL fails to be cleared efficiently 
from the circulation, it may once lipolysis restarts form a cascade of atherogenic 
lipoproteins, including not only small LDL but also long-lived remnants of VLDL and 
IDL, which are believed to contribute to increased risk of CHD. The results from Rapp 
et al 1994 support the view that VLDL and VLDL remnants are potentially atherogenic 
and can indeed cross the endothelium and enter both human atherosclerotic plaques and 
the arterial wall.
FFA, although products of lipolysis, were not previously thought to have an 
important role in regulating lipolysis but now increased levels of FFA (released by the 
enzymatic hydrolysis of triglyceride) have been shown to release LPL from the 
endothelial sites (figure 8.1). This may lead to inefficient clearance of lipoproteins
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(Saxena, Witte and Goldberg 1989, Olivecrona et al 1993, Coniglio 1994). As such it 
remains difficult to interpret the relationship between FFA and the clearance of 
lipoproteins. However, in diabetics there was a correlation between FFA area under the 
curve and apoB48 area under the curve, which was not observed in normal subjects. 
Therefore one reason for the accumulation of FFA in diabetics could be that diabetics 
are more sensitive to FFA accumulation as they possibly have less lipase activity as a 
result of their underlying insulin resistance.
2 Hormone-sensitive lipase.
Hormone-sensitive lipase is believed to be a key enzyme in 
hypertriglyceridaemia, diabetes, and coronary heart disease (CHD). It is a principal 
factor in insulin resistance, and in some subjects, the underlying defect may be an 
inability to shut down HSL activity. This causes an increase in FFA fasting levels 
which results in impaired glucose disposal and insulin resistance. The uncontrolled flow 
of FFA from adipose tissue to the liver is a major promoter of VLDLi production 
(figure 8.1). It was felt that when the relationship between chylomicron and VLDLj 
metabolism (liver-adipose axis) had been elucidated in human studies, that control of 
HSL would be a key element in altering triglyceride regulation to produce clinical 
benefit.
The general aim was to understand how control of HSL activity by drugs could 
affect the flux of triglyceride postprandially and change the liver-adipose tissue 
relationship in fatty acid metabolism.
Abnormally high rates of adipocyte lipolysis are thought not only to result in 
elevated plasma lipid levels linked to an increased risk of atherosclerosis and the 
development of CHD, but are closely linked to the metabolic disturbances characterised 
by insulin resistance. Thus the selective inhibition of HSL (figure 8.1) may contribute 
towards the therapeutic control of excessive adipose tissue lipolysis in various disease 
states. The antilipolytic mechanism of action of a series of compounds was investigated 
in isolated rat adipocytes in vitro (chapter VI), with in vivo dose response experiments 
using nicotinic acid carried out in Zucker fatty rats after initial experiments in Alderley 
Park (Wistar-derived) rats (chapter V). In vitro, in the isolated rat adipocytes, insulin 
was the most potent antilipolytic agent, nicotinic acid (and analogues) were found to be 
Gj receptor agonists (depending on adenosine removal to exert their antilipolytic effect), 
and compound 304205 was a direct inhibitor of HSL (figure 8.1). TZD, fibrates and a 
63 agonist had no inhibitory effects on HSL activity in the isolated rat adipocyte.
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In vivo, the antilipolytic effect of nicotinic acid on HSL mediated adipocyte 
lipolysis in the Zucker and Alderley Park rats suggests the decrease in plasma FFA 
levels observed is a result of nicotinic acid administration. It appears to be an 
immediate effect, with the Zucker rats appearing to be more sensitive to the effects of 
nicotinic acid than the Alderley Park rats.
These preliminary studies with nicotinic acid in the Zucker rat were carried out 
with the long term aim of defining the dose of nicotinic acid which would normalise 
insulin levels in the Zucker rat. This would be of great use, as Zucker rats have 
increased plasma FFA levels, are hyperin sulinaemic and develop marked 
hyperlipoproteinaemia probably as a result of over-production of VLDL. It was hoped 
that by defining a dose of nicotinic acid which would suppress plasma FFA levels e.g. 
for 24 hours or longer, that this would normalise plasma insulin levels and maybe even 
start to correct some of the defects associated with the hyperlipoproteinaemia observed 
in the Zucker rats. Administration in vivo of nicotinic acid to the Zucker rat inhibited 
HSL activity, and would modify the FFA flux to the liver.
3 Directions for future research,
A number of questions have arisen from the studies in this thesis, which could be 
the subject of future research.
Now that the methodology for separation of chylomicrons and VLDL 
subfractions from postprandial blood samples is established, it would be of interest to 
further investigate a larger population of NIDDM subjects; including both normo- and 
hypertriglyceridaemic diabetics. The study of more normotriglyceridaemic NIDDM 
subjects would hopefully confirm the findings of this thesis. The diabetic patient 
included in this thesis who had a fasting triglyceride greater than the normal reference 
range, thus classified as hypertriglyceridaemic, showed several differences in response 
to ingestion of a fat meal compared to the other diabetic patients; including a greater and 
prolonged elevation of triglyceride response curves particularly in the later hours of 
lipaemia suggesting a defect in triglyceride clearance.
It would be of interest to perform oral fat load tests in other patient groups who 
also suffer from disease states that display insulin resistance for example CHD and 
obese subjects to observe if their postprandial responses were similar to those of the 
NIDDM subjects.
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postprandial studies in NIDDM subjects could be undertaken to allow apoB metabolism 
to be followed. The use of FFA tracers during a fat load may help clarify the sources of 
the FFA in normal and NIDDM subjects.
Further investigations are required in the Zucker fatty rat to examine the in vivo 
effects of other antilipolytic agents upon plasma FFA levels and their consequent 
influence on VLDL levels. This may lead to the identification of a drug with an 
identical mode of action as nicotinic acid but without the side effects.
Further investigations in isolated primary rat adipocytes using radiolabelled 
triglyceride would help to determine if FFA esterification is occurring within the 
adipocytes.
4 Characterisation of Triglvceride-rich lipoproteins (TRLs)
Triglyceride-rich lipoproteins can be characterised by either their apolipoprotein 
content or their physiochemical properties; size, lipid content and charge. These 
properties are responsible for a variety of processes, determining rapidity of lipolysis, 
clearance by the liver, rate of delivery of FA and ability to attract cholesteryl ester.
Apolipoproteins have a variety of roles within lipoprotein metabolism (chapter 
1). They are required for secretion of lipoproteins, stabilisation of the surface coat and 
hence maintain the structure of the whole lipoprotein transport system, lipoproteins 
cannot be synthesised and secreted from the liver or intestine without the correspnding 
structural apolipoprotein (apoBlOO, B48). The presence of apoBlOO or apoB48 (in 
man) determines whether a lipoprotein particle was derived from the gut or intestine. 
Chylomicrons and VLDL have different sites of synthesis (intestine and liver 
respectively) and clearance. Chylomicrons are cleared by the LRP, through apoE, while 
VLDL is cleared by the both the LDL receptor, which recognises as ligands both 
apoBlOO and apoE, and the VLDL receptor. Chylomicrons and VLDL have different 
metabolic pathways, but can overlap in size and other physiochemical properties. 
Postprandially there is a delayed clearance of VLDL by LPL and Bjorkegren et al 1997 
obsevered enrichment of apoE, Cl and depletion of CII in VLDL, apoCII is necessary 
for activation of LPL resulting in accumulation of VLDL. Categorising TRLs by 
apolipoprotein content rather than physiochemical properties is therefore a better method 
to isolate metabolically derived TRL particles with the aim of studying their distinct 
roles in triglyceride metabolism.
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Figure 8.1: Schematic representation o f triglyceride 
metabolism. AICAR = 5-amino-4-imidazole carboximide,
CE = cholesterol ester, FFA — free fatty acids, HSL = 
hormone-sensitive lipase, LPL =  lipoprotein lipase, LRP =
LDL receptor-related protein, LDL-R = LDL receptor, TG = 
triglyceride, 304205 = p-nitrophenylethylhexyl phosphonate. 
Inefficient clearance o f lipoprotein and abnormally high rates o f  
adipocyte lipolysis are thought to result in elevated plasma lipid 
levels, linked to an increased risk o f atherosclerosis and CHD; 
these in turn are closely linked to metabolic disturbances 
characterised by insulin resistance. Postprandially the normal 
response to an increased availability o f lipoprotein triglyceride in 
the form o f chylomicrons is to reduce VLDLj release from the 
liver (1) and to suspend its lipolysis thereby relieving postprandial 
competition between chylomicrons and VLDL via the same 
lipolytic pathway. Chylomicron remnants are removed from the 
circulation by both LRP (2) and LDL-R (2). A delayed clearance 
o f VLDLi may be due to an altered apolipoprotein and lipid 
composition o f VLDL, in particular depletion ofapoClI (3), and 
enrichment o f cholesterol (3). Failure to clear VLDL efficiently 
from the circulation may lead to formation o f a cascade o f  
atherogenic lipoproteins. Insulin has a number o f effects upon 
triglyceride metabolism, on (4) VLDL/  synthesis, (5) LRP and (6) 
HSL action , these effects may not be seen in those subjects who 
are insulin resistant. FFA, products o f  lipolysis have been shown 
to release LPL from its endothelial binding sites (7). Increased 
flow  o f FFA from adipose tissue to the liver is a major promoter o f  
VLDLi production. Selective inhibition o f HSL (8) may contribute 
towards the therapeutic control o f excessive adipose tissue 
lipolysis in various disease states.
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Appendix 1.
Manufacturers and suppliers of reagents, hardware and software.
Amicon Inc.
Beverley, MA 01915,
USA.
Baker Instruments Ltd,
Rusham Park,
Whitehall Lane,
Egham,
Surrey,
TW20 9NW,
UK.
Beckman Instruments (UK) Ltd,
Analytical Sales and Service Operation,
Progress Road,
Sands Industrial Estate,
High Wycombe,
Bucks, HP12 4JL,
UK.
Becton Dickinson Labware,
2 Bridgewater Lane,
Lincoln Park,
New Jersey 07035,
(800) 235-5953 
USA.
BDH Laboratory Supplies,
McQuilkin and Co,
21 Polmadie Avenue,
Glasgow,
G5 OBB,
UK.
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Bio-Rad Laboratories,
2000 Alfred Nobel Drive,
Hercules,
CA 94547,
USA.
Boehringer Mannheim UK (diagnostics and biochemicals) Ltd,
Bell Lane,
Lewes,
East Sussex,
BN71LG,
UK.
Chromacol Ltd,
3 Little Mundells,
Welwyn Garden City,
Herts,
AL7 1EW,
UK.
Denley Tech Ltd,
Sussex,
England.
Dynatech,
Guernsey,
Great Britain.
Fisons Instruments,
Crewe Road,
Wythenshaw,
Manchester,
M23 9BE,
UK.
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Hoefer Scientific Instruments,
654 Minnesota Street,
San Fransisco 94107,
USA.
Innogenetics NV,
Canadastraat 21 Haven 1009, 
b-2070 Zwijndrecht,
Belgium.
Lennart Krabish,
Servicon AB,
Thomanders v.20 
224 65 Lund,
Sweden.
Microcal Software Inc,
22 Industrial Drive,
East Northampton,
MA 01060,
USA.
Microsoft Corporation,
1 Microsoft Way,
Redmond, WA,
USA.
M initab Inc.,
3081 Enterprise Drive,
State College,
PA 16801-3008.
Orion Diagnostica,
Espoo,
Finland.
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Paar Scientific Ltd,
594 Kingston Road,
Raynes Park,
London,
SW20 8DN.
Pharmacia Biotech Ltd,
23 Grosvenor Road,
St Albans,
Herts,
AL1 3AW.
Scottish Antibody Production Unit (SAPU),
Law Hospital,
Carluke,
Lanarkshire,
ML8 5ES,
UK.
Sigma Chemical Company,
Fancy Road,
Poole,
Dorset,
BH17 7TG,
UK.
Techne,
Scotlab,
Kirkshaw Road,
Coatbridge,
Lanarkshire,
ML5 8AD.
Treff Lab.,
Treff AG,
CH 9113,
Switzerland.
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Wako Chemicals GmbH,
Nissanstr. 2,
D-41468
Neuss,
Germany.
W hatmann International Ltd,
Whatmann Labsales Ltd,
St. Leonards Road, 20/20 
Maidstone,
Kent,
ME16 OLS.
W orthington Biochemical Corporation, 
UK.
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Appendix 2.
TO MAKE DRUG SOLUTIONS IN DMSO
Weight accurately, approx. 3-5mg
eg. 5/mol. wt (in mg) = x mmoles of compound weighed.
Std solutions; Top std = 5mM
X mmoles/5 = volume of DMSO in mis to be added to give a 5mM solution.
tube nos/std vol std(/xl) vol DMSO(^l) CONC.(mM) FINAL
CONC.(M)
1 100
(5mM)
0 5 1 X 10'4
2 100 of 1 
(5mM)
200 1.66 3 x IO-5
3 100 of 1 
(5mM)
900 0.5 1 x 10-5
4 100 of 2 
(1.66mM)
900 0.166 3 x 10’6
5 100 of 3 
(0.5mM)
900 0.05 1 x 10-6
6 100 of 4 
(0.166mM)
900 0.0166 3 x 10'7
7 100 of 5 
(0.05mM)
900 0.005 1 x 10-7
8 100 of 6 
(0.0166mM)
900 0.0016 3 x 10-8
9 100 of 7 
0.005mM)
900 0.0005 1 x 10*8
10 100 of 8 
(0.00166nM)
900 0.000166 3 x 10-9
11 100 of 9 
(0.0005mM)
900 0.00005 1 x 10-9
12 100 of 10 
(0.000166mM)
900 0.000016 3 x 10-10
13 100 of 11 
(0.00005mM)
900 0.000005
OioX
14 100 of 12 
(0.0000166mM)
900 0.00000166 3 x 10-11
15 100 of 13 
(0.000005mM)
900 0.0000005 1 x 10’ 11
16 100 of 14 
(0.00000166mM)
900 0.000000166 3 x 10-12
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Appendix 3.
Standard nicotinic acid solutions for Zucker rat dose response experiments.
Nicotinic acid solutions:
Stock 200 mg/kg = 40 mg/ ml/ 200 gram rat.
Want 35 ml =  35 x 40 = 1400 mg/ 35 ml.
100 mg/kg =  1 in 2 =  10 ml stock +  10 ml excipient.
50 mg/kg = 1 in 4 = 4 ml stock +  12 ml excipient.
25 mg/kg = 1 in 8 = 2 ml stock +  14 ml excipient.
10 mg/kg = 1 in 10 =  2 ml (100 mg/kg solution) +  18 ml excipient.
5 mg/kg = 1 in 10 =  2 ml (50 mg/kg solution) + 18 ml excipient.
2.5 mg/kg = 1 in 10 = 2 ml (25 mg/kg solution) +  18 ml excipient.
1.25 mg/kg = 1 in 8 =  2 ml (10 mg/kg solution) +  14 ml excipient.
Appendix 4.
Body weights (in grams) of Zucker rats used for nicotinic acid dose response experiment
1.
Control 10 mg/kg 25 mg/kg 50 mg/kg 100 mg/kg 200 mg/kg
624 634 558 600 652 625
606 658 626 626 616 656
626 565 592 720 565 540
565 600 574 580 552 560
620 610 527 565 506 634
650 628 582 608 498 570
Appendix 5.
Body weights (in grams) of Zucker rats used for nicotinic acid dose response experiment
2 .
Control 1.25 mg/kg 2.5 mg/kg 5 mg/kg 10 mg/kg 25 mg/kg
568 448 484 525 600 546
578 486 580 586 590 562
528 462 538 546 620 532
510 498 530 574 608 558
565 484 480 552 610 560
628 527 508 554 570 540
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Appendix 6.
Body weights (in grams) of Zucker rats used in nicotinic acid multiple dosing 
experiment.
Controls Nicotinic acid 
(140 mg/kg) 
12 post dose
Nicotinic acid 
(140 mg/kg)
2 post dose
670 700 550
630 670 580
580 560 555
630 570 630
660 540 640
650 560 640
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Appendix 7.
Reference ranges for fasting plasma lipid, lipoprotein and insulin concentrations.
Param eter Reference Range
Plasma triglyceride < 2 . 3  mmol/L
Plasma total cholesterol <6.5  mmol/L
LDL cholesterol <4.5  mmol/L
HDL cholesterol > 1 .0  mmol/L in males 
> 1 .2  mmol/L in females
Plasma insulin < 13 mU/L
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Appendix 8.
FAT FEEDING PROTOCOL
Patient should fast for 10 hours before start of experiment. Patient fed FAT MEAL 
after blood sample(0 hour) is removed. Patient not allowed to eat during the duration 
of the experiment but can drink low calorie drinks. After fat meal patient must fast for 
a further twelve hours, the duration of the experiment.
BLEEDING SCHEDULE
TIME BLOOD VOLUME ANALYSES PLASMA
(hours) (mis) VOLUME
(mis)
0 4.5ml Lithium Heparin INSULIN
30ml Na2EDTA B Quant 5 ml
Apo E phenotype 0.5ml
Apo B, Apo AT 0.5 ml
FFA 0.5ml
TG/CHOL 0.5ml
sequential preparation of 4ml
lipoprotein
1 4.5ml Lithium Heparin INSULIN
20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AT 0.5ml
sequential preparation of 4ml
lipoproteins
2 4.5ml Lithium Heparin INSULIN
20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AT 0.5ml
sequential preparation of 4ml
lipoproteins
3 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AI 0.5ml
sequential preparation of 4ml
lipoproteins
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4 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
ApoB,Al 0.5ml
sequential preparation of 4ml
lipoproteins
5 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
PROTEIN
Apo B,AI 0.5ml
sequential preparation of 4ml
lipoproteins
6 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AT 0.5ml
sequential preparation of 4ml
lipoproteins
7 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AT 0.5ml
sequential preparation of 4ml
lipoproteins
8 20 ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,At 0.5ml
sequential preparation of 4ml
lipoproteins
9 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,AT 0.5ml
sequential preparation of 4ml
lipoproteins
10 20ml Na2EDTA FFA 0.5ml
TG/CHOL 0.5ml
Apo B,A1 0.5ml
sequential preparation of 4ml
lipoproteins
11 20mlNa2EDTA FFA 0.5ml
TG/CHOL 0.5ml
ApoB,AI 0.5ml
sequential preparation of 4ml
lipoproteins
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Appendix 9.
Postprandial changes in individual plasma triglyceride concentrations (mmol/L) in
normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 1.18 0.98 0.85 1.15 0.95 1.42 0.53 0.85 2.11
1 1.37 1.07 1.13 1.34 1.05 1.32 0.70 0.92 2.47
2 1.82 1.38 2.14 1.53 1.50 2.71 0.99 1.68 3.77
3 3.28 2.16 3.08 2.09 1.14 3.54 0.97 2.11 4.62
4 4.22 2.44 3.51 2.46 1.75 1.66 1.54 1.78 5.37
5 4.42 2.77 2.94 2.91 1.58 1.11 2.01 2.50 5.33
6 4.95 2.32 2.55 2.37 1.36 0.76 1.88 2.77 6.04
7 4.20 2.18 2.56 3.41 1.14 0.67 1.61 1.72 4.34
8 3.65 1.42 1.45 3.01 0.89 0.59 1.91 1.24 3.34
9 3.98 1.18 1.05 2.78 0.85 0.67 1.79 1.73 2.00
10 3.18 0.86 1.20 1.49 0.81 0.72 1.47 1.19 1.57
11 2.11 0.75 0.81 1.20 0.63 0.71 1.20 0.88 1.17
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Appendix 10.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the TRL
(d< 1.006g/ml) fraction isolated by sequential flotation ultracentrifugation in normal
subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.68 0.53 0.45 0.6 0.46 0.89 0.17 0.30 1.37
1 0.85 0.58 0.62 0.75 0.55 0.84 0.37 0.35 1.79
2 1.23 0.89 1.15 0.89 0.92 1.84 0.62 0.92 2.43
3 2.36 1.50 1.65 1.28 0.60 2.46 0.57 1.07 3.13
4 0.27 1.70 1.88 1.61 1.09 1.09 0.83 1.02 3.24
5 3.19 1.86 1.70 1.83 0.82 0.63 1.42 1.83 3.64
6 3.77 1.56 1.31 1.36 0.72 0.33 1.42 1.76 4.35
7 2.97 1.46 1.47 2.29 0.54 0.22 1.01 0.79 2.92
8 2.695 0.93 0.77 2.00 0.38 0.18 1.39 0.45 2.07
9 2.75 0.67 0.50 1.79 0.31 0.26 0.19 0.74 1.19
10 2.14 0.38 0.54 0.81 0.30 0.33 0.95 0.42 0.93
11 1.27 0.31 0.35 0.61 0.19 0.31 0.74 0.28 0.64
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Appendix 11.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the apoB48 
TRL fraction isolated by immunoaffinity chromatography, using a Sepharose bound 
LDL A4 monoclonal antibody in Eppendorf tubes, from the TRL (d<  1.006g/ml) 
fraction in normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.27 0.23 0.05 0.22 0.17 0.30 0.03 0.13 0.52
1 0.35 0.27 0.22 0.37 0.25 0.20 0.17 0.15 0.9
2 0.70 0.47 0.45 0.45 0.50 0.95 0.35 0.57 1.35
3 1.60 1.00 0.90 0.65 0.25 1.50 0.28 0.72 1.95
4 2.03 1.15 1.10 0.85 0.67 0.57 0.50 0.62 1.95
5 2.73 1.35 0.95 0.95 0.45 0.27 1.05 1.42 2.47
6 2.85 LOO 0.60 0.60 0.42 0.15 0.90 1.25 3.00
7 2.20 0.87 0.85 1.10 0.32 0.07 0.60 0.55 1.57
8 1.93 0.55 0.42 1.15 0.2 0.10 0.95 0.27 0.97
9 2.15 0.40 0.20 0.95 0.18 0.10 0.78 0.5 0.45
10 1.55 0.20 0.15 0.37 0.15 0.15 0.62 0.27 0.35
11 0.66 0.20 0.07 0.30 0.10 0.13 0.45 0.15 0.25
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Appendix 12.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the apoBlOO 
TRL fraction isolated by immunoaffinity chromatography, using a Sepharose bound 
LDL A4 monoclonal antibody in Eppendorf tubes, from the TRL (d<  1.006g/ml) 
fraction in normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.33 0.36 0.24 0.36 0.27 0.54 0.12 0.21 0.81
1 0.30 0.36 0.27 0.36 0.27 0.48 0.18 0.18 0.99
2 0.45 0.45 0.30 0.42 0.39 0.66 0.24 0.30 0.99
3 0.48 0.45 0.30 0.60 0.30 0.72 0.24 0.33 1.26
4 0.54 0.57 0.24 0.72 0.33 0.39 0.24 0.33 1.17
5 0.69 0.57 0.30 0.84 0.30 0.33 0.30 0.33 1.35
6 0.60 0.45 0.30 0.66 0.21 0.15 0.30 0.33 1.44
7 0.51 0.39 0.42 0.90 0.15 0.09 0.27 0.24 1.26
8 0.48 0.36 0.24 0.78 0.12 0.09 0.24 0.18 0.99
9 0.45 0.27 0.12 0.78 0.09 0.12 0.24 0.18 0.72
10 0.48 0.15 0.15 0.36 0.09 0.15 0.21 0.12 0.54
11 0.42 0.18 0.12 0.30 0.09 0.15 0.18 0.12 0.42
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Appendix 13.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the large 
VLDLi subfraction after isolation by immunoaffinity chromatography, using a 
Sepharose bound LDL A4 monoclonal antibody in Eppendorf tubes, followed by 
cumulative flotation in normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.22 0.24 0.20 0.16 0.12 0.39 0.02 0.10 0.54
1 0.19 0.22 0.21 0.16 0.13 0.36 0.04 0.10 0.63
2 0.28 0.28 0.33 0.22 0.18 0.48 0.09 0.18 0.76
3 0.28 0.31 0.33 0.33 0.13 0.54 0.09 0.19 0.90
4 0.37 0.39 0.33 0.45 0.16 0.28 0.10 0.18 0.81
5 0.39 0.37 0.39 0.51 0.12 0.16 0.15 0.18 1.03
6 0.33 0.36 0.30 0.42 0.07 0.07 0.18 0.16 1.13
7 0.31 0.28 0.36 0.54 0.07 0.06 0.16 0.07 0.94
8 0.30 0.25 - 0.48 0.06 0.06 0.16 0.06 0.67
9 0.30 0.18 0.12 0.45 0.04 0.07 0.12 0.09 0.49
10 0.25 0.10 0.14 0.16 0.04 0.12 0.12 0.04 0.27
11 0.15 0.15 0.12 0.12 0.04 0.10 0.09 0.04 0.18
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Appendix 14.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the small 
VLDL2 subfraction after isolation by immunoaffinity chromatography, using a 
Sepharose bound LDL A4 monoclonal antibody in Eppendorf tubes, followed by 
cumulative flotation in normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.037 0.105 0.083 0.09 0.09 0.105 0.045 0.0375 0.09
1 0.037 0.112 0.038 0.09 0.075 0.09 0.045 0.0375 0.09
2 0.045 0.112 0.105 0.097 0.0675 0.105 0.0675 0.0375 0.0675
3 0.045 0.12 0.09 0.09 0.0825 0.09 0.0675 0.045 0.0675
4 0.045 0.105 0.09 0.09 0.0675 0.0825 0.06 0.03 0.0675
5 0.03 0.105 0.105 0.09 0.0525 0.0675 0.06 0.0375 0.045
6 0.037 0.097 0.105 0.105 0.06 0.0525 0.045 0.045 0.0675
7 0.053 0.105 0.135 0.09 0.0375 0.03 0.06 0.045 0.09
8 0.053 0.105 _ 0.105 0.03 0.0225 0.0525 0.0375 0.1125
9 0.045 0.105 0.067 0.12 0.0225 0.015 0.0525 0.0225 0.1125
10 0.06 0.09 0.06 0.09 0.015 0.03 0.06 0.015 0.12
11 0.06 0.045 0.052 0.083 0.015 0.03 0.045 0.0075 0.105
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Appendix 15.
Postprandial changes in individual plasma FFA concentrations (mmol/L) in normal
subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.183 0.25 0.16 0.41 0.27 0.75 0.36 0.49 0.04
1 0.174 0.31 0.13 0.44 0.39 0.37 0.15 0.34 0.06
2 0.155 0.33 0.35 0.53 0.39 0.57 0.26 0.59 0.15
3 0.466 0.61 0.64 0.72 0.62 0.92 0.28 0.63 0.31
4 0.64 0.72 0.59 0.68 0.68 0.72 0.39 0.92 0.47
5 0.615 0.81 0.77 0.98 0.94 0.82 0.52 0.73 0.66
6 0.83 0.90 0.95 0.77 0.93 0.74 0.72 1.34 0.83
7 0.908 1.09 0.73 1.42 0.77 0.92 0.57 0.91 0.62
8 0.828 0.88 0.53 1.45 1.00 1.05 0.71 0.71 0.61
9 0.892 0.68 0.53 1.77 0.85 1.15 0.61 0.91 0.33
10 0.807 0.56 0.55 1.11 1.10 0.98 0.53 0.63 0.24
11 0.509 0.67 0.47 1.29 0.96 1.27 0.43 0.61 0.20
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Appendix 16.
Postprandial changes in individual plasma apoB concentrations (g/L) in normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.65 0.77 1.03 0.74 0.76 0.89 0.72 0.78 1.21
1 0.65 0.8 1.11 0.77 0.79 0.9 0.73 0.76 1.21
2 0.73 0.83 1.03 0.84 0.84 0.95 0.75 0.75 1.25
3 0.82 0.79 1.08 0.83 0.89 0.96 0.73 0.76 1.3
4 0.78 0.82 1.08 0.87 0.88 0.91 0.77 0.81 1.37
5 0.79 0.88 1.27 0.86 0.88 0.8 0.75 0.83 1.26
6 0.78 0.85 0.99 0.89 0.78 0.84 0.72 0.75 1.32
7 0.86 0.87 1.07 0.92 0.78 0.83 0.71 0.68 1.31
8 0.81 0.79 0.98 0.9 0.76 0.81 0.72 0.69 1.18
9 0.84 0.75 0.93 0.88 0.81 0.7 0.67 0.73 1.08
10 0.85 0.78 0.94 0.75 0.75 0.85 0.69 0.65 1.11
11 0.82 0.75 0.94 0.73 0.78 0.8 0.71 0.65 0.95
Appendix 17.
Postprandial changes in individual plasma apoAI concentrations (g/L) in normal
subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.83 1.29 1.39 1.65 1.25 1.52 1.02 1.62 1.29
1 0.86 1.25 1.45 1.73 1.34 1.38 1.08 1.49 1.35
2 0.88 1.19 1.31 1.77 1.36 1.52 1.1 1.47 1.31
3 0.93 1.18 1.3 1.79 1.41 1.45 1.12 1.42 1.31
4 0.92 1.3 1.24 1.77 1.39 1.34 1.21 1.41 1.37
5 0.96 1.25 1.56 1.81 1.48 1.3 1.16 1.36 1.29
6 0.9 1.24 1.28 1.83 1.29 1.31 1.14 1.35 1.31
7 1.01 1.32 1.36 1.88 1.32 1.38 1.18 1.32 1.35
8 1.02 1.33 1.34 1.76 1.22 1.32 1.15 1.34 1.28
9 1.02 1.29 1.31 1.69 1.32 1.33 1.16 1.43 1.25
10 0.99 1.24 1.36 1.59 1.22 1.39 1.12 1.43 1.29
11 0.95 1.17 1.37 1.49 1.26 1.44 1.07 1.41 1.2
225
Appendix 18.
Postprandial changes in individual TRL (d< 1.006 g/ml) apoB concentrations (g/L) in
normal subjects.
Time
(hours)
BC M M BJ KE HA CN JM IC AG
0 0.25 0.045 0.025 0.05 0.075 0.06 0.045 0.04 0.125
1 0.225 0.055 0.025 0.06 0.075 0.05 0.045 0.05 0.165
2 0.045 0.055 0.045 0.075 0.08 0.16 0.035 0.05 0.185
3 0.09 0.01 0.095 0.06 0.06 0.20 0.035 0.065 0.26
4 0.105 0.11 0.12 0.15 0.07 0.07 0.05 0.05 0.255
5 0.12 0.185 0.11 0.16 0.055 0.035 0.065 0.055 0.29
6 0.18 0.105 0.065 0.145 0.05 0.01 0.055 0.055 0.35
7 0.13 0.13 0.08 0.215 0.04 0.02 0.055 0.045 0.175
8 0.13 0.075 0.03 0.17 0.03 0.005 0.05 0.05 0.2
9 0.13 0.05 0.015 0.175 0.03 0.01 0.055 0.045 0.13
10 0.11 0.025 0.005 0.1 0.03 0.015 0.05 0.06 0.06
11 0.068 0.02 0.01 0.055 0.03 0.005 0.045 0.055 0.085
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Appendix 19.
Postprandial changes in individual TRL (d< 1.006g/ml) apoAI concentrations (g/L) in
normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 0.1 0.02 0.01 0.02 0.02 0.05 0.035 0.01 0
1 0.05 0.02 0 0.015 0.02 0.025 0.03 0.01 0
2 0.1 0.025 0.015 0.015 0.02 0.02 0.03 0.005 0
3 0.025 0.025 0.015 0.015 0.025 0.02 0.025 0.01 0
4 0.03 0.025 0.025 0.015 0.025 0.01 0.045 0.005 0
5 0.04 0.03 0.015 0.02 0.015 0.05 0.045 0.005 0
6 0.06 0.005 0.015 0.015 0.02 0.005 0.045 0.025 0
7 0.04 0.025 0.015 0.015 0.025 0.005 0.04 0.005 0
8 0.035 0.025 0.02 0.025 0.02 0.035 0.05 0.002 0
9 0.035 0.025 0.02 0.015 0.015 0.03 0.045 0.002 0
10 0.025 0 0.015 0.005 0.02 0.03 0.04 0.002 0
11 0.015 0.02 0.01 0.005 0.02 0.025 0.05 0.002 0
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Appendix 20,
Postprandial changes in individual plasma cholesterol concentrations (mmol/L) in
normal subjects.
Time
(hours)
BC MM BJ KE HA CN JM IC AG
0 3.7 5.55 5.89 4.75 4.88 4.71 3.89 4.77 5.44
1 3.79 5.69 6.1 5.15 4.93 4.6 4.11 4.95 5.67
2 3.83 5.32 5.66 5.11 5.22 4.63 4.11 4.85 5.56
3 3.94 5.26 5.57 5.01 5.21 4.91 4.18 4.86 5.67
4 3.91 5.47 5.41 5.06 5.38 4.82 4.32 4.81 5.84
5 4.41 5.38 5.66 5.04 5.38 4.73 4.14 4.8 5.51
6 4.08 5.26 5.26 5.1 5.37 4.64 4.16 4.65 5.91
7 4.18 5.61 5.61 5.14 5.36 4.77 4.17 4.64 5.93
8 4.25 5.25 5.52 4.95 5.03 4.7 4.18 4.77 5.8
9 4.29 5.43 5.23 4.81 5.48 4.55 4.15 4.68 5.5
10 4.37 5.36 5.47 4.78 5.12 4.7 4.24 4.64 5.43
11 4.17 5.45 5.51 4.51 5.32 4.7 4.19 4.58 5.35
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Appendix 21.
Dear Patient,
We are looking for someone to help us with a study to see how 
people with Diabetes handle fat from their diet.
As you know, Diabetics have trouble controlling blood sugar 
levels. It is also true that they may have difficulties in clearing from 
the bloodstream, the fat that they eat. We are wanting to find out if 
people with Diabetes are able to keep their blood fat levels under 
control when given a standard fat load test.
We are inviting people who attend the Diabetic Centre to 
volunteer to receive a creamy drink in the morning, after fasting 
overnight. After giving you the drink, we can follow the appearance 
of fat in the blood by taking regular samples over a period of eleven 
hours. Special techniques that we use in the laboratory enable us to 
separate the fat that comes from the creamy drink from other fats in 
your bloodstream that the liver makes. We are testing the possibility 
that people with Diabetes have difficulties in keeping the levels of 
both kinds of fat (from the diet and liver) in good control.
It means a day in hospital in our quiet, comfortable clinical 
suite. If you agree to be involved you can bring your favourite 
videos and books, or read some of ours. We would be delighted to 
talk through study details with you either today or at a future date.
The people mentioned below are involved in this effort and can 
be contacted at the telephone numbers given below.
Dr Neil Bennit
Lynne Crawford 0141 211 4589
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Appendix 22.
Patient Information and Consent Knrm
Title; T h e  r e g u l a t i o n  o f  i n t e s t i n a l  a n d  h e p a t i c  l i p o p r o t e i n  s y n t h e s i s  in
NO R M A L ,  C O R O N A R Y  HEART DISEASE A N D  DIABETIC PATIENTS AFTER A FAT MEAL.
I understand that Professor Shepherd and his team are conducting studies to discover how 
blood fat levels are controlled. These studies involve fasting for about 12 hours before being 
given a test breakfast made up mainly of cream with flavourings. After the breakfast I 
understand that I will not be able to eat until about 4.00 p.m. in the afternoon when I will 
receive a light fat-free meal.
Blood samples will be taken over the day of the study with a total of about 200mls of blood 
being donated.
The object of the study is to investigate how my body handles fat in the diet and to measure the 
rate of appearance and disappearance of fat in the blood. The fat test meal b  able to show 
differences between people who have normal blood fat levels and those who have coronary 
heart disease or who have diabetes. The period of fasting b  necessary so that the fiver does not 
produce fat and confuse the results from the test breakfast
In some cases I will be given a small amount of substances that are used by the body to make 
lipoproteins (the particles that carry fat in the blood) these substances will either be included in 
the test meal or be given by injection just prior to eating the breakfast I appreciate that some 
mild discomfort may be associated with the injection and the taking of blood samples.
Taking part in the study will be of little or no direct benefit to myself but w31 help other 
patients in the future. If I wish to stop taking part I may do so at any time and thb wffl not 
affect my present or future medical treatment My General Practitioner will be told of my 
participation and will be given detaib of my results.
CONSENT:
I,(Name) .......   of (Address) ------------ ------ -
agree to take part in the Research Project/Study Programme described above.
Dr/Mr...................................................... has explained to me what I have to do, how K might affect
me and the purpose of the Research Project/Study Programme.
Signed .........      D a te ..................- ................................ .......
Witness  ............................................................  D a te ..................... - .............. ................ ....
230
Appendix 23.
Postprandial changes in individual plasma triglyceride concentrations (mmol/L) in
diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 3.37 0.69 2.59 2.76 1.24
1 3.57 0.91 2.74 2.57 1.37
2 4.36 1.17 3.07 3.05 2.22
3 5.31 1.25 3.47 3.81 2.69
4 7.38 1.79 4.01 4.21 2.78
5 9.11 1.94 4.42 4.40 3.36
6 10.23 2.31 4.52 4.52 2.75
7 9.45 - 4.46 4.14 2.71
8 9.66 2.20 3.96 3.41 2.21
9 8.37 2.33 4.41 2.76 2.09
10 10.89 2.64 4.62 2.25 1.99
11 14.13 1.36 4.35 1.82 1.62
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Appendix 24.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the TRL 
(d<  1.006g/ml) fraction isolated from plasma by sequential flotation ultracentrifugation 
in diabetic subjects.
Time JC SJ PF CE MH
0 2.01 0.31 1.825 1.78 0.67
1 2.33 0.37 2.075 1.58 0.83
2 3.155 0.73 2.07 2.03 1.345
3 3.63 0.74 2.46 2.40 1.665
4 4.92 1.11 2.825 2.89 1.82
5 6.22 1.24 3.13 3.185 2.082
6 7.56 1.66 3.405 2.94 1.176
7 6.45 1.855 3.07 3.09 1.85
8 9.06 1.47 2.745 2.24 1.185
9 9.06 1.23 3.35 1.65 1.26
10 9.525 1.36 3.31 1.335 1.145
11 8.26 0.66 2.955 0.95 0.95
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Appendix 25.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the apoB48 
TRL fraction isolated by immunoaffmity chromatography, using a Sepharose bound 
LDL A4 monoclonal antibody in Eppendorf tubes, from the TRL (d<  1.006g/ml) 
fraction in diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 0.625 0.10 0.5 0.65 0.15
1 0.875 0.125 0.7 0.6 0.3
2 1.5 0.375 0.7 0.9 0.65
3 1.875 0.35 1.1 1.2 0.9
4 3.00 0.55 1.4 1.8 1.00
5 3.75 0.675 1.6 1.85 1.35
6 4.75 1.025 1.8 1.65 1.05
7 4.25 1.175 1.6 1.7 1.1
8 6.5 0.9 1.4 1.05 0.65
9 6.375 0.775 1.8 0.65 0.7
10 5.875 0.75 1.6 0.45 0.6
11 6.00 0.40 1.5 0.25 0.5
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Appendix 26.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the apoBlOO 
TRL fraction isolated by immunoaffinity chromatography, using a Sepharose bound 
LDL A4 monoclonal antibody in Eppendorf tubes, from the TRL (d<  1.006g/ml) 
fraction in diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 1.2 0.15 0.96 0.90 0.36
1 1.35 0.18 0.96 0.84 0.42
2 1.5 0.27 1.08 0.96 0.48
3 1.5 0.30 1.2 1.02 0.6
4 1.65 0.33 1.2 1.2 0.54
5 1.95 0.39 1.32 1.2 0.6
6 2.1 0.42 1.2 1.08 0.54
7 1.8 0.42 1.32 1.2 0.54
8 1.95 0.33 1.2 0.96 0.30
9 2.4 0.27 1.32 0.78 0.36
10 2.4 0.24 1.32 0.66 0.30
11 2.1 0.15 1.08 0.54 0.30
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Appendix 27.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the large 
VLDLi subfraction isolated by immunoaffinity chromatography, using a Sepharose 
bound LDL A4 monoclonal antibody in Eppendorf tubes, followed by cumulative 
flotation in diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 0.6 0.075 0.66 0.60 0.21
1 0.675 0.09 0.66 0.57 0.15
2 0.9 0.165 0.72 0.66 0.33
3 0.9 0.165 0.78 0.69 0.42
4 1.2 0.21 0.84 1.02 0.36
5 1.35 0.225 0.96 0.90 0.36
6 1.575 0.27 0.90 0.75 0.3
7 1.275 0.255 0.96 0.69 0.3
8 1.425 0.18 0.90 0.63 0.15
9 1.65 0.135 0.84 0.48 0.18
10 1.65 0.12 0.72 0.27 0.15
11 1.575 0.045 0.78 0.36 0.15
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Appendix 28.
Postprandial changes in individual triglyceride concentrations (mmol/L) in the small 
VLDL2 subfraction isolated by immunoaffinity chromatography, using a Sepharose 
bound LDL A4 monoclonal antibody in Eppendorf tubes, followed by cumulative 
flotation in diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 0.18 0.03 0.12 0.09 0.12
1 0.037 0.03 0.15 0.12 0.195
2 0.23 0.04 0.09 0.14 0.18
3 0.23 0.05 0.12 0.12 0.18
4 0.038 - 0.03 0.12 0.075
5 0.038 0.053 0.09 0.12 0.075
6 0.15 0.068 0.09 0.12 0.09
7 0.11 0.068 0.12 0.21 0.09
8 0.11 0.060 0.12 0.12 0.09
9 0.15 0.053 0.15 0.15 0.06
10 0.11 0.053 0.09 0.14 0.05
11 0.15 0.037 0.09 0.12 0.03
Appendix 29.
Postprandial changes in individual plasma FFA concentrations (mmol/L) in diabetic
subjects.
Time
(hours)
JC SJ PF CE MH
0 0.622 0.907 0.423 0.477 0.65
1 0.49 0.41 0.534 0.512 0.678
2 0.557 0.258 0.492 0.589 0.55
3 0.667 0.279 0.496 0.677 0.574
4 0.903 0.55 0.664 0.803 0.444
5 1.167 0.709 0.740 0.912 0.581
6 1.464 0.857 0.542 0.757 0.633
7 1.809 0.955 0.741 0.872 0.79
8 1.858 1.071 0.622 0.654 0.624
9 1.96 1.132 0.793 0.724 0.420
10 1.961 1.447 1.08 0.609 0.367
11 1.962 0.869 0.865 0.244 0.163
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Appendix 30.
Postprandial changes in individual plasma cholesterol concentrations (mmol/L) in
diabetic subjects after an oral fat load.
Time
(hours)
JC SJ PF CE MH
0 5.01 5.25 6.52 5.37 5.25
1 5.07 6.56 5.35 5.16 5.2
2 5.01 5.12 6.69 4.91 5.13
3 4.91 5.19 6.17 4.94 5.13
4 5.15 5.19 6.61 5.08 5.02
5 5.29 5.26 6.64 5.12 4.98
6 5.41 5.30 6.4 5.11 5.00
7 5.35 2.7 6.49 5.16 5.26
8 5.51 5.19 6.54 5.4 5.19
9 5.53 5.38 6.67 5.37 5.34
10 5.5 5.18 6.65 4.89 4.93
11 5.5 5.1 6.53 4.83 4.81
Appendix 31.
Postprandial changes in individual plasma apoB concentrations (g/L) in diabetic
subjects.
Time
(hours)
JC SJ PF CE MH
0 1.22 0.8 1.34 1.38 0.99
1 1.31 0.8 1.5 1.32 0.98
2 1.35 0.81 1.46 1.31 0.98
3 1.31 0.83 1.32 1.31 1.01
4 1.4 0.84 1.49 1.33 0.94
5 1.4 0.83 1.54 1.34 1.05
6 1.35 0.81 1.5 1.31 0.92
7 1.23 0.78 1.57 1.26 0.88
8 1.19 0.8 1.46 1.31 0.89
9 1.2 0.81 1.36 1.21 0.97
10 1.24 0.75 1.39 1.12 0.88
11 1.39 0.76 1.17 1.06 0.87
Appendix 32.
Postprandial changes in individual plasma apoAI concentrations (g/L) in diabetic
subjects.
Time
(hours)
JC SJ PF CE MH
0 1.1 1.41 1.24 1.01 1.41
1 1.25 1.43 1.29 0.9 1.36
2 1.14 1.39 1.29 0.88 1.37
3 1.18 1.38 1.14 0.92 1.35
4 1.31 1.4 1.22 0.92 1.29
5 1.27 1.34 1.23 0.97 1.4
6 1.29 1.21 1.21 0.93 1.27
7 1.2 1.25 1.22 0.99 1.32
8 1.16 1.29 1.27 0.95 1.31
9 1.19 1.27 1.29 0.91 1.46
10 1.15 1.22 1.27 0.83 1.33
11 1.12 1.24 1.3 0.83 1.25
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Appendix 33.
Postprandial changes in individual TRL (d< 1.006g/ml) apoB concentrations (g/L) in
diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 0.25 0.02 0.19 0.09 0.055
1 0.29 0.02 0.21 0.22 0.045
2 0.355 0.02 0.195 0.26 0.09
3 0.345 0.025 0.205 0.25 0.1
4 0.41 0.03 0.205 0.315 0.115
5 0.505 0.03 0.225 0.355 0.13
6 0.64 0.08 0.24 0.28 0.115
7 0.395 0.035 0.22 0.34 0.12
8 0.41 0.02 0.2 0.265 0.075
9 0.625 0.01 0.23 0.205 0.075
10 0.595 0.005 0.215 0.155 0.055
11 0.655 0.005 0.2 0.125 0.055
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Appendix 34.
Postprandial changes in individual TRL (d< 1.006g/ml) apoAI concentration (g/L) in
diabetic subjects.
Time
(hours)
JC SJ PF CE MH
0 0.02 0.05 0.005 0 0
1 0.005 0.05 0.02 0 0
2 0.02 0 0.01 0 0
3 0.02 0.01 0.01 0 0
4 0.04 0.01 0.015 0 0
5 0.055 0 0.025 0 0
6 0.09 0.05 0.015 0 0
7 0.07 0.01 0.02 0 0
8 0.11 0.01 0.02 0 0
9 0.165 0.01 0.025 0 0
10 0.165 0.02 0.025 0 0
11 0.175 0 0.015 0 0
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Appendix 35
Individual clinical status of diabetic subjects.
Parmeter JC SJ PF CE MH
Age
(years)
74 69 63 46 65
BMI
(kg/m2)
29 31 35 30 31
BP
(mmHg)
180/100 150/80 150/80 134/92 154/76
Therapy Diet only Diet only Metformin Metformin Metformin
Neuropathy Present None Present None None
Retinopathy None PDR* None None BDR**
HbAx
(%)
9.5 - 7.7 10.1 10.4
H bAic
(%)
7.1 - 5.6 7.4 13.8
Duration of
diabetes
(years)
12 6 5 3 4
*PDR- Proliferative diabetic retinopathy
**BDR- Background diabetic retinopathy
Normal range HbAj 4.9-7.6%
Normal range HbA \ c 3.4-5.2 %
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Glossary.
ACC acetyl CoA-carboxylase
ADA adenosine deaminase
AICAR 5-amino-4-imidazole carboximide
ANOVA analysis of variance
Apo apolipoprotein
ATP adenosine triphosphate
BSA bovine serum albumin
cAMP cyclic adenosine monophosphate
CAD coronary artery disease
CE cholesterol ester
CETP cholesterol ester transfer protein
CHD coronary heart disease
cm centimetre
CNBr cyanogen bromide
CoA co-enzyme A
cpm counts per minute
d density
DAG diacylglycerol
dl decilitre
DMSO dimethyl sulphoxide
dpm disintegrations per minute
EDTA ethylenediaminetetra-acetic acid disodium salt
ELISA enzyme linked immunosorbent assay
FA fatty acids
FC free cholesterol
FCS foetal calf serum
FFA free fatty acids
g grams
g's gravitational force
Gi inhibitory G protein
Gs stimulatory G protein
HAT hypoxanthine aminopterin thymidine solution
HDL high density lipoprotein
HL hepatic lipase
HMG CoA-reductase 3-hydroxy-3-methyl glutaryl co-enzyme A-reductase
HMW high molecular weight marker
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HRP horse radish peroxidase
HSL hormone-sensitive lipase
h 2o water
IBMX 3-isobutyl-1 -methylxan thine
IC50 inhibitor concentration at 50% inhibition
IDDM insulin-dependent diabetes mellitus
IDL intermediate density lipoprotein
IgG immunoglobulin
kcal kilocalorie
kg kilogram
L litre
LCAT lecithin cholesterol acyl-transferase
LDL low density lipoprotein
LMW low molecular weight markers
Lp(a) Lipoprotein(a)
LPDP lipoprotein deficient plasma
LPL lipoprotein lipase
LRP LDL receptor-related protein
M molar solution
mA milliamps
MAG monoacylglycerol
mEq milliequivalents
mg milligram
mins minutes
ml millilitre
mM millimolar
mmol millimoles
MOME monoacylmonoalkylglycerol
mRNA messenger ribonucleic acid
mU milliunits
3M5P 3-methyl-5-pyrazolecarboxylic acid
NaOH sodium hydroxide
NaSCN sodium thiocyanate
NEFA non-esterified fatty acids
ng nanogram
NIDDM non-insulin dependent diabetes mellitus
nM nanomolar
nmol nanomole
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3PAA 3-pyridyl acetic acid hydrochloride
PEG polyethylene glycol
PIA phenyl isopropyl adenosine
PL phospholipids
PP protein phosphatases
PPi pyrophosphate
304205 p-nitrophenylethylhexyl phosphonate
RE retinyl ester
RER rough endoplasmic reticulum
rpm revolutions per minute
RPMI 1640 Roswell Park Memorial Institute Medium 1640
SDS sodium dodecyl sulphate
SDS PAGE sodium dodecyl sulphate polyacrylamide slab gel
electrophoresis
SER smooth endoplasmic reticulum
TAG triacylglycerol
TEMED tetramethylethylenediamine
TG triglyceride
TRL triglyceride-rich lipoproteins
TZD thiazolidinediones
microgram
fj.\ microlitre
juM micromolar
fimol micromole
v volume
VLDL very low density lipoprotein
w weight
ZMP 5-amino-4-imidazolecarboxamide
15-VLDL VLDL remnant, refers to migration pattern on agarose gels
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